var ra=Object.defineProperty;var ca=(i,e,a)=>e in i?ra(i,e,{enumerable:!0,configurable:!0,writable:!0,value:a}):i[e]=a;var Vi=(i,e,a)=>(ca(i,typeof e!="symbol"?e+"":e,a),a);(function(){const e=document.createElement("link").relList;if(e&&e.supports&&e.supports("modulepreload"))return;for(const n of document.querySelectorAll('link[rel="modulepreload"]'))t(n);new MutationObserver(n=>{for(const o of n)if(o.type==="childList")for(const s of o.addedNodes)s.tagName==="LINK"&&s.rel==="modulepreload"&&t(s)}).observe(document,{childList:!0,subtree:!0});function a(n){const o={};return n.integrity&&(o.integrity=n.integrity),n.referrerPolicy&&(o.referrerPolicy=n.referrerPolicy),n.crossOrigin==="use-credentials"?o.credentials="include":n.crossOrigin==="anonymous"?o.credentials="omit":o.credentials="same-origin",o}function t(n){if(n.ep)return;n.ep=!0;const o=a(n);fetch(n.href,o)}})();function R(){}const ne=i=>i;function me(i,e){for(const a in e)i[a]=e[a];return i}function Ze(i){return i()}function ue(){return Object.create(null)}function ii(i){i.forEach(Ze)}function yi(i){return typeof i=="function"}function bi(i,e){return i!=i?e==e:i!==e||i&&typeof i=="object"||typeof i=="function"}let Li;function la(i,e){return i===e?!0:(Li||(Li=document.createElement("a")),Li.href=e,i===Li.href)}function da(i){return Object.keys(i).length===0}function ma(i,...e){if(i==null){for(const t of e)t(void 0);return R}const a=i.subscribe(...e);return a.unsubscribe?()=>a.unsubscribe():a}function W(i,e,a){i.$$.on_destroy.push(ma(e,a))}function he(i){return i??""}const Qe=typeof window<"u";let $e=Qe?()=>window.performance.now():()=>Date.now(),oe=Qe?i=>requestAnimationFrame(i):R;const pi=new Set;function ia(i){pi.forEach(e=>{e.c(i)||(pi.delete(e),e.f())}),pi.size!==0&&oe(ia)}function ea(i){let e;return pi.size===0&&oe(ia),{promise:new Promise(a=>{pi.add(e={c:i,f:a})}),abort(){pi.delete(e)}}}function T(i,e){i.appendChild(e)}function aa(i){if(!i)return document;const e=i.getRootNode?i.getRootNode():i.ownerDocument;return e&&e.host?e:i.ownerDocument}function ua(i){const e=I("style");return e.textContent="/* empty */",ha(aa(i),e),e.sheet}function ha(i,e){return T(i.head||i,e),e.sheet}function z(i,e,a){i.insertBefore(e,a||null)}function k(i){i.parentNode&&i.parentNode.removeChild(i)}function Ai(i,e){for(let a=0;a<i.length;a+=1)i[a]&&i[a].d(e)}function I(i){return document.createElement(i)}function X(i){return document.createElementNS("http://www.w3.org/2000/svg",i)}function j(i){return document.createTextNode(i)}function F(){return j(" ")}function se(){return j("")}function U(i,e,a,t){return i.addEventListener(e,a,t),()=>i.removeEventListener(e,a,t)}function b(i,e,a){a==null?i.removeAttribute(e):i.getAttribute(e)!==a&&i.setAttribute(e,a)}function pa(i){return Array.from(i.childNodes)}function li(i,e){e=""+e,i.data!==e&&(i.data=e)}function pe(i,e){i.value=e??""}function M(i,e,a,t){a==null?i.style.removeProperty(e):i.style.setProperty(e,a,t?"important":"")}let ki;function fa(){if(ki===void 0){ki=!1;try{typeof window<"u"&&window.parent&&window.parent.document}catch{ki=!0}}return ki}function ta(i,e){getComputedStyle(i).position==="static"&&(i.style.position="relative");const t=I("iframe");t.setAttribute("style","display: block; position: absolute; top: 0; left: 0; width: 100%; height: 100%; overflow: hidden; border: 0; opacity: 0; pointer-events: none; z-index: -1;"),t.setAttribute("aria-hidden","true"),t.tabIndex=-1;const n=fa();let o;return n?(t.src="data:text/html,<script>onresize=function(){parent.postMessage(0,'*')}<\/script>",o=U(window,"message",s=>{s.source===t.contentWindow&&e()})):(t.src="about:blank",t.onload=()=>{o=U(t.contentWindow,"resize",e),e()}),T(i,t),()=>{(n||o&&t.contentWindow)&&o(),k(t)}}function ya(i,e,{bubbles:a=!1,cancelable:t=!1}={}){return new CustomEvent(i,{detail:e,bubbles:a,cancelable:t})}const zi=new Map;let Ji=0;function ba(i){let e=5381,a=i.length;for(;a--;)e=(e<<5)-e^i.charCodeAt(a);return e>>>0}function ga(i,e){const a={stylesheet:ua(e),rules:{}};return zi.set(i,a),a}function va(i,e,a,t,n,o,s,c=0){const m=16.666/t;let d=`{
`;for(let v=0;v<=1;v+=m){const h=e+(a-e)*o(v);d+=v*100+`%{${s(h,1-h)}}
`}const r=d+`100% {${s(a,1-a)}}
}`,f=`__svelte_${ba(r)}_${c}`,p=aa(i),{stylesheet:y,rules:x}=zi.get(p)||ga(p,i);x[f]||(x[f]=!0,y.insertRule(`@keyframes ${f} ${r}`,y.cssRules.length));const w=i.style.animation||"";return i.style.animation=`${w?`${w}, `:""}${f} ${t}ms linear ${n}ms 1 both`,Ji+=1,f}function fe(i,e){const a=(i.style.animation||"").split(", "),t=a.filter(e?o=>o.indexOf(e)<0:o=>o.indexOf("__svelte")===-1),n=a.length-t.length;n&&(i.style.animation=t.join(", "),Ji-=n,Ji||wa())}function wa(){oe(()=>{Ji||(zi.forEach(i=>{const{ownerNode:e}=i.stylesheet;e&&k(e)}),zi.clear())})}let re;function wi(i){re=i}const ui=[],ye=[];let fi=[];const be=[],Aa=Promise.resolve();let Zi=!1;function xa(){Zi||(Zi=!0,Aa.then(na))}function ci(i){fi.push(i)}const Yi=new Set;let di=0;function na(){if(di!==0)return;const i=re;do{try{for(;di<ui.length;){const e=ui[di];di++,wi(e),Ca(e.$$)}}catch(e){throw ui.length=0,di=0,e}for(wi(null),ui.length=0,di=0;ye.length;)ye.pop()();for(let e=0;e<fi.length;e+=1){const a=fi[e];Yi.has(a)||(Yi.add(a),a())}fi.length=0}while(ui.length);for(;be.length;)be.pop()();Zi=!1,Yi.clear(),wi(i)}function Ca(i){if(i.fragment!==null){i.update(),ii(i.before_update);const e=i.dirty;i.dirty=[-1],i.fragment&&i.fragment.p(i.ctx,e),i.after_update.forEach(ci)}}function Ta(i){const e=[],a=[];fi.forEach(t=>i.indexOf(t)===-1?e.push(t):a.push(t)),a.forEach(t=>t()),fi=e}let gi;function Sa(){return gi||(gi=Promise.resolve(),gi.then(()=>{gi=null})),gi}function ge(i,e,a){i.dispatchEvent(ya(`${e?"intro":"outro"}${a}`))}const Di=new Set;let ri;function Qi(){ri={r:0,c:[],p:ri}}function $i(){ri.r||ii(ri.c),ri=ri.p}function G(i,e){i&&i.i&&(Di.delete(i),i.i(e))}function Z(i,e,a,t){if(i&&i.o){if(Di.has(i))return;Di.add(i),ri.c.push(()=>{Di.delete(i),t&&(a&&i.d(1),t())}),i.o(e)}else t&&t()}const Ma={duration:0};function Ia(i,e,a){const t={direction:"in"};let n=e(i,a,t),o=!1,s,c,m=0;function d(){s&&fe(i,s)}function r(){const{delay:p=0,duration:y=300,easing:x=ne,tick:w=R,css:v}=n||Ma;v&&(s=va(i,0,1,y,p,x,v,m++)),w(0,1);const h=$e()+p,l=h+y;c&&c.abort(),o=!0,ci(()=>ge(i,!0,"start")),c=ea(u=>{if(o){if(u>=l)return w(1,0),ge(i,!0,"end"),d(),o=!1;if(u>=h){const g=x((u-h)/y);w(g,1-g)}}return o})}let f=!1;return{start(){f||(f=!0,fe(i),yi(n)?(n=n(t),Sa().then(r)):r())},invalidate(){f=!1},end(){o&&(d(),o=!1)}}}function Q(i){return(i==null?void 0:i.length)!==void 0?i:Array.from(i)}function qi(i){i&&i.c()}function Ci(i,e,a){const{fragment:t,after_update:n}=i.$$;t&&t.m(e,a),ci(()=>{const o=i.$$.on_mount.map(Ze).filter(yi);i.$$.on_destroy?i.$$.on_destroy.push(...o):ii(o),i.$$.on_mount=[]}),n.forEach(ci)}function Ti(i,e){const a=i.$$;a.fragment!==null&&(Ta(a.after_update),ii(a.on_destroy),a.fragment&&a.fragment.d(e),a.on_destroy=a.fragment=null,a.ctx=[])}function _a(i,e){i.$$.dirty[0]===-1&&(ui.push(i),xa(),i.$$.dirty.fill(0)),i.$$.dirty[e/31|0]|=1<<e%31}function Si(i,e,a,t,n,o,s=null,c=[-1]){const m=re;wi(i);const d=i.$$={fragment:null,ctx:[],props:o,update:R,not_equal:n,bound:ue(),on_mount:[],on_destroy:[],on_disconnect:[],before_update:[],after_update:[],context:new Map(e.context||(m?m.$$.context:[])),callbacks:ue(),dirty:c,skip_bound:!1,root:e.target||m.$$.root};s&&s(d.root);let r=!1;if(d.ctx=a?a(i,e.props||{},(f,p,...y)=>{const x=y.length?y[0]:p;return d.ctx&&n(d.ctx[f],d.ctx[f]=x)&&(!d.skip_bound&&d.bound[f]&&d.bound[f](x),r&&_a(i,f)),p}):[],d.update(),r=!0,ii(d.before_update),d.fragment=t?t(d.ctx):!1,e.target){if(e.hydrate){const f=pa(e.target);d.fragment&&d.fragment.l(f),f.forEach(k)}else d.fragment&&d.fragment.c();e.intro&&G(i.$$.fragment),Ci(i,e.target,e.anchor),na()}wi(m)}class Mi{constructor(){Vi(this,"$$");Vi(this,"$$set")}$destroy(){Ti(this,1),this.$destroy=R}$on(e,a){if(!yi(a))return R;const t=this.$$.callbacks[e]||(this.$$.callbacks[e]=[]);return t.push(a),()=>{const n=t.indexOf(a);n!==-1&&t.splice(n,1)}}$set(e){this.$$set&&!da(e)&&(this.$$.skip_bound=!0,this.$$set(e),this.$$.skip_bound=!1)}}const Ea="4";typeof window<"u"&&(window.__svelte||(window.__svelte={v:new Set})).v.add(Ea);const mi=[];function Gi(i,e=R){let a;const t=new Set;function n(c){if(bi(i,c)&&(i=c,a)){const m=!mi.length;for(const d of t)d[1](),mi.push(d,i);if(m){for(let d=0;d<mi.length;d+=2)mi[d][0](mi[d+1]);mi.length=0}}}function o(c){n(c(i))}function s(c,m=R){const d=[c,m];return t.add(d),t.size===1&&(a=e(n,o)||R),c(i),()=>{t.delete(d),t.size===0&&a&&(a(),a=null)}}return{set:n,update:o,subscribe:s}}const ve=Gi(0),we=Gi(0),ie=Math.PI,ee=2*ie,si=1e-6,La=ee-si;function oa(i){this._+=i[0];for(let e=1,a=i.length;e<a;++e)this._+=arguments[e]+i[e]}function ka(i){let e=Math.floor(i);if(!(e>=0))throw new Error(`invalid digits: ${i}`);if(e>15)return oa;const a=10**e;return function(t){this._+=t[0];for(let n=1,o=t.length;n<o;++n)this._+=Math.round(arguments[n]*a)/a+t[n]}}class Na{constructor(e){this._x0=this._y0=this._x1=this._y1=null,this._="",this._append=e==null?oa:ka(e)}moveTo(e,a){this._append`M${this._x0=this._x1=+e},${this._y0=this._y1=+a}`}closePath(){this._x1!==null&&(this._x1=this._x0,this._y1=this._y0,this._append`Z`)}lineTo(e,a){this._append`L${this._x1=+e},${this._y1=+a}`}quadraticCurveTo(e,a,t,n){this._append`Q${+e},${+a},${this._x1=+t},${this._y1=+n}`}bezierCurveTo(e,a,t,n,o,s){this._append`C${+e},${+a},${+t},${+n},${this._x1=+o},${this._y1=+s}`}arcTo(e,a,t,n,o){if(e=+e,a=+a,t=+t,n=+n,o=+o,o<0)throw new Error(`negative radius: ${o}`);let s=this._x1,c=this._y1,m=t-e,d=n-a,r=s-e,f=c-a,p=r*r+f*f;if(this._x1===null)this._append`M${this._x1=e},${this._y1=a}`;else if(p>si)if(!(Math.abs(f*m-d*r)>si)||!o)this._append`L${this._x1=e},${this._y1=a}`;else{let y=t-s,x=n-c,w=m*m+d*d,v=y*y+x*x,h=Math.sqrt(w),l=Math.sqrt(p),u=o*Math.tan((ie-Math.acos((w+p-v)/(2*h*l)))/2),g=u/l,A=u/h;Math.abs(g-1)>si&&this._append`L${e+g*r},${a+g*f}`,this._append`A${o},${o},0,0,${+(f*y>r*x)},${this._x1=e+A*m},${this._y1=a+A*d}`}}arc(e,a,t,n,o,s){if(e=+e,a=+a,t=+t,s=!!s,t<0)throw new Error(`negative radius: ${t}`);let c=t*Math.cos(n),m=t*Math.sin(n),d=e+c,r=a+m,f=1^s,p=s?n-o:o-n;this._x1===null?this._append`M${d},${r}`:(Math.abs(this._x1-d)>si||Math.abs(this._y1-r)>si)&&this._append`L${d},${r}`,t&&(p<0&&(p=p%ee+ee),p>La?this._append`A${t},${t},0,1,${f},${e-c},${a-m}A${t},${t},0,1,${f},${this._x1=d},${this._y1=r}`:p>si&&this._append`A${t},${t},0,${+(p>=ie)},${f},${this._x1=e+t*Math.cos(o)},${this._y1=a+t*Math.sin(o)}`)}rect(e,a,t,n){this._append`M${this._x0=this._x1=+e},${this._y0=this._y1=+a}h${t=+t}v${+n}h${-t}Z`}toString(){return this._}}function Da(i){var e=0,a=i.children,t=a&&a.length;if(!t)e=1;else for(;--t>=0;)e+=a[t].value;i.value=e}function za(){return this.eachAfter(Da)}function Ja(i,e){let a=-1;for(const t of this)i.call(e,t,++a,this);return this}function Pa(i,e){for(var a=this,t=[a],n,o,s=-1;a=t.pop();)if(i.call(e,a,++s,this),n=a.children)for(o=n.length-1;o>=0;--o)t.push(n[o]);return this}function Ba(i,e){for(var a=this,t=[a],n=[],o,s,c,m=-1;a=t.pop();)if(n.push(a),o=a.children)for(s=0,c=o.length;s<c;++s)t.push(o[s]);for(;a=n.pop();)i.call(e,a,++m,this);return this}function Fa(i,e){let a=-1;for(const t of this)if(i.call(e,t,++a,this))return t}function qa(i){return this.eachAfter(function(e){for(var a=+i(e.data)||0,t=e.children,n=t&&t.length;--n>=0;)a+=t[n].value;e.value=a})}function Ga(i){return this.eachBefore(function(e){e.children&&e.children.sort(i)})}function Ra(i){for(var e=this,a=Oa(e,i),t=[e];e!==a;)e=e.parent,t.push(e);for(var n=t.length;i!==a;)t.splice(n,0,i),i=i.parent;return t}function Oa(i,e){if(i===e)return i;var a=i.ancestors(),t=e.ancestors(),n=null;for(i=a.pop(),e=t.pop();i===e;)n=i,i=a.pop(),e=t.pop();return n}function Ha(){for(var i=this,e=[i];i=i.parent;)e.push(i);return e}function Wa(){return Array.from(this)}function ja(){var i=[];return this.eachBefore(function(e){e.children||i.push(e)}),i}function Ua(){var i=this,e=[];return i.each(function(a){a!==i&&e.push({source:a.parent,target:a})}),e}function*Va(){var i=this,e,a=[i],t,n,o;do for(e=a.reverse(),a=[];i=e.pop();)if(yield i,t=i.children)for(n=0,o=t.length;n<o;++n)a.push(t[n]);while(a.length)}function ce(i,e){i instanceof Map?(i=[void 0,i],e===void 0&&(e=Ka)):e===void 0&&(e=Xa);for(var a=new Pi(i),t,n=[a],o,s,c,m;t=n.pop();)if((s=e(t.data))&&(m=(s=Array.from(s)).length))for(t.children=s,c=m-1;c>=0;--c)n.push(o=s[c]=new Pi(s[c])),o.parent=t,o.depth=t.depth+1;return a.eachBefore(Qa)}function Ya(){return ce(this).eachBefore(Za)}function Xa(i){return i.children}function Ka(i){return Array.isArray(i)?i[1]:null}function Za(i){i.data.value!==void 0&&(i.value=i.data.value),i.data=i.data.data}function Qa(i){var e=0;do i.height=e;while((i=i.parent)&&i.height<++e)}function Pi(i){this.data=i,this.depth=this.height=0,this.parent=null}Pi.prototype=ce.prototype={constructor:Pi,count:za,each:Ja,eachAfter:Ba,eachBefore:Pa,find:Fa,sum:qa,sort:Ga,path:Ra,ancestors:Ha,descendants:Wa,leaves:ja,links:Ua,copy:Ya,[Symbol.iterator]:Va};function $a(i){i.x0=Math.round(i.x0),i.y0=Math.round(i.y0),i.x1=Math.round(i.x1),i.y1=Math.round(i.y1)}function it(i,e,a,t,n){for(var o=i.children,s,c=-1,m=o.length,d=i.value&&(t-e)/i.value;++c<m;)s=o[c],s.y0=a,s.y1=n,s.x0=e,s.x1=e+=s.value*d}function et(){var i=1,e=1,a=0,t=!1;function n(s){var c=s.height+1;return s.x0=s.y0=a,s.x1=i,s.y1=e/c,s.eachBefore(o(e,c)),t&&s.eachBefore($a),s}function o(s,c){return function(m){m.children&&it(m,m.x0,s*(m.depth+1)/c,m.x1,s*(m.depth+2)/c);var d=m.x0,r=m.y0,f=m.x1-a,p=m.y1-a;f<d&&(d=f=(d+f)/2),p<r&&(r=p=(r+p)/2),m.x0=d,m.y0=r,m.x1=f,m.y1=p}}return n.round=function(s){return arguments.length?(t=!!s,n):t},n.size=function(s){return arguments.length?(i=+s[0],e=+s[1],n):[i,e]},n.padding=function(s){return arguments.length?(a=+s,n):a},n}function ei(i){return function(){return i}}const Ae=Math.abs,B=Math.atan2,oi=Math.cos,at=Math.max,Xi=Math.min,K=Math.sin,hi=Math.sqrt,q=1e-12,xi=Math.PI,Bi=xi/2,tt=2*xi;function nt(i){return i>1?0:i<-1?xi:Math.acos(i)}function xe(i){return i>=1?Bi:i<=-1?-Bi:Math.asin(i)}function ot(i){let e=3;return i.digits=function(a){if(!arguments.length)return e;if(a==null)e=null;else{const t=Math.floor(a);if(!(t>=0))throw new RangeError(`invalid digits: ${a}`);e=t}return i},()=>new Na(e)}function st(i){return i.innerRadius}function rt(i){return i.outerRadius}function ct(i){return i.startAngle}function lt(i){return i.endAngle}function dt(i){return i&&i.padAngle}function mt(i,e,a,t,n,o,s,c){var m=a-i,d=t-e,r=s-n,f=c-o,p=f*m-r*d;if(!(p*p<q))return p=(r*(e-o)-f*(i-n))/p,[i+p*m,e+p*d]}function Ni(i,e,a,t,n,o,s){var c=i-a,m=e-t,d=(s?o:-o)/hi(c*c+m*m),r=d*m,f=-d*c,p=i+r,y=e+f,x=a+r,w=t+f,v=(p+x)/2,h=(y+w)/2,l=x-p,u=w-y,g=l*l+u*u,A=n-o,L=p*w-x*y,O=(u<0?-1:1)*hi(at(0,A*A*g-L*L)),V=(L*u-l*O)/g,Y=(-L*l-u*O)/g,H=(L*u+l*O)/g,J=(-L*l+u*O)/g,_=V-v,C=Y-h,S=H-v,N=J-h;return _*_+C*C>S*S+N*N&&(V=H,Y=J),{cx:V,cy:Y,x01:-r,y01:-f,x11:V*(n/A-1),y11:Y*(n/A-1)}}function ut(){var i=st,e=rt,a=ei(0),t=null,n=ct,o=lt,s=dt,c=null,m=ot(d);function d(){var r,f,p=+i.apply(this,arguments),y=+e.apply(this,arguments),x=n.apply(this,arguments)-Bi,w=o.apply(this,arguments)-Bi,v=Ae(w-x),h=w>x;if(c||(c=r=m()),y<p&&(f=y,y=p,p=f),!(y>q))c.moveTo(0,0);else if(v>tt-q)c.moveTo(y*oi(x),y*K(x)),c.arc(0,0,y,x,w,!h),p>q&&(c.moveTo(p*oi(w),p*K(w)),c.arc(0,0,p,w,x,h));else{var l=x,u=w,g=x,A=w,L=v,O=v,V=s.apply(this,arguments)/2,Y=V>q&&(t?+t.apply(this,arguments):hi(p*p+y*y)),H=Xi(Ae(y-p)/2,+a.apply(this,arguments)),J=H,_=H,C,S;if(Y>q){var N=xe(Y/p*K(V)),D=xe(Y/y*K(V));(L-=N*2)>q?(N*=h?1:-1,g+=N,A-=N):(L=0,g=A=(x+w)/2),(O-=D*2)>q?(D*=h?1:-1,l+=D,u-=D):(O=0,l=u=(x+w)/2)}var P=y*oi(l),E=y*K(l),ni=p*oi(A),Ii=p*K(A);if(H>q){var _i=y*oi(u),Ei=y*K(u),Ri=p*oi(g),Oi=p*K(g),$;if(v<xi)if($=mt(P,E,Ri,Oi,_i,Ei,ni,Ii)){var Hi=P-$[0],Wi=E-$[1],ji=_i-$[0],Ui=Ei-$[1],le=1/K(nt((Hi*ji+Wi*Ui)/(hi(Hi*Hi+Wi*Wi)*hi(ji*ji+Ui*Ui)))/2),de=hi($[0]*$[0]+$[1]*$[1]);J=Xi(H,(p-de)/(le-1)),_=Xi(H,(y-de)/(le+1))}else J=_=0}O>q?_>q?(C=Ni(Ri,Oi,P,E,y,_,h),S=Ni(_i,Ei,ni,Ii,y,_,h),c.moveTo(C.cx+C.x01,C.cy+C.y01),_<H?c.arc(C.cx,C.cy,_,B(C.y01,C.x01),B(S.y01,S.x01),!h):(c.arc(C.cx,C.cy,_,B(C.y01,C.x01),B(C.y11,C.x11),!h),c.arc(0,0,y,B(C.cy+C.y11,C.cx+C.x11),B(S.cy+S.y11,S.cx+S.x11),!h),c.arc(S.cx,S.cy,_,B(S.y11,S.x11),B(S.y01,S.x01),!h))):(c.moveTo(P,E),c.arc(0,0,y,l,u,!h)):c.moveTo(P,E),!(p>q)||!(L>q)?c.lineTo(ni,Ii):J>q?(C=Ni(ni,Ii,_i,Ei,p,-J,h),S=Ni(P,E,Ri,Oi,p,-J,h),c.lineTo(C.cx+C.x01,C.cy+C.y01),J<H?c.arc(C.cx,C.cy,J,B(C.y01,C.x01),B(S.y01,S.x01),!h):(c.arc(C.cx,C.cy,J,B(C.y01,C.x01),B(C.y11,C.x11),!h),c.arc(0,0,p,B(C.cy+C.y11,C.cx+C.x11),B(S.cy+S.y11,S.cx+S.x11),h),c.arc(S.cx,S.cy,J,B(S.y11,S.x11),B(S.y01,S.x01),!h))):c.arc(0,0,p,A,g,h)}if(c.closePath(),r)return c=null,r+""||null}return d.centroid=function(){var r=(+i.apply(this,arguments)+ +e.apply(this,arguments))/2,f=(+n.apply(this,arguments)+ +o.apply(this,arguments))/2-xi/2;return[oi(f)*r,K(f)*r]},d.innerRadius=function(r){return arguments.length?(i=typeof r=="function"?r:ei(+r),d):i},d.outerRadius=function(r){return arguments.length?(e=typeof r=="function"?r:ei(+r),d):e},d.cornerRadius=function(r){return arguments.length?(a=typeof r=="function"?r:ei(+r),d):a},d.padRadius=function(r){return arguments.length?(t=r==null?null:typeof r=="function"?r:ei(+r),d):t},d.startAngle=function(r){return arguments.length?(n=typeof r=="function"?r:ei(+r),d):n},d.endAngle=function(r){return arguments.length?(o=typeof r=="function"?r:ei(+r),d):o},d.padAngle=function(r){return arguments.length?(s=typeof r=="function"?r:ei(+r),d):s},d.context=function(r){return arguments.length?(c=r??null,d):c},d}function vi(i,e,a){this.k=i,this.x=e,this.y=a}vi.prototype={constructor:vi,scale:function(i){return i===1?this:new vi(this.k*i,this.x,this.y)},translate:function(i,e){return i===0&e===0?this:new vi(this.k,this.x+this.k*i,this.y+this.k*e)},apply:function(i){return[i[0]*this.k+this.x,i[1]*this.k+this.y]},applyX:function(i){return i*this.k+this.x},applyY:function(i){return i*this.k+this.y},invert:function(i){return[(i[0]-this.x)/this.k,(i[1]-this.y)/this.k]},invertX:function(i){return(i-this.x)/this.k},invertY:function(i){return(i-this.y)/this.k},rescaleX:function(i){return i.copy().domain(i.range().map(this.invertX,this).map(i.invert,i))},rescaleY:function(i){return i.copy().domain(i.range().map(this.invertY,this).map(i.invert,i))},toString:function(){return"translate("+this.x+","+this.y+") scale("+this.k+")"}};vi.prototype;function ai(i){return i<.5?4*i*i*i:.5*Math.pow(2*i-2,3)+1}function Ce(i){return Object.prototype.toString.call(i)==="[object Date]"}function ae(i,e){if(i===e||i!==i)return()=>i;const a=typeof i;if(a!==typeof e||Array.isArray(i)!==Array.isArray(e))throw new Error("Cannot interpolate values of different type");if(Array.isArray(i)){const t=e.map((n,o)=>ae(i[o],n));return n=>t.map(o=>o(n))}if(a==="object"){if(!i||!e)throw new Error("Object cannot be null");if(Ce(i)&&Ce(e)){i=i.getTime(),e=e.getTime();const o=e-i;return s=>new Date(i+s*o)}const t=Object.keys(e),n={};return t.forEach(o=>{n[o]=ae(i[o],e[o])}),o=>{const s={};return t.forEach(c=>{s[c]=n[c](o)}),s}}if(a==="number"){const t=e-i;return n=>i+n*t}throw new Error(`Cannot interpolate ${a} values`)}function ti(i,e={}){const a=Gi(i);let t,n=i;function o(s,c){if(i==null)return a.set(i=s),Promise.resolve();n=s;let m=t,d=!1,{delay:r=0,duration:f=400,easing:p=ne,interpolate:y=ae}=me(me({},e),c);if(f===0)return m&&(m.abort(),m=null),a.set(i=n),Promise.resolve();const x=$e()+r;let w;return t=ea(v=>{if(v<x)return!0;d||(w=y(i,s),typeof f=="function"&&(f=f(i,s)),d=!0),m&&(m.abort(),m=null);const h=v-x;return h>f?(a.set(i=s),!1):(a.set(i=w(p(h/f))),!0)}),t.promise}return{set:o,update:(s,c)=>o(s(n,i),c),subscribe:a.subscribe}}function ht(i){let e,a,t,n;return{c(){e=X("path"),b(e,"d",a=i[1](i[8])),M(e,"cursor",i[0].children?"pointer":"default"),b(e,"fill",i[2]),b(e,"fill-opacity",i[3]),b(e,"pointer-events",i[4]),b(e,"class","svelte-18d0bq")},m(o,s){z(o,e,s),t||(n=[U(e,"click",i[17]),U(e,"mouseover",function(){yi(i[6](i[0]))&&i[6](i[0]).apply(this,arguments)}),U(e,"mouseout",function(){yi(i[6](null))&&i[6](null).apply(this,arguments)})],t=!0)},p(o,[s]){i=o,s&258&&a!==(a=i[1](i[8]))&&b(e,"d",a),s&1&&M(e,"cursor",i[0].children?"pointer":"default"),s&4&&b(e,"fill",i[2]),s&8&&b(e,"fill-opacity",i[3]),s&16&&b(e,"pointer-events",i[4])},i:R,o:R,d(o){o&&k(e),t=!1,ii(n)}}}function pt(i,e,a){let t,n,o,s,c,{d:m}=e,{arc_d3:d}=e,{color:r}=e,{fill_opacity:f}=e,{pointer_events:p}=e,{handleClick:y}=e,{handleHover:x}=e,{handleSelection:w}=e,v=ti(m.current.x0,{duration:700,easing:ai});W(i,v,A=>a(16,c=A));let h=ti(m.current.x1,{duration:700,easing:ai});W(i,h,A=>a(15,s=A));let l=ti(m.current.y0,{duration:700,easing:ai});W(i,l,A=>a(14,o=A));let u=ti(m.current.y1,{duration:700,easing:ai});W(i,u,A=>a(13,n=A));const g=()=>{w(m.data.name),m.children&&y(m)};return i.$$set=A=>{"d"in A&&a(0,m=A.d),"arc_d3"in A&&a(1,d=A.arc_d3),"color"in A&&a(2,r=A.color),"fill_opacity"in A&&a(3,f=A.fill_opacity),"pointer_events"in A&&a(4,p=A.pointer_events),"handleClick"in A&&a(5,y=A.handleClick),"handleHover"in A&&a(6,x=A.handleHover),"handleSelection"in A&&a(7,w=A.handleSelection)},i.$$.update=()=>{i.$$.dirty&1&&(v.set(m.current.x0),h.set(m.current.x1),l.set(m.current.y0),u.set(m.current.y1)),i.$$.dirty&122880&&a(8,t={x0:c,x1:s,y0:o,y1:n})},[m,d,r,f,p,y,x,w,t,v,h,l,u,n,o,s,c,g]}class ft extends Mi{constructor(e){super(),Si(this,e,pt,ht,bi,{d:0,arc_d3:1,color:2,fill_opacity:3,pointer_events:4,handleClick:5,handleHover:6,handleSelection:7})}}function yt(i){let e,a,t;return{c(){e=X("text"),a=j(i[2]),b(e,"dy",i[0]),b(e,"font-size",i[3]),b(e,"fill-opacity",i[1]),b(e,"transform",t=i[12](i[4],i[5],i[6],i[7])),b(e,"class","svelte-1dq5844")},m(n,o){z(n,e,o),T(e,a)},p(n,[o]){o&4&&li(a,n[2]),o&1&&b(e,"dy",n[0]),o&8&&b(e,"font-size",n[3]),o&2&&b(e,"fill-opacity",n[1]),o&240&&t!==(t=n[12](n[4],n[5],n[6],n[7]))&&b(e,"transform",t)},i:R,o:R,d(n){n&&k(e)}}}function bt(i,e,a){let t,n,o,s,{dy:c}=e,{fill_opacity:m}=e,{title:d}=e,{d:r}=e,{radius:f}=e,{fontSize:p}=e,y=ti(r.current.x0,{duration:700,easing:ai});W(i,y,l=>a(4,t=l));let x=ti(r.current.x1,{duration:700,easing:ai});W(i,x,l=>a(5,n=l));let w=ti(r.current.y0,{duration:700,easing:ai});W(i,w,l=>a(6,o=l));let v=ti(r.current.y1,{duration:700,easing:ai});W(i,v,l=>a(7,s=l));function h(l,u,g,A){const L=(l+u)/2*180/Math.PI,O=(g+A)/2*f;return`rotate(${L-90}) translate(${O},0) rotate(${L<180?0:180})`}return i.$$set=l=>{"dy"in l&&a(0,c=l.dy),"fill_opacity"in l&&a(1,m=l.fill_opacity),"title"in l&&a(2,d=l.title),"d"in l&&a(13,r=l.d),"radius"in l&&a(14,f=l.radius),"fontSize"in l&&a(3,p=l.fontSize)},i.$$.update=()=>{i.$$.dirty&8192&&(y.set(r.current.x0),x.set(r.current.x1),w.set(r.current.y0),v.set(r.current.y1))},[c,m,d,p,t,n,o,s,y,x,w,v,h,r,f]}class gt extends Mi{constructor(e){super(),Si(this,e,bt,yt,bi,{dy:0,fill_opacity:1,title:2,d:13,radius:14,fontSize:3})}}const vt="Antibiotics",wt=[{name:"Other",children:[{name:"Aminoglycosides",data:[{name:"Amikacin",ATC_code:"J01GB06",EML:"Yes",value:1,"description.x":`Amikacin is a semi-synthetic aminoglycoside antibiotic that is derived from kanamycin A.FDA label Amikacin is synthesized by acylation with the l-(-)-γ-amino-α-hydroxybutyryl side chain at the C-1 amino group of the deoxystreptamine moiety of kanamycin A.\r
\r
Amikacin's unique property is that it exerts activity against more resistant gram-negative bacilli such as Acinetobacter baumanii and Pseudomonas aeruginosa. Amikacin also exerts excellent activity against most aerobic gram-negative bacilli from the Enterobacteriaceae family, including Nocardia and some Mycobacterium (M. avium-intracellulare, M. chelonae, and M. fortuitum). M. avium-intracellulare (MAC) is a type of nontuberculous mycobacteria (NTM) found in water and soil. Symptoms of this disease include a persistent cough, fatigue, weight loss, night sweats, and shortness of breath and the coughing up of blood.\r
\r
Several forms of amikacin are used currently, including an intravenous (IV) or intramuscular (IM) injection. In September 2018, a liposomal inhalation suspension of this drug was approved by the FDA for the treatment of lung disease caused by Mycobacterium avium complex (MAC) bacteria in a small population of patients with the disease who do not respond to traditional treatment.`,description:`Amikacin is a semi-synthetic aminoglycoside antibiotic that is derived from kanamycin A.FDA label Amikacin is synthesized by acylation with the l-(-)-γ-amino-α-hydroxybutyryl side chain at the C-1 amino group of the deoxystreptamine moiety of kanamycin A.\r
\r
Amikacin's unique property is that it exerts activity against more resistant gram-negative bacilli such as Acinetobacter baumanii and Pseudomonas aeruginosa. Amikacin also exerts excellent activity against most aerobic gram-negative bacilli from the Enterobacteriaceae family, including Nocardia and some Mycobacterium (M. avium-intracellulare, M. chelonae, and M. fortuitum). M. avium-intracellulare (MAC) is a type of nontuberculous mycobacteria (NTM) found in water and soil. Symptoms of this disease include a persistent cough, fatigue, weight loss, night sweats, and shortness of breath and the coughing up of blood.\r
\r
Several forms of amikacin are used currently, including an intravenous (IV) or intramuscular (IM) injection. In September 2018, a liposomal inhalation suspension of this drug was approved by the FDA for the treatment of lung disease caused by Mycobacterium avium complex (MAC) bacteria in a small population of patients with the disease who do not respond to traditional treatment.`},{name:"Arbekacin",ATC_code:"J01GB12",EML:"No",value:1,"description.x":"An semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant Staphylococcus aureus (MRSA).",description:"An semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant Staphylococcus aureus (MRSA)."},{name:"Bekanamycin",ATC_code:"J01GB13",EML:"No",value:1,"description.x":"Other aminoglycosides",description:"Other aminoglycosides"},{name:"Dibekacin",ATC_code:"J01GB09",EML:"No",value:1,"description.x":"Dibekacin is an aminoglycoside antibiotic marketed in Japan .",description:"Dibekacin is an aminoglycoside antibiotic marketed in Japan ."},{name:"Gentamicin",ATC_code:"J01GB03",EML:"Yes",value:1,"description.x":`Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from Micromonospora purpurea in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability. Gentamicin is effective against both gram-positive and gram-negative organisms but is particularly useful for the treatment of severe gram-negative infections including those caused by Pseudomonas aeruginosa. There is the added benefit of synergy when gentamicin is co-administered with other antibacterials such as beta-lactams. This synergistic activity is not only important for the treatment of complex infections, but can also contribute to dose optimization and reduced adverse effects.\r
\r
Although gentamicin is well-established and may be used in a variety of clinical applications, it is also associated with severe adverse effects including nephrotoxicity and ototoxicity which may limit its use.`,description:`Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from Micromonospora purpurea in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability. Gentamicin is effective against both gram-positive and gram-negative organisms but is particularly useful for the treatment of severe gram-negative infections including those caused by Pseudomonas aeruginosa. There is the added benefit of synergy when gentamicin is co-administered with other antibacterials such as beta-lactams. This synergistic activity is not only important for the treatment of complex infections, but can also contribute to dose optimization and reduced adverse effects.\r
\r
Although gentamicin is well-established and may be used in a variety of clinical applications, it is also associated with severe adverse effects including nephrotoxicity and ototoxicity which may limit its use.`},{name:"Isepamicin",ATC_code:"J01GB11",EML:"No",value:1,"description.x":"Other aminoglycosides",description:"Other aminoglycosides"},{name:"Kanamycin_IV",ATC_code:"J01GB04",EML:"No",value:1,"description.x":"Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate.",description:"Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate."},{name:"Kanamycin_oral",ATC_code:"A07AA08",EML:"No",value:1,"description.x":"Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate.",description:"Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate."},{name:"Micronomicin",ATC_code:"to be assigned",EML:"No",value:1,description:"Micronomicin is an aminoglycoside antibiotic primarily used for treating eye infections. It falls under the category of systemic antibiotics and is known for its effectiveness against specific bacterial infections. Micronomicin is administered either as eye drops or intravenously. It has been identified as a useful medication in ophthalmology due to its properties as an aminoglycoside antibiotic, a class known for treating various bacterial infections. Source: Wikepedia"},{name:"Neomycin_IV",ATC_code:"J01GB05",EML:"No",value:1,"description.x":`Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin. Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. \r
\r
Neomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units. Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma. It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear. Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye. Neomycin is also available in over-the-counter topical products to prevent minor skin infections.`,description:`Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin. Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. \r
\r
Neomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units. Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma. It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear. Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye. Neomycin is also available in over-the-counter topical products to prevent minor skin infections.`},{name:"Neomycin_oral",ATC_code:"A07AA01",EML:"No",value:1,"description.x":`Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin. Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. \r
\r
Neomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units. Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma. It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear. Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye. Neomycin is also available in over-the-counter topical products to prevent minor skin infections.`,description:`Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin. Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. \r
\r
Neomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units. Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma. It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear. Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye. Neomycin is also available in over-the-counter topical products to prevent minor skin infections.`},{name:"Netilmicin",ATC_code:"J01GB07",EML:"No",value:1,"description.x":"Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity. Netilmicin inhibits protein synthesis in susceptible organisms by binding to the bacterial 30S ribosomal subunit and interfering with mRNA binding and the acceptor tRNA site. The bactericidal effect of netilmiicin is not fully understood.",description:"Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity. Netilmicin inhibits protein synthesis in susceptible organisms by binding to the bacterial 30S ribosomal subunit and interfering with mRNA binding and the acceptor tRNA site. The bactericidal effect of netilmiicin is not fully understood."},{name:"Plazomicin",ATC_code:"J01GB14",EML:"Yes",value:1,"description.x":"Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to  at position 1 and 2-hydroxyethyl group at position 6' . It was designed to evade all clinically relevant aminoglycoside-modifying enzymes, which contribute to the main resistance mechanism for aminoglycoside therapy . However, acquired resistance of aminoglycosides may arise through over expression of efflux pumps and ribosomal modification by bacteria, which results from amino acid or rRNA sequence mutations . Like other aminoglycosides, plazomicin is ineffective against bacterial isolates that produce 16S rRNA methyltransferases FDA Label. Plazomicin mediates the antibacterial activity against pathogens including carbapenem-resistant (CRE) and extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae. It mediates the antibacterial activity by binding to bacterial 30S ribosomal subunit and inhibiting protein synthesis FDA Label. On June 28th, 2018, plazomicin sulfate was approved by the FDA for use in adult patients for the treatment of complicated urinary tract infections (cUTI) including Pyelonephritis. It is marketed as Zemdri and is administered via once-daily intravenous infusion.",description:"Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to  at position 1 and 2-hydroxyethyl group at position 6' . It was designed to evade all clinically relevant aminoglycoside-modifying enzymes, which contribute to the main resistance mechanism for aminoglycoside therapy . However, acquired resistance of aminoglycosides may arise through over expression of efflux pumps and ribosomal modification by bacteria, which results from amino acid or rRNA sequence mutations . Like other aminoglycosides, plazomicin is ineffective against bacterial isolates that produce 16S rRNA methyltransferases FDA Label. Plazomicin mediates the antibacterial activity against pathogens including carbapenem-resistant (CRE) and extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae. It mediates the antibacterial activity by binding to bacterial 30S ribosomal subunit and inhibiting protein synthesis FDA Label. On June 28th, 2018, plazomicin sulfate was approved by the FDA for use in adult patients for the treatment of complicated urinary tract infections (cUTI) including Pyelonephritis. It is marketed as Zemdri and is administered via once-daily intravenous infusion."},{name:"Ribostamycin",ATC_code:"J01GB10",EML:"No",value:1,"description.x":"Ribostamycin is an aminoglycoside antibiotic isolated from Streptomyces ribosidificus listed as one of the World Health Organization's critically important antimicrobials.",description:"Ribostamycin is an aminoglycoside antibiotic isolated from Streptomyces ribosidificus listed as one of the World Health Organization's critically important antimicrobials."},{name:"Sisomicin",ATC_code:"J01GB08",EML:"No",value:1,"description.x":"Sisomicin has been used in trials studying the treatment of Pyoderma.",description:"Sisomicin has been used in trials studying the treatment of Pyoderma."},{name:"Streptoduocin",ATC_code:"J01GA02",EML:"No",value:1,description:"Streptoduocin is an aminoglycoside antibiotic, which is a combination of streptomycin and dihydrostreptomycin. These components make it effective against a range of bacterial infections. Aminoglycoside antibiotics like streptoduocin work by interfering with bacterial protein synthesis, which is crucial for their growth and survival. This type of antibiotic is known for its effectiveness, particularly against certain types of bacteria. Source: Wikepedia"},{name:"Streptomycin_IV",ATC_code:"J01GA01",EML:"No",value:1,"description.x":"Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s. Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity. Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis.",description:"Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s. Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity. Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis."},{name:"Streptomycin_oral",ATC_code:"A07AA04",EML:"No",value:1,"description.x":"Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s. Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity. Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis.",description:"Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s. Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity. Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis."},{name:"Tobramycin",ATC_code:"J01GB01",EML:"No",value:1,"description.x":`Aminoglycosides, many of which are derived directly from Streptomyces spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms. Inhaled tobramycin is notable for its use in treating chronic Pseudomonas aeruginosa infections in cystic fibrosis patients, as P. aeruginosa is notoriously inherently resistant to many antibiotics. However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria. Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics such as β-lactams and cephalosporins.\r
\r
Tobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to the eye (ophthalmic).`,description:`Aminoglycosides, many of which are derived directly from Streptomyces spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms. Inhaled tobramycin is notable for its use in treating chronic Pseudomonas aeruginosa infections in cystic fibrosis patients, as P. aeruginosa is notoriously inherently resistant to many antibiotics. However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria. Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics such as β-lactams and cephalosporins.\r
\r
Tobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to the eye (ophthalmic).`}],children:[{name:"Access",children:[{name:"Amikacin",ATC_code:"J01GB06",EML:"Yes",value:1,"description.x":`Amikacin is a semi-synthetic aminoglycoside antibiotic that is derived from kanamycin A.FDA label Amikacin is synthesized by acylation with the l-(-)-γ-amino-α-hydroxybutyryl side chain at the C-1 amino group of the deoxystreptamine moiety of kanamycin A.\r
\r
Amikacin's unique property is that it exerts activity against more resistant gram-negative bacilli such as Acinetobacter baumanii and Pseudomonas aeruginosa. Amikacin also exerts excellent activity against most aerobic gram-negative bacilli from the Enterobacteriaceae family, including Nocardia and some Mycobacterium (M. avium-intracellulare, M. chelonae, and M. fortuitum). M. avium-intracellulare (MAC) is a type of nontuberculous mycobacteria (NTM) found in water and soil. Symptoms of this disease include a persistent cough, fatigue, weight loss, night sweats, and shortness of breath and the coughing up of blood.\r
\r
Several forms of amikacin are used currently, including an intravenous (IV) or intramuscular (IM) injection. In September 2018, a liposomal inhalation suspension of this drug was approved by the FDA for the treatment of lung disease caused by Mycobacterium avium complex (MAC) bacteria in a small population of patients with the disease who do not respond to traditional treatment.`,description:`Amikacin is a semi-synthetic aminoglycoside antibiotic that is derived from kanamycin A.FDA label Amikacin is synthesized by acylation with the l-(-)-γ-amino-α-hydroxybutyryl side chain at the C-1 amino group of the deoxystreptamine moiety of kanamycin A.\r
\r
Amikacin's unique property is that it exerts activity against more resistant gram-negative bacilli such as Acinetobacter baumanii and Pseudomonas aeruginosa. Amikacin also exerts excellent activity against most aerobic gram-negative bacilli from the Enterobacteriaceae family, including Nocardia and some Mycobacterium (M. avium-intracellulare, M. chelonae, and M. fortuitum). M. avium-intracellulare (MAC) is a type of nontuberculous mycobacteria (NTM) found in water and soil. Symptoms of this disease include a persistent cough, fatigue, weight loss, night sweats, and shortness of breath and the coughing up of blood.\r
\r
Several forms of amikacin are used currently, including an intravenous (IV) or intramuscular (IM) injection. In September 2018, a liposomal inhalation suspension of this drug was approved by the FDA for the treatment of lung disease caused by Mycobacterium avium complex (MAC) bacteria in a small population of patients with the disease who do not respond to traditional treatment.`},{name:"Gentamicin",ATC_code:"J01GB03",EML:"Yes",value:1,"description.x":`Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from Micromonospora purpurea in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability. Gentamicin is effective against both gram-positive and gram-negative organisms but is particularly useful for the treatment of severe gram-negative infections including those caused by Pseudomonas aeruginosa. There is the added benefit of synergy when gentamicin is co-administered with other antibacterials such as beta-lactams. This synergistic activity is not only important for the treatment of complex infections, but can also contribute to dose optimization and reduced adverse effects.\r
\r
Although gentamicin is well-established and may be used in a variety of clinical applications, it is also associated with severe adverse effects including nephrotoxicity and ototoxicity which may limit its use.`,description:`Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from Micromonospora purpurea in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability. Gentamicin is effective against both gram-positive and gram-negative organisms but is particularly useful for the treatment of severe gram-negative infections including those caused by Pseudomonas aeruginosa. There is the added benefit of synergy when gentamicin is co-administered with other antibacterials such as beta-lactams. This synergistic activity is not only important for the treatment of complex infections, but can also contribute to dose optimization and reduced adverse effects.\r
\r
Although gentamicin is well-established and may be used in a variety of clinical applications, it is also associated with severe adverse effects including nephrotoxicity and ototoxicity which may limit its use.`}]},{name:"Watch",children:[{name:"Arbekacin",ATC_code:"J01GB12",EML:"No",value:1,"description.x":"An semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant Staphylococcus aureus (MRSA).",description:"An semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant Staphylococcus aureus (MRSA)."},{name:"Bekanamycin",ATC_code:"J01GB13",EML:"No",value:1,"description.x":"Other aminoglycosides",description:"Other aminoglycosides"},{name:"Dibekacin",ATC_code:"J01GB09",EML:"No",value:1,"description.x":"Dibekacin is an aminoglycoside antibiotic marketed in Japan .",description:"Dibekacin is an aminoglycoside antibiotic marketed in Japan ."},{name:"Isepamicin",ATC_code:"J01GB11",EML:"No",value:1,"description.x":"Other aminoglycosides",description:"Other aminoglycosides"},{name:"Kanamycin_IV",ATC_code:"J01GB04",EML:"No",value:1,"description.x":"Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate.",description:"Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate."},{name:"Kanamycin_oral",ATC_code:"A07AA08",EML:"No",value:1,"description.x":"Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate.",description:"Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate."},{name:"Micronomicin",ATC_code:"to be assigned",EML:"No",value:1,description:"Micronomicin is an aminoglycoside antibiotic primarily used for treating eye infections. It falls under the category of systemic antibiotics and is known for its effectiveness against specific bacterial infections. Micronomicin is administered either as eye drops or intravenously. It has been identified as a useful medication in ophthalmology due to its properties as an aminoglycoside antibiotic, a class known for treating various bacterial infections. Source: Wikepedia"},{name:"Neomycin_IV",ATC_code:"J01GB05",EML:"No",value:1,"description.x":`Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin. Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. \r
\r
Neomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units. Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma. It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear. Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye. Neomycin is also available in over-the-counter topical products to prevent minor skin infections.`,description:`Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin. Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. \r
\r
Neomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units. Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma. It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear. Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye. Neomycin is also available in over-the-counter topical products to prevent minor skin infections.`},{name:"Neomycin_oral",ATC_code:"A07AA01",EML:"No",value:1,"description.x":`Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin. Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. \r
\r
Neomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units. Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma. It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear. Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye. Neomycin is also available in over-the-counter topical products to prevent minor skin infections.`,description:`Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin. Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. \r
\r
Neomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units. Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma. It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear. Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye. Neomycin is also available in over-the-counter topical products to prevent minor skin infections.`},{name:"Netilmicin",ATC_code:"J01GB07",EML:"No",value:1,"description.x":"Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity. Netilmicin inhibits protein synthesis in susceptible organisms by binding to the bacterial 30S ribosomal subunit and interfering with mRNA binding and the acceptor tRNA site. The bactericidal effect of netilmiicin is not fully understood.",description:"Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity. Netilmicin inhibits protein synthesis in susceptible organisms by binding to the bacterial 30S ribosomal subunit and interfering with mRNA binding and the acceptor tRNA site. The bactericidal effect of netilmiicin is not fully understood."},{name:"Ribostamycin",ATC_code:"J01GB10",EML:"No",value:1,"description.x":"Ribostamycin is an aminoglycoside antibiotic isolated from Streptomyces ribosidificus listed as one of the World Health Organization's critically important antimicrobials.",description:"Ribostamycin is an aminoglycoside antibiotic isolated from Streptomyces ribosidificus listed as one of the World Health Organization's critically important antimicrobials."},{name:"Sisomicin",ATC_code:"J01GB08",EML:"No",value:1,"description.x":"Sisomicin has been used in trials studying the treatment of Pyoderma.",description:"Sisomicin has been used in trials studying the treatment of Pyoderma."},{name:"Streptoduocin",ATC_code:"J01GA02",EML:"No",value:1,description:"Streptoduocin is an aminoglycoside antibiotic, which is a combination of streptomycin and dihydrostreptomycin. These components make it effective against a range of bacterial infections. Aminoglycoside antibiotics like streptoduocin work by interfering with bacterial protein synthesis, which is crucial for their growth and survival. This type of antibiotic is known for its effectiveness, particularly against certain types of bacteria. Source: Wikepedia"},{name:"Streptomycin_IV",ATC_code:"J01GA01",EML:"No",value:1,"description.x":"Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s. Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity. Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis.",description:"Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s. Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity. Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis."},{name:"Streptomycin_oral",ATC_code:"A07AA04",EML:"No",value:1,"description.x":"Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s. Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity. Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis.",description:"Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s. Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity. Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis."},{name:"Tobramycin",ATC_code:"J01GB01",EML:"No",value:1,"description.x":`Aminoglycosides, many of which are derived directly from Streptomyces spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms. Inhaled tobramycin is notable for its use in treating chronic Pseudomonas aeruginosa infections in cystic fibrosis patients, as P. aeruginosa is notoriously inherently resistant to many antibiotics. However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria. Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics such as β-lactams and cephalosporins.\r
\r
Tobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to the eye (ophthalmic).`,description:`Aminoglycosides, many of which are derived directly from Streptomyces spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms. Inhaled tobramycin is notable for its use in treating chronic Pseudomonas aeruginosa infections in cystic fibrosis patients, as P. aeruginosa is notoriously inherently resistant to many antibiotics. However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria. Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics such as β-lactams and cephalosporins.\r
\r
Tobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to the eye (ophthalmic).`}]},{name:"Reserve",children:[{name:"Plazomicin",ATC_code:"J01GB14",EML:"Yes",value:1,"description.x":"Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to  at position 1 and 2-hydroxyethyl group at position 6' . It was designed to evade all clinically relevant aminoglycoside-modifying enzymes, which contribute to the main resistance mechanism for aminoglycoside therapy . However, acquired resistance of aminoglycosides may arise through over expression of efflux pumps and ribosomal modification by bacteria, which results from amino acid or rRNA sequence mutations . Like other aminoglycosides, plazomicin is ineffective against bacterial isolates that produce 16S rRNA methyltransferases FDA Label. Plazomicin mediates the antibacterial activity against pathogens including carbapenem-resistant (CRE) and extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae. It mediates the antibacterial activity by binding to bacterial 30S ribosomal subunit and inhibiting protein synthesis FDA Label. On June 28th, 2018, plazomicin sulfate was approved by the FDA for use in adult patients for the treatment of complicated urinary tract infections (cUTI) including Pyelonephritis. It is marketed as Zemdri and is administered via once-daily intravenous infusion.",description:"Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to  at position 1 and 2-hydroxyethyl group at position 6' . It was designed to evade all clinically relevant aminoglycoside-modifying enzymes, which contribute to the main resistance mechanism for aminoglycoside therapy . However, acquired resistance of aminoglycosides may arise through over expression of efflux pumps and ribosomal modification by bacteria, which results from amino acid or rRNA sequence mutations . Like other aminoglycosides, plazomicin is ineffective against bacterial isolates that produce 16S rRNA methyltransferases FDA Label. Plazomicin mediates the antibacterial activity against pathogens including carbapenem-resistant (CRE) and extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae. It mediates the antibacterial activity by binding to bacterial 30S ribosomal subunit and inhibiting protein synthesis FDA Label. On June 28th, 2018, plazomicin sulfate was approved by the FDA for use in adult patients for the treatment of complicated urinary tract infections (cUTI) including Pyelonephritis. It is marketed as Zemdri and is administered via once-daily intravenous infusion."}]}]},{name:"Macrolides",data:[{name:"Azithromycin",ATC_code:"J01FA10",EML:"Yes",value:1,"description.x":`Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 .\r
\r
It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin .\r
\r
Azithromycin 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin is a part of the azalide subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides .\r
\r
In March 2020, a small study was funded by the French government to investigate the treatment of COVID-19 with a combination of azithromycin and the anti-malaria drug hydroxychloroquine. The results were positive, all patients taking the combination were virologically cured within 6 days of treatment, however, larger studies are required.`,description:`Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 .\r
\r
It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin .\r
\r
Azithromycin 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin is a part of the azalide subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides .\r
\r
In March 2020, a small study was funded by the French government to investigate the treatment of COVID-19 with a combination of azithromycin and the anti-malaria drug hydroxychloroquine. The results were positive, all patients taking the combination were virologically cured within 6 days of treatment, however, larger studies are required.`},{name:"Clarithromycin",ATC_code:"J01FA09",EML:"Yes",value:1,"description.x":"Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.",description:"Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration."},{name:"Dirithromycin",ATC_code:"J01FA13",EML:"No",value:1,"description.x":"Dirithromycin is a macrolide glycopeptide antibiotic used to treat many different types of bacterial infections, such as bronchitis, pneumonia, tonsillitis, and even skin infections.",description:"Dirithromycin is a macrolide glycopeptide antibiotic used to treat many different types of bacterial infections, such as bronchitis, pneumonia, tonsillitis, and even skin infections."},{name:"Erythromycin",ATC_code:"J01FA01",EML:"Yes (therapeutic alternative to clarithromycin (EMLc))",value:1,"description.x":"Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists of Azithromycin, Clarithromycin, Spiramycin and others. It was originally discovered in 1952. Erythromycin is widely used for treating a variety of infections, including those caused by gram-positive and gram-negative bacteria. It is available for administration in various forms, including intravenous, topical, and eye drop preparations.",description:"Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists of Azithromycin, Clarithromycin, Spiramycin and others. It was originally discovered in 1952. Erythromycin is widely used for treating a variety of infections, including those caused by gram-positive and gram-negative bacteria. It is available for administration in various forms, including intravenous, topical, and eye drop preparations."},{name:"Fidaxomicin",ATC_code:"A07AA12",EML:"No",value:1,"description.x":`Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by Clostridioides (formerly Clostridium) difficile in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug. The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the bactericidal activity is time-dependent, and not concentration-dependent. Fidaxomicin was the first macrocyclic lactone antibiotic with activity against C. difficile, and it displays a narrow spectrum of activity against gram-positive anaerobes. It mediates its potent bactericidal action on the bacteria by inhibiting the bacterial RNA synthase, thereby disrupting bacterial transcription. The minimum inhibitory concentration (MIC<sub>90</sub>) for fidaxomicin is four times less than that of vancomycin, which was the primary drug of choice for C. difficile infection before the approval of fidaxomicin. Unlike vancomycin, however, fidaxomicin has a negligible effect on normal colonic microflora.\r
\r
The FDA initially approved fidaxomicin in May 2011 for the treatment of C. difficile-associated diarrhea in adult patients over the age of 18. Later that year in December, the drug was also approved by the European Medicine Agency. In June 2012, fidaxomicin was also granted approval by Health Canada. The approved indication of fidaxomicin was expanded by the FDA in January 2020 to include pediatric patients over the age of 6 months in the treatment population.`,description:`Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by Clostridioides (formerly Clostridium) difficile in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug. The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the bactericidal activity is time-dependent, and not concentration-dependent. Fidaxomicin was the first macrocyclic lactone antibiotic with activity against C. difficile, and it displays a narrow spectrum of activity against gram-positive anaerobes. It mediates its potent bactericidal action on the bacteria by inhibiting the bacterial RNA synthase, thereby disrupting bacterial transcription. The minimum inhibitory concentration (MIC<sub>90</sub>) for fidaxomicin is four times less than that of vancomycin, which was the primary drug of choice for C. difficile infection before the approval of fidaxomicin. Unlike vancomycin, however, fidaxomicin has a negligible effect on normal colonic microflora.\r
\r
The FDA initially approved fidaxomicin in May 2011 for the treatment of C. difficile-associated diarrhea in adult patients over the age of 18. Later that year in December, the drug was also approved by the European Medicine Agency. In June 2012, fidaxomicin was also granted approval by Health Canada. The approved indication of fidaxomicin was expanded by the FDA in January 2020 to include pediatric patients over the age of 6 months in the treatment population.`},{name:"Flurithromycin",ATC_code:"J01FA14",EML:"No",value:1,"description.x":"Macrolides",description:"Macrolides"},{name:"Josamycin",ATC_code:"J01FA07",EML:"No",value:1,"description.x":"A macrolide antibiotic from Streptomyces narbonensis. The drug has antimicrobial activity against a wide spectrum of pathogens.",description:"A macrolide antibiotic from Streptomyces narbonensis. The drug has antimicrobial activity against a wide spectrum of pathogens."},{name:"Midecamycin",ATC_code:"J01FA03",EML:"No",value:1,"description.x":"Midecamycin is a naturally occurring 16-membered macrolide that fits under the category of acetoxy-substituted macrolide antibiotics. In this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on position 4 of the terminal sugar. Until 2017, midecamycin was still under the list of approved antimicrobial active pharmaceutical ingredients by Health Canada.",description:"Midecamycin is a naturally occurring 16-membered macrolide that fits under the category of acetoxy-substituted macrolide antibiotics. In this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on position 4 of the terminal sugar. Until 2017, midecamycin was still under the list of approved antimicrobial active pharmaceutical ingredients by Health Canada."},{name:"Miocamycin",ATC_code:"J01FA11",EML:"No",value:1,"description.x":"Miocamycin is a macrolide type antimicrobial . This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia . It has shown to be effective against several gram-positive and gram-negative microbes and may be useful in the treatment of upper and lower respiratory tract infections, and urogenital tract infections or as an alternative to erythromycin treatment .",description:"Miocamycin is a macrolide type antimicrobial . This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia . It has shown to be effective against several gram-positive and gram-negative microbes and may be useful in the treatment of upper and lower respiratory tract infections, and urogenital tract infections or as an alternative to erythromycin treatment ."},{name:"Oleandomycin",ATC_code:"J01FA05",EML:"No",value:1,"description.x":"Oleandomycin is a macrolide antibiotic, though it is less effective than erythromycin. It is synthesized from strains of Streptomyces antibioticus.",description:"Oleandomycin is a macrolide antibiotic, though it is less effective than erythromycin. It is synthesized from strains of Streptomyces antibioticus."},{name:"Rokitamycin",ATC_code:"J01FA12",EML:"No",value:1,"description.x":"Macrolides",description:"Macrolides"},{name:"Roxithromycin",ATC_code:"J01FA06",EML:"No",value:1,"description.x":"Roxithromycin is a semi-synthethic macrolide antibiotic that is structurally and pharmacologically similar to erythromycin, azithromycin, or clarithromycin. It was shown to be more effective against certain Gram-negative bacteria, particularly Legionella pneumophila. Roxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis. It is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections.",description:"Roxithromycin is a semi-synthethic macrolide antibiotic that is structurally and pharmacologically similar to erythromycin, azithromycin, or clarithromycin. It was shown to be more effective against certain Gram-negative bacteria, particularly Legionella pneumophila. Roxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis. It is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections."},{name:"Solithromycin",ATC_code:"J01FA16",EML:"No",value:1,"description.x":"Solithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP) and other infections.",description:"Solithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP) and other infections."},{name:"Spiramycin",ATC_code:"J01FA02",EML:"No",value:1,"description.x":`Spiramycin is a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types of spirochetes, Toxoplasma gondii and Cryptosporidium.\r
Spiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens that has been available in oral formulations since 1955, and parenteral formulations since 1987. Resistant organisms include Enterobacteria, pseudomonads, and moulds.`,description:`Spiramycin is a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types of spirochetes, Toxoplasma gondii and Cryptosporidium.\r
Spiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens that has been available in oral formulations since 1955, and parenteral formulations since 1987. Resistant organisms include Enterobacteria, pseudomonads, and moulds.`},{name:"Telithromycin",ATC_code:"J01FA15",EML:"No",value:1,"description.x":"Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections.",description:"Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections."},{name:"Troleandomycin",ATC_code:"J01FA08",EML:"No",value:1,"description.x":"A macrolide antibiotic that is similar to erythromycin.",description:"A macrolide antibiotic that is similar to erythromycin."}],children:[{name:"Watch",children:[{name:"Azithromycin",ATC_code:"J01FA10",EML:"Yes",value:1,"description.x":`Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 .\r
\r
It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin .\r
\r
Azithromycin 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin is a part of the azalide subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides .\r
\r
In March 2020, a small study was funded by the French government to investigate the treatment of COVID-19 with a combination of azithromycin and the anti-malaria drug hydroxychloroquine. The results were positive, all patients taking the combination were virologically cured within 6 days of treatment, however, larger studies are required.`,description:`Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 .\r
\r
It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin .\r
\r
Azithromycin 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin is a part of the azalide subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides .\r
\r
In March 2020, a small study was funded by the French government to investigate the treatment of COVID-19 with a combination of azithromycin and the anti-malaria drug hydroxychloroquine. The results were positive, all patients taking the combination were virologically cured within 6 days of treatment, however, larger studies are required.`},{name:"Clarithromycin",ATC_code:"J01FA09",EML:"Yes",value:1,"description.x":"Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.",description:"Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration."},{name:"Dirithromycin",ATC_code:"J01FA13",EML:"No",value:1,"description.x":"Dirithromycin is a macrolide glycopeptide antibiotic used to treat many different types of bacterial infections, such as bronchitis, pneumonia, tonsillitis, and even skin infections.",description:"Dirithromycin is a macrolide glycopeptide antibiotic used to treat many different types of bacterial infections, such as bronchitis, pneumonia, tonsillitis, and even skin infections."},{name:"Erythromycin",ATC_code:"J01FA01",EML:"Yes (therapeutic alternative to clarithromycin (EMLc))",value:1,"description.x":"Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists of Azithromycin, Clarithromycin, Spiramycin and others. It was originally discovered in 1952. Erythromycin is widely used for treating a variety of infections, including those caused by gram-positive and gram-negative bacteria. It is available for administration in various forms, including intravenous, topical, and eye drop preparations.",description:"Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists of Azithromycin, Clarithromycin, Spiramycin and others. It was originally discovered in 1952. Erythromycin is widely used for treating a variety of infections, including those caused by gram-positive and gram-negative bacteria. It is available for administration in various forms, including intravenous, topical, and eye drop preparations."},{name:"Fidaxomicin",ATC_code:"A07AA12",EML:"No",value:1,"description.x":`Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by Clostridioides (formerly Clostridium) difficile in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug. The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the bactericidal activity is time-dependent, and not concentration-dependent. Fidaxomicin was the first macrocyclic lactone antibiotic with activity against C. difficile, and it displays a narrow spectrum of activity against gram-positive anaerobes. It mediates its potent bactericidal action on the bacteria by inhibiting the bacterial RNA synthase, thereby disrupting bacterial transcription. The minimum inhibitory concentration (MIC<sub>90</sub>) for fidaxomicin is four times less than that of vancomycin, which was the primary drug of choice for C. difficile infection before the approval of fidaxomicin. Unlike vancomycin, however, fidaxomicin has a negligible effect on normal colonic microflora.\r
\r
The FDA initially approved fidaxomicin in May 2011 for the treatment of C. difficile-associated diarrhea in adult patients over the age of 18. Later that year in December, the drug was also approved by the European Medicine Agency. In June 2012, fidaxomicin was also granted approval by Health Canada. The approved indication of fidaxomicin was expanded by the FDA in January 2020 to include pediatric patients over the age of 6 months in the treatment population.`,description:`Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by Clostridioides (formerly Clostridium) difficile in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug. The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the bactericidal activity is time-dependent, and not concentration-dependent. Fidaxomicin was the first macrocyclic lactone antibiotic with activity against C. difficile, and it displays a narrow spectrum of activity against gram-positive anaerobes. It mediates its potent bactericidal action on the bacteria by inhibiting the bacterial RNA synthase, thereby disrupting bacterial transcription. The minimum inhibitory concentration (MIC<sub>90</sub>) for fidaxomicin is four times less than that of vancomycin, which was the primary drug of choice for C. difficile infection before the approval of fidaxomicin. Unlike vancomycin, however, fidaxomicin has a negligible effect on normal colonic microflora.\r
\r
The FDA initially approved fidaxomicin in May 2011 for the treatment of C. difficile-associated diarrhea in adult patients over the age of 18. Later that year in December, the drug was also approved by the European Medicine Agency. In June 2012, fidaxomicin was also granted approval by Health Canada. The approved indication of fidaxomicin was expanded by the FDA in January 2020 to include pediatric patients over the age of 6 months in the treatment population.`},{name:"Flurithromycin",ATC_code:"J01FA14",EML:"No",value:1,"description.x":"Macrolides",description:"Macrolides"},{name:"Josamycin",ATC_code:"J01FA07",EML:"No",value:1,"description.x":"A macrolide antibiotic from Streptomyces narbonensis. The drug has antimicrobial activity against a wide spectrum of pathogens.",description:"A macrolide antibiotic from Streptomyces narbonensis. The drug has antimicrobial activity against a wide spectrum of pathogens."},{name:"Midecamycin",ATC_code:"J01FA03",EML:"No",value:1,"description.x":"Midecamycin is a naturally occurring 16-membered macrolide that fits under the category of acetoxy-substituted macrolide antibiotics. In this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on position 4 of the terminal sugar. Until 2017, midecamycin was still under the list of approved antimicrobial active pharmaceutical ingredients by Health Canada.",description:"Midecamycin is a naturally occurring 16-membered macrolide that fits under the category of acetoxy-substituted macrolide antibiotics. In this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on position 4 of the terminal sugar. Until 2017, midecamycin was still under the list of approved antimicrobial active pharmaceutical ingredients by Health Canada."},{name:"Miocamycin",ATC_code:"J01FA11",EML:"No",value:1,"description.x":"Miocamycin is a macrolide type antimicrobial . This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia . It has shown to be effective against several gram-positive and gram-negative microbes and may be useful in the treatment of upper and lower respiratory tract infections, and urogenital tract infections or as an alternative to erythromycin treatment .",description:"Miocamycin is a macrolide type antimicrobial . This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia . It has shown to be effective against several gram-positive and gram-negative microbes and may be useful in the treatment of upper and lower respiratory tract infections, and urogenital tract infections or as an alternative to erythromycin treatment ."},{name:"Oleandomycin",ATC_code:"J01FA05",EML:"No",value:1,"description.x":"Oleandomycin is a macrolide antibiotic, though it is less effective than erythromycin. It is synthesized from strains of Streptomyces antibioticus.",description:"Oleandomycin is a macrolide antibiotic, though it is less effective than erythromycin. It is synthesized from strains of Streptomyces antibioticus."},{name:"Rokitamycin",ATC_code:"J01FA12",EML:"No",value:1,"description.x":"Macrolides",description:"Macrolides"},{name:"Roxithromycin",ATC_code:"J01FA06",EML:"No",value:1,"description.x":"Roxithromycin is a semi-synthethic macrolide antibiotic that is structurally and pharmacologically similar to erythromycin, azithromycin, or clarithromycin. It was shown to be more effective against certain Gram-negative bacteria, particularly Legionella pneumophila. Roxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis. It is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections.",description:"Roxithromycin is a semi-synthethic macrolide antibiotic that is structurally and pharmacologically similar to erythromycin, azithromycin, or clarithromycin. It was shown to be more effective against certain Gram-negative bacteria, particularly Legionella pneumophila. Roxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis. It is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections."},{name:"Solithromycin",ATC_code:"J01FA16",EML:"No",value:1,"description.x":"Solithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP) and other infections.",description:"Solithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP) and other infections."},{name:"Spiramycin",ATC_code:"J01FA02",EML:"No",value:1,"description.x":`Spiramycin is a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types of spirochetes, Toxoplasma gondii and Cryptosporidium.\r
Spiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens that has been available in oral formulations since 1955, and parenteral formulations since 1987. Resistant organisms include Enterobacteria, pseudomonads, and moulds.`,description:`Spiramycin is a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types of spirochetes, Toxoplasma gondii and Cryptosporidium.\r
Spiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens that has been available in oral formulations since 1955, and parenteral formulations since 1987. Resistant organisms include Enterobacteria, pseudomonads, and moulds.`},{name:"Telithromycin",ATC_code:"J01FA15",EML:"No",value:1,"description.x":"Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections.",description:"Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections."},{name:"Troleandomycin",ATC_code:"J01FA08",EML:"No",value:1,"description.x":"A macrolide antibiotic that is similar to erythromycin.",description:"A macrolide antibiotic that is similar to erythromycin."}]}]},{name:"Trimethoprim-derivatives",data:[{name:"Brodimoprim",ATC_code:"J01EA02",EML:"No",value:1,"description.x":"Trimethoprim and derivatives",description:"Trimethoprim and derivatives"},{name:"Iclaprim",ATC_code:"J01EA03",EML:"No",value:1,"description.x":"Trimethoprim and derivatives",description:"Trimethoprim and derivatives"},{name:"Trimethoprim",ATC_code:"J01EA01",EML:"Yes",value:1,"description.x":"Trimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it prevents the synthesis of bacterial DNA and ultimately continued bacterial survival. Trimethoprim is often used in combination with sulfamethoxazole due to their complementary and synergistic mechanisms but may be used as a monotherapy in the treatment and/or prophylaxis of urinary tract infections. It is structurally and chemically related to pyrimethamine, another antifolate antimicrobial used in the treatment of plasmodial infections.",description:"Trimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it prevents the synthesis of bacterial DNA and ultimately continued bacterial survival. Trimethoprim is often used in combination with sulfamethoxazole due to their complementary and synergistic mechanisms but may be used as a monotherapy in the treatment and/or prophylaxis of urinary tract infections. It is structurally and chemically related to pyrimethamine, another antifolate antimicrobial used in the treatment of plasmodial infections."}],children:[{name:"Access",children:[{name:"Brodimoprim",ATC_code:"J01EA02",EML:"No",value:1,"description.x":"Trimethoprim and derivatives",description:"Trimethoprim and derivatives"},{name:"Trimethoprim",ATC_code:"J01EA01",EML:"Yes",value:1,"description.x":"Trimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it prevents the synthesis of bacterial DNA and ultimately continued bacterial survival. Trimethoprim is often used in combination with sulfamethoxazole due to their complementary and synergistic mechanisms but may be used as a monotherapy in the treatment and/or prophylaxis of urinary tract infections. It is structurally and chemically related to pyrimethamine, another antifolate antimicrobial used in the treatment of plasmodial infections.",description:"Trimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it prevents the synthesis of bacterial DNA and ultimately continued bacterial survival. Trimethoprim is often used in combination with sulfamethoxazole due to their complementary and synergistic mechanisms but may be used as a monotherapy in the treatment and/or prophylaxis of urinary tract infections. It is structurally and chemically related to pyrimethamine, another antifolate antimicrobial used in the treatment of plasmodial infections."}]},{name:"Reserve",children:[{name:"Iclaprim",ATC_code:"J01EA03",EML:"No",value:1,"description.x":"Trimethoprim and derivatives",description:"Trimethoprim and derivatives"}]}]},{name:"Amphenicols",data:[{name:"Chloramphenicol",ATC_code:"J01BA01",EML:"Yes",value:1,"description.x":`An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106)\r
\r
The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.`,description:`An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106)\r
\r
The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.`},{name:"Thiamphenicol",ATC_code:"J01BA02",EML:"No",value:1,"description.x":"Amphenicols",description:"Amphenicols"}],children:[{name:"Access",children:[{name:"Chloramphenicol",ATC_code:"J01BA01",EML:"Yes",value:1,"description.x":`An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106)\r
\r
The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.`,description:`An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106)\r
\r
The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.`},{name:"Thiamphenicol",ATC_code:"J01BA02",EML:"No",value:1,"description.x":"Amphenicols",description:"Amphenicols"}]}]},{name:"Tetracyclines",data:[{name:"Chlortetracycline",ATC_code:"J01AA03",EML:"No",value:1,"description.x":"Chlortetracycline is a tetracycline antibiotic, and historically the first member of this class to be identified. It was discovered in 1945 by the scientist, Benjamin Minge Duggar, working at Lederle Laboratories under the supervision of Yellapragada Subbarow. He discovered that this antibiotic was the product of an actinomycete strain he cultured and obtained from a soil sample from a field in Missouri. The organism was named Streptomyces aureofaciens due to its gold-hued color.",description:"Chlortetracycline is a tetracycline antibiotic, and historically the first member of this class to be identified. It was discovered in 1945 by the scientist, Benjamin Minge Duggar, working at Lederle Laboratories under the supervision of Yellapragada Subbarow. He discovered that this antibiotic was the product of an actinomycete strain he cultured and obtained from a soil sample from a field in Missouri. The organism was named Streptomyces aureofaciens due to its gold-hued color."},{name:"Clomocycline",ATC_code:"J01AA11",EML:"No",value:1,"description.x":"Clomocycline is a tetracycline used to treat bacterial infections.",description:"Clomocycline is a tetracycline used to treat bacterial infections."},{name:"Demeclocycline",ATC_code:"J01AA01",EML:"No",value:1,"description.x":"A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.",description:"A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time."},{name:"Doxycycline",ATC_code:"J01AA02",EML:"Yes",value:1,"description.x":"Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.",description:"Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria."},{name:"Eravacycline",ATC_code:"J01AA13",EML:"No",value:1,"description.x":"Eravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens . It was first approved by the FDA on August 27, 2018 . Eravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections .",description:"Eravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens . It was first approved by the FDA on August 27, 2018 . Eravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections ."},{name:"Lymecycline",ATC_code:"J01AA04",EML:"No",value:1,"description.x":"Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and other susceptible bacterial infections. It has been proven a cost-effective alternative to treatment with minocycline with comparable safety and efficacy. Lymecycline was initially discovered in 1961. It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. Lymecycline is not marketed in the USA, however, equivalent drugs are available, such as minocycline and tetracycline.",description:"Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and other susceptible bacterial infections. It has been proven a cost-effective alternative to treatment with minocycline with comparable safety and efficacy. Lymecycline was initially discovered in 1961. It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. Lymecycline is not marketed in the USA, however, equivalent drugs are available, such as minocycline and tetracycline."},{name:"Metacycline",ATC_code:"J01AA05",EML:"No",value:1,"description.x":"A broad-spectrum semisynthetic antibiotic related to tetracycline but excreted more slowly and maintaining effective blood levels for a more extended period.",description:"A broad-spectrum semisynthetic antibiotic related to tetracycline but excreted more slowly and maintaining effective blood levels for a more extended period."},{name:"Minocycline_IV",ATC_code:"J01AA08",EML:"No",value:1,"description.x":`Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.\r
\r
Minocycline was granted FDA approval on 30 June 1971.`,description:`Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.\r
\r
Minocycline was granted FDA approval on 30 June 1971.`},{name:"Minocycline_oral",ATC_code:"J01AA08",EML:"No",value:1,"description.x":`Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.\r
\r
Minocycline was granted FDA approval on 30 June 1971.`,description:`Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.\r
\r
Minocycline was granted FDA approval on 30 June 1971.`},{name:"Omadacycline",ATC_code:"J01AA15",EML:"No",value:1,"description.x":"Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent infections caused by gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), and by gram-negative, atypical and anaerobic bacteria, including those resistant to currently available classes of antibiotics and known to cause diseases such as pneumonias, urinary tract infections, skin diseases and blood-borne infections in both the hospital and community settings.",description:"Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent infections caused by gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), and by gram-negative, atypical and anaerobic bacteria, including those resistant to currently available classes of antibiotics and known to cause diseases such as pneumonias, urinary tract infections, skin diseases and blood-borne infections in both the hospital and community settings."},{name:"Oxytetracycline",ATC_code:"J01AA06",EML:"No",value:1,"description.x":"A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions.",description:"A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions."},{name:"Penimepicycline",ATC_code:"J01AA10",EML:"No",value:1,"description.x":"Penimepicycline is a tetracycline-class antibiotic. It is mentioned on List A produced by the Government of Canada, which is a list of antimicrobial active pharmaceutical ingredients . In the classification of the active ingredients included on this list, the classification document states that tetracycline class antibiotics are of medium importance, and are used in humans .",description:"Penimepicycline is a tetracycline-class antibiotic. It is mentioned on List A produced by the Government of Canada, which is a list of antimicrobial active pharmaceutical ingredients . In the classification of the active ingredients included on this list, the classification document states that tetracycline class antibiotics are of medium importance, and are used in humans ."},{name:"Rolitetracycline",ATC_code:"J01AA09",EML:"No",value:1,"description.x":"A pyrrolidinylmethyl tetracycline.",description:"A pyrrolidinylmethyl tetracycline."},{name:"Sarecycline",ATC_code:"J01AA14",EML:"No",value:1,"description.x":`Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe facial acne vulgaris  the US Food and Drug Administration approved Barcelona based Almirall, S.A.'s Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients nine years of age and older . Seysara (sarecycline) was originally part of Allergan's US Medical Dermatology portfolio, before Almirall acquired the portfolio in the second half of 2018 as a means of consolidating and reinforcing the dermatology-focused pharmaceutical company's presence in the United States .\r
\r
Acne vulgaris itself is a common chronic skin condition associated with the blockage and/or inflammation of hair follicles and their accompanying sebaceous glands . The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well . Based upon data from Global Burden of Disease studies, the acne vulgaris condition affects up to 85% of young adults aged 12 to 25 years globally - with the possibility of permanent physical and mental scarring resulting from cases of severe acne .\r
\r
Subsequently, while a number of first line tetracycline therapies like doxycycline and minocycline do exist for treating acne vulgaris, sarecycline presents a new and innovative therapy choice because it exhibits the necessary antibacterial activity against relevant pathogens that cause acne vulgaris but also possesses a low propensity for resistance development in such pathogens and a narrower, more specific spectrum of antibacterial activity, resulting in fewer off-target antibacterial effects on endogenous intestinal flora and consequently fewer resultant adverse effects associated with diarrhea, fungal overgrowth, etc.`,description:`Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe facial acne vulgaris  the US Food and Drug Administration approved Barcelona based Almirall, S.A.'s Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients nine years of age and older . Seysara (sarecycline) was originally part of Allergan's US Medical Dermatology portfolio, before Almirall acquired the portfolio in the second half of 2018 as a means of consolidating and reinforcing the dermatology-focused pharmaceutical company's presence in the United States .\r
\r
Acne vulgaris itself is a common chronic skin condition associated with the blockage and/or inflammation of hair follicles and their accompanying sebaceous glands . The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well . Based upon data from Global Burden of Disease studies, the acne vulgaris condition affects up to 85% of young adults aged 12 to 25 years globally - with the possibility of permanent physical and mental scarring resulting from cases of severe acne .\r
\r
Subsequently, while a number of first line tetracycline therapies like doxycycline and minocycline do exist for treating acne vulgaris, sarecycline presents a new and innovative therapy choice because it exhibits the necessary antibacterial activity against relevant pathogens that cause acne vulgaris but also possesses a low propensity for resistance development in such pathogens and a narrower, more specific spectrum of antibacterial activity, resulting in fewer off-target antibacterial effects on endogenous intestinal flora and consequently fewer resultant adverse effects associated with diarrhea, fungal overgrowth, etc.`},{name:"Tetracycline",ATC_code:"J01AA07",EML:"No",value:1,"description.x":`Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.\r
\r
The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml. Other formulations of tetracycline continue to be used.`,description:`Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.\r
\r
The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml. Other formulations of tetracycline continue to be used.`}],children:[{name:"Watch",children:[{name:"Chlortetracycline",ATC_code:"J01AA03",EML:"No",value:1,"description.x":"Chlortetracycline is a tetracycline antibiotic, and historically the first member of this class to be identified. It was discovered in 1945 by the scientist, Benjamin Minge Duggar, working at Lederle Laboratories under the supervision of Yellapragada Subbarow. He discovered that this antibiotic was the product of an actinomycete strain he cultured and obtained from a soil sample from a field in Missouri. The organism was named Streptomyces aureofaciens due to its gold-hued color.",description:"Chlortetracycline is a tetracycline antibiotic, and historically the first member of this class to be identified. It was discovered in 1945 by the scientist, Benjamin Minge Duggar, working at Lederle Laboratories under the supervision of Yellapragada Subbarow. He discovered that this antibiotic was the product of an actinomycete strain he cultured and obtained from a soil sample from a field in Missouri. The organism was named Streptomyces aureofaciens due to its gold-hued color."},{name:"Clomocycline",ATC_code:"J01AA11",EML:"No",value:1,"description.x":"Clomocycline is a tetracycline used to treat bacterial infections.",description:"Clomocycline is a tetracycline used to treat bacterial infections."},{name:"Demeclocycline",ATC_code:"J01AA01",EML:"No",value:1,"description.x":"A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.",description:"A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time."},{name:"Lymecycline",ATC_code:"J01AA04",EML:"No",value:1,"description.x":"Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and other susceptible bacterial infections. It has been proven a cost-effective alternative to treatment with minocycline with comparable safety and efficacy. Lymecycline was initially discovered in 1961. It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. Lymecycline is not marketed in the USA, however, equivalent drugs are available, such as minocycline and tetracycline.",description:"Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and other susceptible bacterial infections. It has been proven a cost-effective alternative to treatment with minocycline with comparable safety and efficacy. Lymecycline was initially discovered in 1961. It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. Lymecycline is not marketed in the USA, however, equivalent drugs are available, such as minocycline and tetracycline."},{name:"Metacycline",ATC_code:"J01AA05",EML:"No",value:1,"description.x":"A broad-spectrum semisynthetic antibiotic related to tetracycline but excreted more slowly and maintaining effective blood levels for a more extended period.",description:"A broad-spectrum semisynthetic antibiotic related to tetracycline but excreted more slowly and maintaining effective blood levels for a more extended period."},{name:"Minocycline_oral",ATC_code:"J01AA08",EML:"No",value:1,"description.x":`Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.\r
\r
Minocycline was granted FDA approval on 30 June 1971.`,description:`Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.\r
\r
Minocycline was granted FDA approval on 30 June 1971.`},{name:"Oxytetracycline",ATC_code:"J01AA06",EML:"No",value:1,"description.x":"A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions.",description:"A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions."},{name:"Penimepicycline",ATC_code:"J01AA10",EML:"No",value:1,"description.x":"Penimepicycline is a tetracycline-class antibiotic. It is mentioned on List A produced by the Government of Canada, which is a list of antimicrobial active pharmaceutical ingredients . In the classification of the active ingredients included on this list, the classification document states that tetracycline class antibiotics are of medium importance, and are used in humans .",description:"Penimepicycline is a tetracycline-class antibiotic. It is mentioned on List A produced by the Government of Canada, which is a list of antimicrobial active pharmaceutical ingredients . In the classification of the active ingredients included on this list, the classification document states that tetracycline class antibiotics are of medium importance, and are used in humans ."},{name:"Rolitetracycline",ATC_code:"J01AA09",EML:"No",value:1,"description.x":"A pyrrolidinylmethyl tetracycline.",description:"A pyrrolidinylmethyl tetracycline."},{name:"Sarecycline",ATC_code:"J01AA14",EML:"No",value:1,"description.x":`Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe facial acne vulgaris  the US Food and Drug Administration approved Barcelona based Almirall, S.A.'s Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients nine years of age and older . Seysara (sarecycline) was originally part of Allergan's US Medical Dermatology portfolio, before Almirall acquired the portfolio in the second half of 2018 as a means of consolidating and reinforcing the dermatology-focused pharmaceutical company's presence in the United States .\r
\r
Acne vulgaris itself is a common chronic skin condition associated with the blockage and/or inflammation of hair follicles and their accompanying sebaceous glands . The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well . Based upon data from Global Burden of Disease studies, the acne vulgaris condition affects up to 85% of young adults aged 12 to 25 years globally - with the possibility of permanent physical and mental scarring resulting from cases of severe acne .\r
\r
Subsequently, while a number of first line tetracycline therapies like doxycycline and minocycline do exist for treating acne vulgaris, sarecycline presents a new and innovative therapy choice because it exhibits the necessary antibacterial activity against relevant pathogens that cause acne vulgaris but also possesses a low propensity for resistance development in such pathogens and a narrower, more specific spectrum of antibacterial activity, resulting in fewer off-target antibacterial effects on endogenous intestinal flora and consequently fewer resultant adverse effects associated with diarrhea, fungal overgrowth, etc.`,description:`Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe facial acne vulgaris  the US Food and Drug Administration approved Barcelona based Almirall, S.A.'s Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients nine years of age and older . Seysara (sarecycline) was originally part of Allergan's US Medical Dermatology portfolio, before Almirall acquired the portfolio in the second half of 2018 as a means of consolidating and reinforcing the dermatology-focused pharmaceutical company's presence in the United States .\r
\r
Acne vulgaris itself is a common chronic skin condition associated with the blockage and/or inflammation of hair follicles and their accompanying sebaceous glands . The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well . Based upon data from Global Burden of Disease studies, the acne vulgaris condition affects up to 85% of young adults aged 12 to 25 years globally - with the possibility of permanent physical and mental scarring resulting from cases of severe acne .\r
\r
Subsequently, while a number of first line tetracycline therapies like doxycycline and minocycline do exist for treating acne vulgaris, sarecycline presents a new and innovative therapy choice because it exhibits the necessary antibacterial activity against relevant pathogens that cause acne vulgaris but also possesses a low propensity for resistance development in such pathogens and a narrower, more specific spectrum of antibacterial activity, resulting in fewer off-target antibacterial effects on endogenous intestinal flora and consequently fewer resultant adverse effects associated with diarrhea, fungal overgrowth, etc.`}]},{name:"Access",children:[{name:"Doxycycline",ATC_code:"J01AA02",EML:"Yes",value:1,"description.x":"Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.",description:"Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria."},{name:"Tetracycline",ATC_code:"J01AA07",EML:"No",value:1,"description.x":`Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.\r
\r
The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml. Other formulations of tetracycline continue to be used.`,description:`Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.\r
\r
The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml. Other formulations of tetracycline continue to be used.`}]},{name:"Reserve",children:[{name:"Eravacycline",ATC_code:"J01AA13",EML:"No",value:1,"description.x":"Eravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens . It was first approved by the FDA on August 27, 2018 . Eravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections .",description:"Eravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens . It was first approved by the FDA on August 27, 2018 . Eravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections ."},{name:"Minocycline_IV",ATC_code:"J01AA08",EML:"No",value:1,"description.x":`Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.\r
\r
Minocycline was granted FDA approval on 30 June 1971.`,description:`Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.\r
\r
Minocycline was granted FDA approval on 30 June 1971.`},{name:"Omadacycline",ATC_code:"J01AA15",EML:"No",value:1,"description.x":"Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent infections caused by gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), and by gram-negative, atypical and anaerobic bacteria, including those resistant to currently available classes of antibiotics and known to cause diseases such as pneumonias, urinary tract infections, skin diseases and blood-borne infections in both the hospital and community settings.",description:"Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent infections caused by gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), and by gram-negative, atypical and anaerobic bacteria, including those resistant to currently available classes of antibiotics and known to cause diseases such as pneumonias, urinary tract infections, skin diseases and blood-borne infections in both the hospital and community settings."}]}]},{name:"Quinolones",data:[{name:"Cinoxacin",ATC_code:"J01MB06",EML:"No",value:1,"description.x":"Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.",description:"Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections."},{name:"Flumequine",ATC_code:"J01MB07",EML:"No",value:1,"description.x":"Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections.",description:"Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections."},{name:"Nemonoxacin",ATC_code:"J01MB08",EML:"No",value:1,"description.x":"Other quinolones",description:"Other quinolones"},{name:"Oxolinic-acid",ATC_code:"J01MB05",EML:"No",value:1,"description.x":"Other quinolones",description:"Other quinolones"},{name:"Pipemidic-acid",ATC_code:"J01MB04",EML:"No",value:1,"description.x":"Other quinolones",description:"Other quinolones"},{name:"Piromidic-acid",ATC_code:"J01MB03",EML:"No",value:1,"description.x":"Other quinolones",description:"Other quinolones"},{name:"Rosoxacin",ATC_code:"J01MB01",EML:"No",value:1,"description.x":"Rosoxacin is a quinolone derivative antibiotic for the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients. Rosoxacin is known to be effective against penicillin resistant strains and is a single dose orally administered drug, which avoids all complications of parenteral administration seen with penicillin, especially anaphylactic shock.",description:"Rosoxacin is a quinolone derivative antibiotic for the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients. Rosoxacin is known to be effective against penicillin resistant strains and is a single dose orally administered drug, which avoids all complications of parenteral administration seen with penicillin, especially anaphylactic shock."}],children:[{name:"Watch",children:[{name:"Cinoxacin",ATC_code:"J01MB06",EML:"No",value:1,"description.x":"Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.",description:"Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections."},{name:"Flumequine",ATC_code:"J01MB07",EML:"No",value:1,"description.x":"Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections.",description:"Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections."},{name:"Nemonoxacin",ATC_code:"J01MB08",EML:"No",value:1,"description.x":"Other quinolones",description:"Other quinolones"},{name:"Oxolinic-acid",ATC_code:"J01MB05",EML:"No",value:1,"description.x":"Other quinolones",description:"Other quinolones"},{name:"Pipemidic-acid",ATC_code:"J01MB04",EML:"No",value:1,"description.x":"Other quinolones",description:"Other quinolones"},{name:"Piromidic-acid",ATC_code:"J01MB03",EML:"No",value:1,"description.x":"Other quinolones",description:"Other quinolones"},{name:"Rosoxacin",ATC_code:"J01MB01",EML:"No",value:1,"description.x":"Rosoxacin is a quinolone derivative antibiotic for the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients. Rosoxacin is known to be effective against penicillin resistant strains and is a single dose orally administered drug, which avoids all complications of parenteral administration seen with penicillin, especially anaphylactic shock.",description:"Rosoxacin is a quinolone derivative antibiotic for the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients. Rosoxacin is known to be effective against penicillin resistant strains and is a single dose orally administered drug, which avoids all complications of parenteral administration seen with penicillin, especially anaphylactic shock."}]}]},{name:"Fluoroquinolones",data:[{name:"Ciprofloxacin",ATC_code:"J01MA02",EML:"Yes",value:1,"description.x":`Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.\r
\r
The first ciprofloxacin containing product was FDA approved on 22 October 1987.`,description:`Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.\r
\r
The first ciprofloxacin containing product was FDA approved on 22 October 1987.`},{name:"Delafloxacin",ATC_code:"J01MA23",EML:"No",value:1,"description.x":"Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections.",description:"Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections."},{name:"Enoxacin",ATC_code:"J01MA04",EML:"No",value:1,"description.x":"A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.",description:"A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid."},{name:"Fleroxacin",ATC_code:"J01MA08",EML:"No",value:1,"description.x":"Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2.",description:"Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2."},{name:"Garenoxacin",ATC_code:"J01MA19",EML:"No",value:1,"description.x":"Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.",description:"Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections."},{name:"Gatifloxacin",ATC_code:"J01MA16",EML:"No",value:1,"description.x":`Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan.\r
\r
The FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.`,description:`Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan.\r
\r
The FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.`},{name:"Gemifloxacin",ATC_code:"J01MA15",EML:"No",value:1,"description.x":"Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.",description:"Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth."},{name:"Grepafloxacin",ATC_code:"J01MA11",EML:"No",value:1,"description.x":"Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States.",description:"Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States."},{name:"Lascufloxacin",ATC_code:"J01MA25",EML:"No",value:1,description:"Lascufloxacin, marketed under the trade name Lasvic, is a fluoroquinolone antibiotic drug. It was approved in Japan in 2019 for the treatment of various bacterial infections such as community-acquired pneumonia, otorhinolaryngological infections, and respiratory tract infections. Lascufloxacin is effective against several Gram-positive bacteria, including Streptococcus pneumoniae and Streptococcus anginosus. This antibiotic provides a treatment option for specific bacterial infections, particularly those affecting the respiratory tract. Source: Wikepedia"},{name:"Levofloxacin",ATC_code:"J01MA12",EML:"No",value:1,"description.x":`Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as gatifloxacin and moxifloxacin, is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.\r
\r
Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.`,description:`Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as gatifloxacin and moxifloxacin, is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.\r
\r
Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.`},{name:"Levonadifloxacin",ATC_code:"J01MA24",EML:"No",value:1,"description.x":"Levonadifloxacin is under investigation in clinical trial NCT03405064 (Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)).",description:"Levonadifloxacin is under investigation in clinical trial NCT03405064 (Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI))."},{name:"Lomefloxacin",ATC_code:"J01MA07",EML:"No",value:1,"description.x":"Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well.",description:"Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well."},{name:"Moxifloxacin",ATC_code:"J01MA14",EML:"No",value:1,"description.x":"Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.",description:"Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment."},{name:"Norfloxacin",ATC_code:"J01MA06",EML:"No",value:1,"description.x":"A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase.",description:"A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase."},{name:"Ofloxacin",ATC_code:"J01MA01",EML:"No",value:1,"description.x":"A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.",description:"A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication."},{name:"Pazufloxacin",ATC_code:"J01MA18",EML:"No",value:1,"description.x":"Pazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol).",description:"Pazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol)."},{name:"Pefloxacin",ATC_code:"J01MA03",EML:"No",value:1,"description.x":"A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.",description:"A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria."},{name:"Prulifloxacin",ATC_code:"J01MA17",EML:"No",value:1,"description.x":"Prulifloxacin has been investigated for the treatment of Urinary Tract Infection.",description:"Prulifloxacin has been investigated for the treatment of Urinary Tract Infection."},{name:"Rufloxacin",ATC_code:"J01MA10",EML:"No",value:1,"description.x":"Rufloxacin is a quinolone antibiotic. ",description:"Rufloxacin is a quinolone antibiotic. "},{name:"Sitafloxacin",ATC_code:"J01MA21",EML:"No",value:1,"description.x":"Fluoroquinolones",description:"Fluoroquinolones"},{name:"Sparfloxacin",ATC_code:"J01MA09",EML:"No",value:1,"description.x":"Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription.",description:"Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription."},{name:"Temafloxacin",ATC_code:"J01MA05",EML:"No",value:1,"description.x":"Temafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class. It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three deaths.",description:"Temafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class. It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three deaths."},{name:"Tosufloxacin",ATC_code:"J01MA22",EML:"No",value:1,"description.x":"Fluoroquinolones",description:"Fluoroquinolones"},{name:"Trovafloxacin",ATC_code:"J01MA13",EML:"No",value:1,"description.x":"Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones. Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market.",description:"Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones. Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market."}],children:[{name:"Watch",children:[{name:"Ciprofloxacin",ATC_code:"J01MA02",EML:"Yes",value:1,"description.x":`Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.\r
\r
The first ciprofloxacin containing product was FDA approved on 22 October 1987.`,description:`Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.\r
\r
The first ciprofloxacin containing product was FDA approved on 22 October 1987.`},{name:"Delafloxacin",ATC_code:"J01MA23",EML:"No",value:1,"description.x":"Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections.",description:"Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections."},{name:"Enoxacin",ATC_code:"J01MA04",EML:"No",value:1,"description.x":"A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.",description:"A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid."},{name:"Fleroxacin",ATC_code:"J01MA08",EML:"No",value:1,"description.x":"Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2.",description:"Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2."},{name:"Garenoxacin",ATC_code:"J01MA19",EML:"No",value:1,"description.x":"Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.",description:"Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections."},{name:"Gatifloxacin",ATC_code:"J01MA16",EML:"No",value:1,"description.x":`Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan.\r
\r
The FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.`,description:`Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan.\r
\r
The FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.`},{name:"Gemifloxacin",ATC_code:"J01MA15",EML:"No",value:1,"description.x":"Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.",description:"Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth."},{name:"Grepafloxacin",ATC_code:"J01MA11",EML:"No",value:1,"description.x":"Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States.",description:"Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States."},{name:"Lascufloxacin",ATC_code:"J01MA25",EML:"No",value:1,description:"Lascufloxacin, marketed under the trade name Lasvic, is a fluoroquinolone antibiotic drug. It was approved in Japan in 2019 for the treatment of various bacterial infections such as community-acquired pneumonia, otorhinolaryngological infections, and respiratory tract infections. Lascufloxacin is effective against several Gram-positive bacteria, including Streptococcus pneumoniae and Streptococcus anginosus. This antibiotic provides a treatment option for specific bacterial infections, particularly those affecting the respiratory tract. Source: Wikepedia"},{name:"Levofloxacin",ATC_code:"J01MA12",EML:"No",value:1,"description.x":`Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as gatifloxacin and moxifloxacin, is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.\r
\r
Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.`,description:`Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as gatifloxacin and moxifloxacin, is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.\r
\r
Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.`},{name:"Levonadifloxacin",ATC_code:"J01MA24",EML:"No",value:1,"description.x":"Levonadifloxacin is under investigation in clinical trial NCT03405064 (Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)).",description:"Levonadifloxacin is under investigation in clinical trial NCT03405064 (Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI))."},{name:"Lomefloxacin",ATC_code:"J01MA07",EML:"No",value:1,"description.x":"Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well.",description:"Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well."},{name:"Moxifloxacin",ATC_code:"J01MA14",EML:"No",value:1,"description.x":"Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.",description:"Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment."},{name:"Norfloxacin",ATC_code:"J01MA06",EML:"No",value:1,"description.x":"A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase.",description:"A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase."},{name:"Ofloxacin",ATC_code:"J01MA01",EML:"No",value:1,"description.x":"A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.",description:"A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication."},{name:"Pazufloxacin",ATC_code:"J01MA18",EML:"No",value:1,"description.x":"Pazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol).",description:"Pazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol)."},{name:"Pefloxacin",ATC_code:"J01MA03",EML:"No",value:1,"description.x":"A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.",description:"A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria."},{name:"Prulifloxacin",ATC_code:"J01MA17",EML:"No",value:1,"description.x":"Prulifloxacin has been investigated for the treatment of Urinary Tract Infection.",description:"Prulifloxacin has been investigated for the treatment of Urinary Tract Infection."},{name:"Rufloxacin",ATC_code:"J01MA10",EML:"No",value:1,"description.x":"Rufloxacin is a quinolone antibiotic. ",description:"Rufloxacin is a quinolone antibiotic. "},{name:"Sitafloxacin",ATC_code:"J01MA21",EML:"No",value:1,"description.x":"Fluoroquinolones",description:"Fluoroquinolones"},{name:"Sparfloxacin",ATC_code:"J01MA09",EML:"No",value:1,"description.x":"Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription.",description:"Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription."},{name:"Temafloxacin",ATC_code:"J01MA05",EML:"No",value:1,"description.x":"Temafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class. It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three deaths.",description:"Temafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class. It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three deaths."},{name:"Tosufloxacin",ATC_code:"J01MA22",EML:"No",value:1,"description.x":"Fluoroquinolones",description:"Fluoroquinolones"},{name:"Trovafloxacin",ATC_code:"J01MA13",EML:"No",value:1,"description.x":"Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones. Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market.",description:"Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones. Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market."}]}]},{name:"Lincosamides",data:[{name:"Clindamycin",ATC_code:"J01FF01",EML:"Yes",value:1,"description.x":`Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli. Interestingly, clindamycin appears to carry some activity against protozoans, and has been used off-label in the treatment of toxoplasmosis, malaria, and babesiosis.\r
\r
Clindamycin is derived from, and has largely replaced, lincomycin, a naturally occurring lincosamide and the eponymous member of this antibiotic class, due to its improved properties over the parent compound. The name lincomycin is derived from Lincoln, Nebraska, where it was first isolated from Streptomyces lincolnensis found in a soil sample.`,description:`Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli. Interestingly, clindamycin appears to carry some activity against protozoans, and has been used off-label in the treatment of toxoplasmosis, malaria, and babesiosis.\r
\r
Clindamycin is derived from, and has largely replaced, lincomycin, a naturally occurring lincosamide and the eponymous member of this antibiotic class, due to its improved properties over the parent compound. The name lincomycin is derived from Lincoln, Nebraska, where it was first isolated from Streptomyces lincolnensis found in a soil sample.`},{name:"Lincomycin",ATC_code:"J01FF02",EML:"No",value:1,"description.x":`Lincomycin is a lincosamide antibiotic first isolated from the soil bacterium Streptomyces lincolnensis in Lincoln, Nebraska. Clinical use of lincomycin has largely been superseded by its semisynthetic derivative clindamycin due to its higher efficacy and a wider range of susceptible organisms, though lincomycin remains in use.\r
\r
Lincomycin was approved by the FDA on December 29, 1964.`,description:`Lincomycin is a lincosamide antibiotic first isolated from the soil bacterium Streptomyces lincolnensis in Lincoln, Nebraska. Clinical use of lincomycin has largely been superseded by its semisynthetic derivative clindamycin due to its higher efficacy and a wider range of susceptible organisms, though lincomycin remains in use.\r
\r
Lincomycin was approved by the FDA on December 29, 1964.`}],children:[{name:"Access",children:[{name:"Clindamycin",ATC_code:"J01FF01",EML:"Yes",value:1,"description.x":`Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli. Interestingly, clindamycin appears to carry some activity against protozoans, and has been used off-label in the treatment of toxoplasmosis, malaria, and babesiosis.\r
\r
Clindamycin is derived from, and has largely replaced, lincomycin, a naturally occurring lincosamide and the eponymous member of this antibiotic class, due to its improved properties over the parent compound. The name lincomycin is derived from Lincoln, Nebraska, where it was first isolated from Streptomyces lincolnensis found in a soil sample.`,description:`Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli. Interestingly, clindamycin appears to carry some activity against protozoans, and has been used off-label in the treatment of toxoplasmosis, malaria, and babesiosis.\r
\r
Clindamycin is derived from, and has largely replaced, lincomycin, a naturally occurring lincosamide and the eponymous member of this antibiotic class, due to its improved properties over the parent compound. The name lincomycin is derived from Lincoln, Nebraska, where it was first isolated from Streptomyces lincolnensis found in a soil sample.`}]},{name:"Watch",children:[{name:"Lincomycin",ATC_code:"J01FF02",EML:"No",value:1,"description.x":`Lincomycin is a lincosamide antibiotic first isolated from the soil bacterium Streptomyces lincolnensis in Lincoln, Nebraska. Clinical use of lincomycin has largely been superseded by its semisynthetic derivative clindamycin due to its higher efficacy and a wider range of susceptible organisms, though lincomycin remains in use.\r
\r
Lincomycin was approved by the FDA on December 29, 1964.`,description:`Lincomycin is a lincosamide antibiotic first isolated from the soil bacterium Streptomyces lincolnensis in Lincoln, Nebraska. Clinical use of lincomycin has largely been superseded by its semisynthetic derivative clindamycin due to its higher efficacy and a wider range of susceptible organisms, though lincomycin remains in use.\r
\r
Lincomycin was approved by the FDA on December 29, 1964.`}]}]},{name:"Phenol derivatives",data:[{name:"Clofoctol",ATC_code:"J01XX03",EML:"No",value:2,"description.x":"Other antibacterials",description:"Other antibacterials"}],children:[{name:"Watch",children:[{name:"Clofoctol",ATC_code:"J01XX03",EML:"No",value:2,"description.x":"Other antibacterials",description:"Other antibacterials"}]}]},{name:"Polymyxins",data:[{name:"Colistin_IV",ATC_code:"J01XB01",EML:"Yes",value:1,"description.x":"Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.",description:"Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally."},{name:"Colistin_oral",ATC_code:"A07AA10",EML:"No",value:1,"description.x":"Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.",description:"Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally."},{name:"Polymyxin-B_IV",ATC_code:"J01XB02",EML:"Yes",value:1,"description.x":"Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxicA176426,FDA Label. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosaFDA Label. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line.",description:"Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxicA176426,FDA Label. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosaFDA Label. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line."},{name:"Polymyxin-B_oral",ATC_code:"A07AA05",EML:"No",value:1,"description.x":"Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxicA176426,FDA Label. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosaFDA Label. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line.",description:"Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxicA176426,FDA Label. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosaFDA Label. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line."}],children:[{name:"Reserve",children:[{name:"Colistin_IV",ATC_code:"J01XB01",EML:"Yes",value:1,"description.x":"Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.",description:"Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally."},{name:"Colistin_oral",ATC_code:"A07AA10",EML:"No",value:1,"description.x":"Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.",description:"Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally."},{name:"Polymyxin-B_IV",ATC_code:"J01XB02",EML:"Yes",value:1,"description.x":"Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxicA176426,FDA Label. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosaFDA Label. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line.",description:"Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxicA176426,FDA Label. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosaFDA Label. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line."},{name:"Polymyxin-B_oral",ATC_code:"A07AA05",EML:"No",value:1,"description.x":"Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxicA176426,FDA Label. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosaFDA Label. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line.",description:"Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxicA176426,FDA Label. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosaFDA Label. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line."}]}]},{name:"Glycopeptides",data:[{name:"Dalbavancin",ATC_code:"J01XA04",EML:"No",value:1,"description.x":"Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin . Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing FDA Label, F2356, A4072, A4073. Its use is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), S. pyogenes, S. agalactiae, S. dysgalactiae, the S. anginosus group (including S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin susceptible strains) FDA Label, F2356. Dalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking FDA Label, F2356, A4072, A4073.",description:"Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin . Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing FDA Label, F2356, A4072, A4073. Its use is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), S. pyogenes, S. agalactiae, S. dysgalactiae, the S. anginosus group (including S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin susceptible strains) FDA Label, F2356. Dalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking FDA Label, F2356, A4072, A4073."},{name:"Oritavancin",ATC_code:"J01XA05",EML:"No",value:1,"description.x":`Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of single-dose administration and has been proven as non-inferior to a full course of vancomycin therapy.\r
\r
On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg. Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and skin structure infections.`,description:`Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of single-dose administration and has been proven as non-inferior to a full course of vancomycin therapy.\r
\r
On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg. Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and skin structure infections.`},{name:"Teicoplanin",ATC_code:"J01XA02",EML:"No",value:1,"description.x":"Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine moiety.",description:"Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine moiety."},{name:"Telavancin",ATC_code:"J01XA03",EML:"No",value:1,"description.x":"Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.  MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others.",description:"Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.  MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others."},{name:"Vancomycin_IV",ATC_code:"J01XA01",EML:"Yes",value:1,"description.x":`Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.\r
\r
As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains . Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products .`,description:`Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.\r
\r
As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains . Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products .`},{name:"Vancomycin_oral",ATC_code:"A07AA09",EML:"Yes",value:1,"description.x":`Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.\r
\r
As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains . Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products .`,description:`Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.\r
\r
As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains . Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products .`}],children:[{name:"Reserve",children:[{name:"Dalbavancin",ATC_code:"J01XA04",EML:"No",value:1,"description.x":"Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin . Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing FDA Label, F2356, A4072, A4073. Its use is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), S. pyogenes, S. agalactiae, S. dysgalactiae, the S. anginosus group (including S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin susceptible strains) FDA Label, F2356. Dalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking FDA Label, F2356, A4072, A4073.",description:"Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin . Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing FDA Label, F2356, A4072, A4073. Its use is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), S. pyogenes, S. agalactiae, S. dysgalactiae, the S. anginosus group (including S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin susceptible strains) FDA Label, F2356. Dalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking FDA Label, F2356, A4072, A4073."},{name:"Oritavancin",ATC_code:"J01XA05",EML:"No",value:1,"description.x":`Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of single-dose administration and has been proven as non-inferior to a full course of vancomycin therapy.\r
\r
On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg. Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and skin structure infections.`,description:`Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of single-dose administration and has been proven as non-inferior to a full course of vancomycin therapy.\r
\r
On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg. Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and skin structure infections.`},{name:"Telavancin",ATC_code:"J01XA03",EML:"No",value:1,"description.x":"Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.  MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others.",description:"Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.  MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others."}]},{name:"Watch",children:[{name:"Teicoplanin",ATC_code:"J01XA02",EML:"No",value:1,"description.x":"Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine moiety.",description:"Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine moiety."},{name:"Vancomycin_IV",ATC_code:"J01XA01",EML:"Yes",value:1,"description.x":`Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.\r
\r
As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains . Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products .`,description:`Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.\r
\r
As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains . Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products .`},{name:"Vancomycin_oral",ATC_code:"A07AA09",EML:"Yes",value:1,"description.x":`Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.\r
\r
As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains . Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products .`,description:`Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.\r
\r
As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains . Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products .`}]}]},{name:"Streptogramins",data:[{name:"Dalfopristin/quinupristin",ATC_code:"J01FG02",EML:"No",value:1,description:"Quinupristin/dalfopristin, sold under the trade name Synercid, is a combination of two antibiotics used to treat infections caused by staphylococci and vancomycin-resistant Enterococcus faecium. Both quinupristin and dalfopristin are streptogramin antibiotics derived from pristinamycin. They are combined in a ratio of 30% quinupristin to 70% dalfopristin. This combination functions by inhibiting protein synthesis in bacteria in a synergistic manner, exhibiting bactericidal activity when used together. The drug is administered intravenously and is known to inhibit liver enzyme P450, affecting the metabolism of various other drugs. Source: Wikepedia"},{name:"Pristinamycin",ATC_code:"J01FG01",EML:"No",value:1,description:"Streptogramins","description.x":"Streptogramins"}],children:[{name:"Reserve",children:[{name:"Dalfopristin/quinupristin",ATC_code:"J01FG02",EML:"No",value:1,description:"Quinupristin/dalfopristin, sold under the trade name Synercid, is a combination of two antibiotics used to treat infections caused by staphylococci and vancomycin-resistant Enterococcus faecium. Both quinupristin and dalfopristin are streptogramin antibiotics derived from pristinamycin. They are combined in a ratio of 30% quinupristin to 70% dalfopristin. This combination functions by inhibiting protein synthesis in bacteria in a synergistic manner, exhibiting bactericidal activity when used together. The drug is administered intravenously and is known to inhibit liver enzyme P450, affecting the metabolism of various other drugs. Source: Wikepedia"}]},{name:"Watch",children:[{name:"Pristinamycin",ATC_code:"J01FG01",EML:"No",value:1,"description.x":"Streptogramins",description:"Streptogramins"}]}]},{name:"Lipopeptides",data:[{name:"Daptomycin",ATC_code:"J01XX09",EML:"No",value:2,"description.x":`Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant Staphylococcus aureus (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE). Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked ring and the N-terminal tryptophan covalently bonded to decanoic acid. Daptomycin was first discovered in the early 1980s by researchers at Eli Lilly in soil samples from Mount Ararat in Turkey. Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing scheme reduced side effects while retaining efficacy.\r
\r
Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).`,description:`Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant Staphylococcus aureus (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE). Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked ring and the N-terminal tryptophan covalently bonded to decanoic acid. Daptomycin was first discovered in the early 1980s by researchers at Eli Lilly in soil samples from Mount Ararat in Turkey. Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing scheme reduced side effects while retaining efficacy.\r
\r
Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).`}],children:[{name:"Reserve",children:[{name:"Daptomycin",ATC_code:"J01XX09",EML:"No",value:2,"description.x":`Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant Staphylococcus aureus (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE). Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked ring and the N-terminal tryptophan covalently bonded to decanoic acid. Daptomycin was first discovered in the early 1980s by researchers at Eli Lilly in soil samples from Mount Ararat in Turkey. Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing scheme reduced side effects while retaining efficacy.\r
\r
Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).`,description:`Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant Staphylococcus aureus (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE). Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked ring and the N-terminal tryptophan covalently bonded to decanoic acid. Daptomycin was first discovered in the early 1980s by researchers at Eli Lilly in soil samples from Mount Ararat in Turkey. Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing scheme reduced side effects while retaining efficacy.\r
\r
Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).`}]}]},{name:"Phosphonics",data:[{name:"Fosfomycin_IV",ATC_code:"J01XX01",EML:"Yes",value:1,"description.x":`Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by Streptomyces fradiae. It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring.\r
\r
Due to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated urinary tract infections (UTIs) in females. Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria. As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.`,description:`Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by Streptomyces fradiae. It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring.\r
\r
Due to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated urinary tract infections (UTIs) in females. Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria. As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.`},{name:"Fosfomycin_oral",ATC_code:"J01XX01",EML:"No",value:1,"description.x":`Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by Streptomyces fradiae. It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring.\r
\r
Due to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated urinary tract infections (UTIs) in females. Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria. As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.`,description:`Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by Streptomyces fradiae. It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring.\r
\r
Due to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated urinary tract infections (UTIs) in females. Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria. As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.`}],children:[{name:"Reserve",children:[{name:"Fosfomycin_IV",ATC_code:"J01XX01",EML:"Yes",value:1,"description.x":`Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by Streptomyces fradiae. It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring.\r
\r
Due to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated urinary tract infections (UTIs) in females. Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria. As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.`,description:`Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by Streptomyces fradiae. It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring.\r
\r
Due to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated urinary tract infections (UTIs) in females. Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria. As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.`}]},{name:"Watch",children:[{name:"Fosfomycin_oral",ATC_code:"J01XX01",EML:"No",value:1,"description.x":`Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by Streptomyces fradiae. It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring.\r
\r
Due to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated urinary tract infections (UTIs) in females. Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria. As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.`,description:`Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by Streptomyces fradiae. It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring.\r
\r
Due to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated urinary tract infections (UTIs) in females. Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria. As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.`}]}]},{name:"Nitrofuran derivatives",data:[{name:"Furazidin",ATC_code:"J01XE03",EML:"No",value:1,"description.x":"Nitrofuran derivatives",description:"Nitrofuran derivatives"},{name:"Nifurtoinol",ATC_code:"J01XE02",EML:"No",value:1,"description.x":"Nitrofuran derivatives",description:"Nitrofuran derivatives"}],children:[{name:"Access",children:[{name:"Furazidin",ATC_code:"J01XE03",EML:"No",value:1,"description.x":"Nitrofuran derivatives",description:"Nitrofuran derivatives"},{name:"Nifurtoinol",ATC_code:"J01XE02",EML:"No",value:1,"description.x":"Nitrofuran derivatives",description:"Nitrofuran derivatives"}]}]},{name:"Steroid antibacterials",data:[{name:"Fusidic-acid",ATC_code:"J01XC01",EML:"No",value:2,"description.x":"An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis. It is often used topically in creams and eyedrops but is available in systemic formulations including tablets and injections.",description:"An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis. It is often used topically in creams and eyedrops but is available in systemic formulations including tablets and injections."}],children:[{name:"Watch",children:[{name:"Fusidic-acid",ATC_code:"J01XC01",EML:"No",value:2,"description.x":"An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis. It is often used topically in creams and eyedrops but is available in systemic formulations including tablets and injections.",description:"An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis. It is often used topically in creams and eyedrops but is available in systemic formulations including tablets and injections."}]}]},{name:"Pleuromutilin",data:[{name:"Lefamulin",ATC_code:"J01XX12",EML:"No",value:2,"description.x":"Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019.  This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity.",description:"Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019.  This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity."}],children:[{name:"Reserve",children:[{name:"Lefamulin",ATC_code:"J01XX12",EML:"No",value:2,"description.x":"Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019.  This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity.",description:"Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019.  This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity."}]}]},{name:"Oxazolidinones",data:[{name:"Linezolid",ATC_code:"J01XX08",EML:"Yes",value:1,"description.x":`Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit and, in doing so, prevents the formation of the 70S initiation complex which is essential for bacterial reproduction.\r
\r
Linezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class. A second member of this class, tedizolid, was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor.`,description:`Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit and, in doing so, prevents the formation of the 70S initiation complex which is essential for bacterial reproduction.\r
\r
Linezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class. A second member of this class, tedizolid, was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor.`},{name:"Tedizolid",ATC_code:"J01XX11",EML:"Yes (therapeutic alternative to linezolid (EML))",value:1,"description.x":`Drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and penicillin-resistant Streptococcus penumoniae, represent a massive public health threat. Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved linezolid and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than linezolid.\r
\r
Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®). This product is currently available as both an oral tablet and as a powder for intravenous injection.`,description:`Drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and penicillin-resistant Streptococcus penumoniae, represent a massive public health threat. Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved linezolid and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than linezolid.\r
\r
Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®). This product is currently available as both an oral tablet and as a powder for intravenous injection.`}],children:[{name:"Reserve",children:[{name:"Linezolid",ATC_code:"J01XX08",EML:"Yes",value:1,"description.x":`Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit and, in doing so, prevents the formation of the 70S initiation complex which is essential for bacterial reproduction.\r
\r
Linezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class. A second member of this class, tedizolid, was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor.`,description:`Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit and, in doing so, prevents the formation of the 70S initiation complex which is essential for bacterial reproduction.\r
\r
Linezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class. A second member of this class, tedizolid, was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor.`},{name:"Tedizolid",ATC_code:"J01XX11",EML:"Yes (therapeutic alternative to linezolid (EML))",value:1,"description.x":`Drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and penicillin-resistant Streptococcus penumoniae, represent a massive public health threat. Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved linezolid and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than linezolid.\r
\r
Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®). This product is currently available as both an oral tablet and as a powder for intravenous injection.`,description:`Drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and penicillin-resistant Streptococcus penumoniae, represent a massive public health threat. Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved linezolid and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than linezolid.\r
\r
Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®). This product is currently available as both an oral tablet and as a powder for intravenous injection.`}]}]},{name:"Imidazoles",data:[{name:"Metronidazole_IV",ATC_code:"J01XD01",EML:"Yes",value:1,"description.x":"Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.",description:"Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections."},{name:"Metronidazole_oral",ATC_code:"P01AB01",EML:"Yes",value:1,"description.x":"Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.",description:"Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections."},{name:"Ornidazole_IV",ATC_code:"J01XD03",EML:"No",value:1,"description.x":"Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.",description:"Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery."},{name:"Ornidazole_oral",ATC_code:"P01AB03",EML:"No",value:1,"description.x":"Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.",description:"Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery."},{name:"Secnidazole",ATC_code:"P01AB07",EML:"No",value:1,"description.x":`Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including  and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria as well as protozoa. Once it enters bacteria and parasites, secnidazole is activated by bacterial or parasitic enzymes to form a radical anion, thereby damaging and killing the target pathogen.\r
\r
Secnidazole has been available in many other countries in Europe, Asia, South America, and Africa for decades. In September 2017, FDA approved secnidazole under the market name Solosec for the treatment of trichomoniasis and bacterial vaginosis.`,description:`Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including  and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria as well as protozoa. Once it enters bacteria and parasites, secnidazole is activated by bacterial or parasitic enzymes to form a radical anion, thereby damaging and killing the target pathogen.\r
\r
Secnidazole has been available in many other countries in Europe, Asia, South America, and Africa for decades. In September 2017, FDA approved secnidazole under the market name Solosec for the treatment of trichomoniasis and bacterial vaginosis.`},{name:"Tinidazole_IV",ATC_code:"J01XD02",EML:"No",value:1,"description.x":"A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.",description:"A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections."},{name:"Tinidazole_oral",ATC_code:"P01AB02",EML:"No",value:1,"description.x":"A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.",description:"A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections."}],children:[{name:"Access",children:[{name:"Metronidazole_IV",ATC_code:"J01XD01",EML:"Yes",value:1,"description.x":"Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.",description:"Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections."},{name:"Metronidazole_oral",ATC_code:"P01AB01",EML:"Yes",value:1,"description.x":"Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.",description:"Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections."},{name:"Ornidazole_IV",ATC_code:"J01XD03",EML:"No",value:1,"description.x":"Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.",description:"Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery."},{name:"Ornidazole_oral",ATC_code:"P01AB03",EML:"No",value:1,"description.x":"Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.",description:"Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery."},{name:"Secnidazole",ATC_code:"P01AB07",EML:"No",value:1,"description.x":`Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including  and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria as well as protozoa. Once it enters bacteria and parasites, secnidazole is activated by bacterial or parasitic enzymes to form a radical anion, thereby damaging and killing the target pathogen.\r
\r
Secnidazole has been available in many other countries in Europe, Asia, South America, and Africa for decades. In September 2017, FDA approved secnidazole under the market name Solosec for the treatment of trichomoniasis and bacterial vaginosis.`,description:`Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including  and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria as well as protozoa. Once it enters bacteria and parasites, secnidazole is activated by bacterial or parasitic enzymes to form a radical anion, thereby damaging and killing the target pathogen.\r
\r
Secnidazole has been available in many other countries in Europe, Asia, South America, and Africa for decades. In September 2017, FDA approved secnidazole under the market name Solosec for the treatment of trichomoniasis and bacterial vaginosis.`},{name:"Tinidazole_IV",ATC_code:"J01XD02",EML:"No",value:1,"description.x":"A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.",description:"A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections."},{name:"Tinidazole_oral",ATC_code:"P01AB02",EML:"No",value:1,"description.x":"A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.",description:"A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections."}]}]},{name:"Nitrofuran-derivatives",data:[{name:"Nitrofurantoin",ATC_code:"J01XE01",EML:"Yes",value:2,"description.x":`Nitrofurantoin is a nitrofuran antibiotic used to treat uncomplicated urinary tract infections. Nitrofurantoin is converted by bacterial nitroreductases to electrophilic intermediates which inhibit the citric acid cycle as well as synthesis of DNA, RNA, and protein. This drug is more resistant to the development of bacterial resistance because it acts on many targets at once. Nitrofurantoin is a second line treatment to trimethoprim/sulfamethoxazole.\r
\r
Nitrofurantoin was granted FDA approval on 6 February 1953.`,description:`Nitrofurantoin is a nitrofuran antibiotic used to treat uncomplicated urinary tract infections. Nitrofurantoin is converted by bacterial nitroreductases to electrophilic intermediates which inhibit the citric acid cycle as well as synthesis of DNA, RNA, and protein. This drug is more resistant to the development of bacterial resistance because it acts on many targets at once. Nitrofurantoin is a second line treatment to trimethoprim/sulfamethoxazole.\r
\r
Nitrofurantoin was granted FDA approval on 6 February 1953.`}],children:[{name:"Access",children:[{name:"Nitrofurantoin",ATC_code:"J01XE01",EML:"Yes",value:2,"description.x":`Nitrofurantoin is a nitrofuran antibiotic used to treat uncomplicated urinary tract infections. Nitrofurantoin is converted by bacterial nitroreductases to electrophilic intermediates which inhibit the citric acid cycle as well as synthesis of DNA, RNA, and protein. This drug is more resistant to the development of bacterial resistance because it acts on many targets at once. Nitrofurantoin is a second line treatment to trimethoprim/sulfamethoxazole.\r
\r
Nitrofurantoin was granted FDA approval on 6 February 1953.`,description:`Nitrofurantoin is a nitrofuran antibiotic used to treat uncomplicated urinary tract infections. Nitrofurantoin is converted by bacterial nitroreductases to electrophilic intermediates which inhibit the citric acid cycle as well as synthesis of DNA, RNA, and protein. This drug is more resistant to the development of bacterial resistance because it acts on many targets at once. Nitrofurantoin is a second line treatment to trimethoprim/sulfamethoxazole.\r
\r
Nitrofurantoin was granted FDA approval on 6 February 1953.`}]}]},{name:"Rifamycins",data:[{name:"Rifabutin",ATC_code:"J04AB04",EML:"No",value:1,"description.x":"A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.",description:"A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients."},{name:"Rifampicin",ATC_code:"J04AB02",EML:"No",value:1,"description.x":"A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)",description:"A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)"},{name:"Rifamycin_IV",ATC_code:"J04AB03",EML:"No",value:1,"description.x":`Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. Some small modifications where performed in this inactive compound and with the creation of rifamycin SV there was the first antibiotic used intravenously for the treatment of tuberculosis.\r
\r
Rifamycin has had several direct derivative products such as rifamycin SV, rifaximin, rifampin and rifamycin CV. All of the derivatives have slight different physicochemical properties when compared to the parent structure.\r
\r
Rifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it to have a status a priority review. This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.`,description:`Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. Some small modifications where performed in this inactive compound and with the creation of rifamycin SV there was the first antibiotic used intravenously for the treatment of tuberculosis.\r
\r
Rifamycin has had several direct derivative products such as rifamycin SV, rifaximin, rifampin and rifamycin CV. All of the derivatives have slight different physicochemical properties when compared to the parent structure.\r
\r
Rifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it to have a status a priority review. This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.`},{name:"Rifamycin_oral",ATC_code:"A07AA13",EML:"No",value:1,"description.x":`Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. Some small modifications where performed in this inactive compound and with the creation of rifamycin SV there was the first antibiotic used intravenously for the treatment of tuberculosis.\r
\r
Rifamycin has had several direct derivative products such as rifamycin SV, rifaximin, rifampin and rifamycin CV. All of the derivatives have slight different physicochemical properties when compared to the parent structure.\r
\r
Rifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it to have a status a priority review. This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.`,description:`Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. Some small modifications where performed in this inactive compound and with the creation of rifamycin SV there was the first antibiotic used intravenously for the treatment of tuberculosis.\r
\r
Rifamycin has had several direct derivative products such as rifamycin SV, rifaximin, rifampin and rifamycin CV. All of the derivatives have slight different physicochemical properties when compared to the parent structure.\r
\r
Rifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it to have a status a priority review. This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.`},{name:"Rifaximin",ATC_code:"A07AA11",EML:"No",value:1,"description.x":"Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals.",description:"Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals."}],children:[{name:"Watch",children:[{name:"Rifabutin",ATC_code:"J04AB04",EML:"No",value:1,"description.x":"A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.",description:"A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients."},{name:"Rifampicin",ATC_code:"J04AB02",EML:"No",value:1,"description.x":"A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)",description:"A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)"},{name:"Rifamycin_IV",ATC_code:"J04AB03",EML:"No",value:1,"description.x":`Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. Some small modifications where performed in this inactive compound and with the creation of rifamycin SV there was the first antibiotic used intravenously for the treatment of tuberculosis.\r
\r
Rifamycin has had several direct derivative products such as rifamycin SV, rifaximin, rifampin and rifamycin CV. All of the derivatives have slight different physicochemical properties when compared to the parent structure.\r
\r
Rifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it to have a status a priority review. This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.`,description:`Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. Some small modifications where performed in this inactive compound and with the creation of rifamycin SV there was the first antibiotic used intravenously for the treatment of tuberculosis.\r
\r
Rifamycin has had several direct derivative products such as rifamycin SV, rifaximin, rifampin and rifamycin CV. All of the derivatives have slight different physicochemical properties when compared to the parent structure.\r
\r
Rifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it to have a status a priority review. This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.`},{name:"Rifamycin_oral",ATC_code:"A07AA13",EML:"No",value:1,"description.x":`Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. Some small modifications where performed in this inactive compound and with the creation of rifamycin SV there was the first antibiotic used intravenously for the treatment of tuberculosis.\r
\r
Rifamycin has had several direct derivative products such as rifamycin SV, rifaximin, rifampin and rifamycin CV. All of the derivatives have slight different physicochemical properties when compared to the parent structure.\r
\r
Rifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it to have a status a priority review. This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.`,description:`Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. Some small modifications where performed in this inactive compound and with the creation of rifamycin SV there was the first antibiotic used intravenously for the treatment of tuberculosis.\r
\r
Rifamycin has had several direct derivative products such as rifamycin SV, rifaximin, rifampin and rifamycin CV. All of the derivatives have slight different physicochemical properties when compared to the parent structure.\r
\r
Rifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it to have a status a priority review. This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.`},{name:"Rifaximin",ATC_code:"A07AA11",EML:"No",value:1,"description.x":"Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals.",description:"Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals."}]}]},{name:"Aminocyclitols",data:[{name:"Spectinomycin",ATC_code:"J01XX04",EML:"Yes",value:2,"description.x":"An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.",description:"An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea."}],children:[{name:"Access",children:[{name:"Spectinomycin",ATC_code:"J01XX04",EML:"Yes",value:2,"description.x":"An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.",description:"An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea."}]}]},{name:"Sulfonamides",data:[{name:"Sulfadiazine",ATC_code:"J01EC02",EML:"No",value:1,"description.x":"One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.",description:"One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections."},{name:"Sulfadimethoxine",ATC_code:"J01ED01",EML:"No",value:1,"description.x":`Sulfadimethoxine is a sulfonamide antibiotic. Sulfadimethoxine is used to treat many infections, including treatment of respiratory, urinary tract, enteric, and soft tissue infections. It is most frequently used in veterinary medicine, although it is approved in some countries for use in humans. Sulfadimethoxine inhibits bacterial synthesis of folic acid (pteroylglutamic acid) from para-aminobenzoic acid. Sulfadimethoxine is approved in Russia for use in humans, including children, and has been successfully used there for more than 35 years. It is widely available in Russia as an over-the-counter drug manufactured by a number of Russian pharmaceutical companies.\r
\r
In the US, sulfadimethoxine is one of the products that have been withdrawn or removed from the market after being found to be unsafe or not effective.`,description:`Sulfadimethoxine is a sulfonamide antibiotic. Sulfadimethoxine is used to treat many infections, including treatment of respiratory, urinary tract, enteric, and soft tissue infections. It is most frequently used in veterinary medicine, although it is approved in some countries for use in humans. Sulfadimethoxine inhibits bacterial synthesis of folic acid (pteroylglutamic acid) from para-aminobenzoic acid. Sulfadimethoxine is approved in Russia for use in humans, including children, and has been successfully used there for more than 35 years. It is widely available in Russia as an over-the-counter drug manufactured by a number of Russian pharmaceutical companies.\r
\r
In the US, sulfadimethoxine is one of the products that have been withdrawn or removed from the market after being found to be unsafe or not effective.`},{name:"Sulfadimidine",ATC_code:"J01EB03",EML:"No",value:1,"description.x":"A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.",description:"A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides."},{name:"Sulfafurazole",ATC_code:"J01EB05",EML:"No",value:1,"description.x":"A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.",description:"A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms."},{name:"Sulfaisodimidine",ATC_code:"J01EB01",EML:"No",value:1,"description.x":"Sulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of urinary tract infections in the 1950s, however, it is unclear whether this drug has been officially approved for use anywhere .",description:"Sulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of urinary tract infections in the 1950s, however, it is unclear whether this drug has been officially approved for use anywhere ."},{name:"Sulfalene",ATC_code:"J01ED02",EML:"No",value:1,"description.x":"Long-acting plasma-bound sulfonamide used for respiratory and urinary tract infections and also for malaria.",description:"Long-acting plasma-bound sulfonamide used for respiratory and urinary tract infections and also for malaria."},{name:"Sulfamazone",ATC_code:"J01ED09",EML:"No",value:1,"description.x":"Long-acting sulfonamides",description:"Long-acting sulfonamides"},{name:"Sulfamerazine",ATC_code:"J01ED07",EML:"No",value:1,"description.x":"A sulfanilamide that is used as an antibacterial agent.",description:"A sulfanilamide that is used as an antibacterial agent."},{name:"Sulfamethizole",ATC_code:"J01EB02",EML:"No",value:1,"description.x":"A sulfathiazole antibacterial agent.",description:"A sulfathiazole antibacterial agent."},{name:"Sulfamethoxazole",ATC_code:"J01EC01",EML:"No",value:1,"description.x":"Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with trimethoprim, which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance. In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts.",description:"Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with trimethoprim, which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance. In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts."},{name:"Sulfamethoxypyridazine",ATC_code:"J01ED05",EML:"No",value:1,"description.x":"Long-acting sulfonamides",description:"Long-acting sulfonamides"},{name:"Sulfametomidine",ATC_code:"J01ED03",EML:"No",value:1,"description.x":"Long-acting sulfonamides",description:"Long-acting sulfonamides"},{name:"Sulfametoxydiazine",ATC_code:"J01ED04",EML:"No",value:1,"description.x":"Long acting sulfonamide used in leprosy, urinary, and respiratory tract infections.",description:"Long acting sulfonamide used in leprosy, urinary, and respiratory tract infections."},{name:"Sulfamoxole",ATC_code:"J01EC03",EML:"No",value:1,"description.x":"Sulfamoxole is an antibacterial in the sulfonamide class.",description:"Sulfamoxole is an antibacterial in the sulfonamide class."},{name:"Sulfanilamide",ATC_code:"J01EB06",EML:"No",value:1,"description.x":"Sulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline.",description:"Sulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline."},{name:"Sulfaperin",ATC_code:"J01ED06",EML:"No",value:1,"description.x":"Long-acting sulfonamides",description:"Long-acting sulfonamides"},{name:"Sulfaphenazole",ATC_code:"J01ED08",EML:"No",value:1,"description.x":"Sulfaphenazole is a sulfonamide antibacterial.",description:"Sulfaphenazole is a sulfonamide antibacterial."},{name:"Sulfapyridine",ATC_code:"J01EB04",EML:"No",value:1,"description.x":"Antibacterial, potentially toxic, and previously used to treat certain skin diseases. No longer prescribed.",description:"Antibacterial, potentially toxic, and previously used to treat certain skin diseases. No longer prescribed."},{name:"Sulfathiazole",ATC_code:"J01EB07",EML:"No",value:1,"description.x":`Sulfathiazole is a short-acting sulfa drug. It used to be a common oral and topical antimicrobial until less toxic alternatives were discovered. It is still occasionally used, sometimes in combination with sulfabenzamide and sulfacetamide.\r
\r
Except for those formulated for vaginal use, the FDA withdrew its approval for the use of all drug products containing sulfathiazole.`,description:`Sulfathiazole is a short-acting sulfa drug. It used to be a common oral and topical antimicrobial until less toxic alternatives were discovered. It is still occasionally used, sometimes in combination with sulfabenzamide and sulfacetamide.\r
\r
Except for those formulated for vaginal use, the FDA withdrew its approval for the use of all drug products containing sulfathiazole.`},{name:"Sulfathiourea",ATC_code:"J01EB08",EML:"No",value:1,"description.x":"Short-acting sulfonamides",description:"Short-acting sulfonamides"}],children:[{name:"Access",children:[{name:"Sulfadiazine",ATC_code:"J01EC02",EML:"No",value:1,"description.x":"One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.",description:"One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections."},{name:"Sulfadimethoxine",ATC_code:"J01ED01",EML:"No",value:1,"description.x":`Sulfadimethoxine is a sulfonamide antibiotic. Sulfadimethoxine is used to treat many infections, including treatment of respiratory, urinary tract, enteric, and soft tissue infections. It is most frequently used in veterinary medicine, although it is approved in some countries for use in humans. Sulfadimethoxine inhibits bacterial synthesis of folic acid (pteroylglutamic acid) from para-aminobenzoic acid. Sulfadimethoxine is approved in Russia for use in humans, including children, and has been successfully used there for more than 35 years. It is widely available in Russia as an over-the-counter drug manufactured by a number of Russian pharmaceutical companies.\r
\r
In the US, sulfadimethoxine is one of the products that have been withdrawn or removed from the market after being found to be unsafe or not effective.`,description:`Sulfadimethoxine is a sulfonamide antibiotic. Sulfadimethoxine is used to treat many infections, including treatment of respiratory, urinary tract, enteric, and soft tissue infections. It is most frequently used in veterinary medicine, although it is approved in some countries for use in humans. Sulfadimethoxine inhibits bacterial synthesis of folic acid (pteroylglutamic acid) from para-aminobenzoic acid. Sulfadimethoxine is approved in Russia for use in humans, including children, and has been successfully used there for more than 35 years. It is widely available in Russia as an over-the-counter drug manufactured by a number of Russian pharmaceutical companies.\r
\r
In the US, sulfadimethoxine is one of the products that have been withdrawn or removed from the market after being found to be unsafe or not effective.`},{name:"Sulfadimidine",ATC_code:"J01EB03",EML:"No",value:1,"description.x":"A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.",description:"A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides."},{name:"Sulfafurazole",ATC_code:"J01EB05",EML:"No",value:1,"description.x":"A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.",description:"A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms."},{name:"Sulfaisodimidine",ATC_code:"J01EB01",EML:"No",value:1,"description.x":"Sulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of urinary tract infections in the 1950s, however, it is unclear whether this drug has been officially approved for use anywhere .",description:"Sulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of urinary tract infections in the 1950s, however, it is unclear whether this drug has been officially approved for use anywhere ."},{name:"Sulfalene",ATC_code:"J01ED02",EML:"No",value:1,"description.x":"Long-acting plasma-bound sulfonamide used for respiratory and urinary tract infections and also for malaria.",description:"Long-acting plasma-bound sulfonamide used for respiratory and urinary tract infections and also for malaria."},{name:"Sulfamazone",ATC_code:"J01ED09",EML:"No",value:1,"description.x":"Long-acting sulfonamides",description:"Long-acting sulfonamides"},{name:"Sulfamerazine",ATC_code:"J01ED07",EML:"No",value:1,"description.x":"A sulfanilamide that is used as an antibacterial agent.",description:"A sulfanilamide that is used as an antibacterial agent."},{name:"Sulfamethizole",ATC_code:"J01EB02",EML:"No",value:1,"description.x":"A sulfathiazole antibacterial agent.",description:"A sulfathiazole antibacterial agent."},{name:"Sulfamethoxazole",ATC_code:"J01EC01",EML:"No",value:1,"description.x":"Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with trimethoprim, which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance. In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts.",description:"Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with trimethoprim, which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance. In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts."},{name:"Sulfamethoxypyridazine",ATC_code:"J01ED05",EML:"No",value:1,"description.x":"Long-acting sulfonamides",description:"Long-acting sulfonamides"},{name:"Sulfametomidine",ATC_code:"J01ED03",EML:"No",value:1,"description.x":"Long-acting sulfonamides",description:"Long-acting sulfonamides"},{name:"Sulfametoxydiazine",ATC_code:"J01ED04",EML:"No",value:1,"description.x":"Long acting sulfonamide used in leprosy, urinary, and respiratory tract infections.",description:"Long acting sulfonamide used in leprosy, urinary, and respiratory tract infections."},{name:"Sulfamoxole",ATC_code:"J01EC03",EML:"No",value:1,"description.x":"Sulfamoxole is an antibacterial in the sulfonamide class.",description:"Sulfamoxole is an antibacterial in the sulfonamide class."},{name:"Sulfanilamide",ATC_code:"J01EB06",EML:"No",value:1,"description.x":"Sulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline.",description:"Sulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline."},{name:"Sulfaperin",ATC_code:"J01ED06",EML:"No",value:1,"description.x":"Long-acting sulfonamides",description:"Long-acting sulfonamides"},{name:"Sulfaphenazole",ATC_code:"J01ED08",EML:"No",value:1,"description.x":"Sulfaphenazole is a sulfonamide antibacterial.",description:"Sulfaphenazole is a sulfonamide antibacterial."},{name:"Sulfapyridine",ATC_code:"J01EB04",EML:"No",value:1,"description.x":"Antibacterial, potentially toxic, and previously used to treat certain skin diseases. No longer prescribed.",description:"Antibacterial, potentially toxic, and previously used to treat certain skin diseases. No longer prescribed."},{name:"Sulfathiazole",ATC_code:"J01EB07",EML:"No",value:1,"description.x":`Sulfathiazole is a short-acting sulfa drug. It used to be a common oral and topical antimicrobial until less toxic alternatives were discovered. It is still occasionally used, sometimes in combination with sulfabenzamide and sulfacetamide.\r
\r
Except for those formulated for vaginal use, the FDA withdrew its approval for the use of all drug products containing sulfathiazole.`,description:`Sulfathiazole is a short-acting sulfa drug. It used to be a common oral and topical antimicrobial until less toxic alternatives were discovered. It is still occasionally used, sometimes in combination with sulfabenzamide and sulfacetamide.\r
\r
Except for those formulated for vaginal use, the FDA withdrew its approval for the use of all drug products containing sulfathiazole.`},{name:"Sulfathiourea",ATC_code:"J01EB08",EML:"No",value:1,"description.x":"Short-acting sulfonamides",description:"Short-acting sulfonamides"}]}]},{name:"Sulfonamide-trimethoprim-combos",data:[{name:"Sulfadiazine/tetroxoprim",ATC_code:"J01EE06",EML:"No",value:1,description:"Tetroxoprim is a derivative of trimethoprim, first described in 1979. It is used in combination with sulfadiazine, an antibiotic, and this combination is coded under ATC code J01EE06 by the WHO. Tetroxoprim acts as an inhibitor of bacterial dihydrofolate reductase, contributing to its antibacterial effects. Source: Wikepedia"},{name:"Sulfadiazine/trimethoprim",ATC_code:"J01EE02",EML:"No",value:1,description:"Sulfadiazine/trimethoprim, marketed under trade names like Tucoprim and Tribrissen, is a combination drug consisting of sulfadiazine and trimethoprim. This medication is primarily used in the treatment of bacterial infections in animals, particularly horses​. Source: Wikepedia"},{name:"Sulfadimidine/trimethoprim",ATC_code:"J01EE05",EML:"No",value:1,description:"Sulfadimidine is a sulfonamide antibiotic that inhibits bacterial synthesis of dihydrofolic acid, while trimethoprim further blocks the production of tetrahydrofolic acid, a form of folic acid bacteria use for growth and multiplication. This combination results in a synergistic effect, enhancing the overall antibacterial efficacy. Source: Wikepedia"},{name:"Sulfamerazine/trimethoprim",ATC_code:"J01EE07",EML:"No",value:1,description:"Sulfamerazine is a sulfonamide antibacterial agent. This type of medication is part of a class of antibiotics known for their effectiveness against bacterial infections by inhibiting certain processes necessary for bacterial growth. Sulfonamides like Sulfamerazine are generally used in combination with Trimethoprim to enhance their antibacterial effectiveness. Source: Wikepedia"},{name:"Sulfamethoxazole/trimethoprim",ATC_code:"J01EE01",EML:"Yes",value:1,description:"Trimethoprim/sulfamethoxazole, commonly known as Bactrim, is a combination antibiotic used to treat a variety of bacterial infections. It includes one part trimethoprim and five parts sulfamethoxazole. This medication is effective against urinary tract infections, methicillin-resistant Staphylococcus aureus (MRSA) skin infections, travelers' diarrhea, respiratory tract infections, cholera, and more. It's also used for both treating and preventing pneumocystis pneumonia and toxoplasmosis in people with HIV/AIDS and others with weakened immune systems. It can be administered orally or through intravenous infusion. Source: Wikepedia"},{name:"Sulfametrole/trimethoprim",ATC_code:"J01EE03",EML:"No",value:1,description:"The combination of trimethoprim and sulfametrole, used as an alternative to the more common combination of trimethoprim/sulfamethoxazole, has been studied for its effectiveness and safety in treating various infections. It has shown promise in treating difficult-to-treat infections, particularly when administered intravenously. Source: Wikepedia"},{name:"Sulfamoxole/trimethoprim",ATC_code:"J01EE04",EML:"No",value:1,description:"Sulfamoxole is a sulfonamide antibacterial agent. This type of medication is part of a class of antibiotics known for their effectiveness against bacterial infections by inhibiting certain processes necessary for bacterial growth. Sulfonamides like Sulfamoxole are generally used in combination with Trimethoprim to enhance their antibacterial effectiveness. Source: Wikepedia"}],children:[{name:"Access",children:[{name:"Sulfadiazine/tetroxoprim",ATC_code:"J01EE06",EML:"No",value:1,description:"Tetroxoprim is a derivative of trimethoprim, first described in 1979. It is used in combination with sulfadiazine, an antibiotic, and this combination is coded under ATC code J01EE06 by the WHO. Tetroxoprim acts as an inhibitor of bacterial dihydrofolate reductase, contributing to its antibacterial effects. Source: Wikepedia"},{name:"Sulfadiazine/trimethoprim",ATC_code:"J01EE02",EML:"No",value:1,description:"Sulfadiazine/trimethoprim, marketed under trade names like Tucoprim and Tribrissen, is a combination drug consisting of sulfadiazine and trimethoprim. This medication is primarily used in the treatment of bacterial infections in animals, particularly horses​. Source: Wikepedia"},{name:"Sulfadimidine/trimethoprim",ATC_code:"J01EE05",EML:"No",value:1,description:"Sulfadimidine is a sulfonamide antibiotic that inhibits bacterial synthesis of dihydrofolic acid, while trimethoprim further blocks the production of tetrahydrofolic acid, a form of folic acid bacteria use for growth and multiplication. This combination results in a synergistic effect, enhancing the overall antibacterial efficacy. Source: Wikepedia"},{name:"Sulfamerazine/trimethoprim",ATC_code:"J01EE07",EML:"No",value:1,description:"Sulfamerazine is a sulfonamide antibacterial agent. This type of medication is part of a class of antibiotics known for their effectiveness against bacterial infections by inhibiting certain processes necessary for bacterial growth. Sulfonamides like Sulfamerazine are generally used in combination with Trimethoprim to enhance their antibacterial effectiveness. Source: Wikepedia"},{name:"Sulfamethoxazole/trimethoprim",ATC_code:"J01EE01",EML:"Yes",value:1,description:"Trimethoprim/sulfamethoxazole, commonly known as Bactrim, is a combination antibiotic used to treat a variety of bacterial infections. It includes one part trimethoprim and five parts sulfamethoxazole. This medication is effective against urinary tract infections, methicillin-resistant Staphylococcus aureus (MRSA) skin infections, travelers' diarrhea, respiratory tract infections, cholera, and more. It's also used for both treating and preventing pneumocystis pneumonia and toxoplasmosis in people with HIV/AIDS and others with weakened immune systems. It can be administered orally or through intravenous infusion. Source: Wikepedia"},{name:"Sulfametrole/trimethoprim",ATC_code:"J01EE03",EML:"No",value:1,description:"The combination of trimethoprim and sulfametrole, used as an alternative to the more common combination of trimethoprim/sulfamethoxazole, has been studied for its effectiveness and safety in treating various infections. It has shown promise in treating difficult-to-treat infections, particularly when administered intravenously. Source: Wikepedia"},{name:"Sulfamoxole/trimethoprim",ATC_code:"J01EE04",EML:"No",value:1,description:"Sulfamoxole is a sulfonamide antibacterial agent. This type of medication is part of a class of antibiotics known for their effectiveness against bacterial infections by inhibiting certain processes necessary for bacterial growth. Sulfonamides like Sulfamoxole are generally used in combination with Trimethoprim to enhance their antibacterial effectiveness. Source: Wikepedia"}]}]},{name:"Glycylcyclines",data:[{name:"Tigecycline",ATC_code:"J01AA12",EML:"No",value:2,"description.x":"Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.",description:"Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005."}],children:[{name:"Reserve",children:[{name:"Tigecycline",ATC_code:"J01AA12",EML:"No",value:2,"description.x":"Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.",description:"Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005."}]}]}]},{name:"Beta-Lactams",children:[{name:"Penicillins",data:[{name:"Amoxicillin",ATC_code:"J01CA04",EML:"Yes",value:1,"description.x":`Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.\r
\r
Amoxicillin was granted FDA approval on 18 January 1974.`,description:`Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.\r
\r
Amoxicillin was granted FDA approval on 18 January 1974.`},{name:"Ampicillin",ATC_code:"J01CA01 ",EML:"Yes",value:1,description:"Ampicillin is an antibiotic that belongs to the aminopenicillin class within the penicillin family. It's used to prevent and treat various bacterial infections such as respiratory and urinary tract infections, meningitis, salmonellosis, and endocarditis. Ampicillin can also be used to prevent group B streptococcal infection in newborns. It can be administered orally, by intramuscular injection, or intravenously. Source: Wikepedia"},{name:"Aspoxicillin",ATC_code:"J01CA19",EML:"No",value:1,"description.x":"Penicillins with extended spectrum",description:"Penicillins with extended spectrum"},{name:"Azidocillin",ATC_code:"J01CE04",EML:"No",value:1,"description.x":"Azidocillin is a penicillin antibiotic similir to ampicillin.",description:"Azidocillin is a penicillin antibiotic similir to ampicillin."},{name:"Azlocillin",ATC_code:"J01CA09",EML:"No",value:1,"description.x":"Azlocillin is a semisynthetic ampicillin-derived acylureido penicillin.",description:"Azlocillin is a semisynthetic ampicillin-derived acylureido penicillin."},{name:"Bacampicillin",ATC_code:"J01CA06",EML:"No",value:1,"description.x":"Bacampicillin is a prodrug of ampicillin and is microbiologically inactive. It is absorbed following oral administration. During absorption from the gastrointestinal tract, bacampicillin is hydrolyzed by esterases present in the intestinal wall. It is microbiologically active as ampicillin, and exerts a bactericidal action through the inhibition of the biosynthesis of cell wall mucopeptides.  It is used to cure infection of upper and lower respiratory tract; skin and soft tissue; urinary tract and acute uncomplicated gonococcal urethritis etc.",description:"Bacampicillin is a prodrug of ampicillin and is microbiologically inactive. It is absorbed following oral administration. During absorption from the gastrointestinal tract, bacampicillin is hydrolyzed by esterases present in the intestinal wall. It is microbiologically active as ampicillin, and exerts a bactericidal action through the inhibition of the biosynthesis of cell wall mucopeptides.  It is used to cure infection of upper and lower respiratory tract; skin and soft tissue; urinary tract and acute uncomplicated gonococcal urethritis etc."},{name:"Benzathine-benzylpenicillin",ATC_code:"J01CE08",EML:"Yes",value:1,"description.x":`Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms.\r
 \r
Natural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as *Streptococcus pneumoniae*, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (*S. agalactiae*), *S. viridans*, and *Enterococcus faecalis*. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as *Bacillus anthracis*, *Corynebacterium diphtheriae*, and *Erysipelothrix rhusiopathiae*. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused by *Neisseria meningitidis* and *Pasteurella*. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions.`,description:`Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms.\r
 \r
Natural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as *Streptococcus pneumoniae*, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (*S. agalactiae*), *S. viridans*, and *Enterococcus faecalis*. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as *Bacillus anthracis*, *Corynebacterium diphtheriae*, and *Erysipelothrix rhusiopathiae*. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused by *Neisseria meningitidis* and *Pasteurella*. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions.`},{name:"Benzylpenicillin",ATC_code:"J01CE01",EML:"Yes",value:1,"description.x":`Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms.\r
 \r
Natural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as *Streptococcus pneumoniae*, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (*S. agalactiae*), *S. viridans*, and *Enterococcus faecalis*. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as *Bacillus anthracis*, *Corynebacterium diphtheriae*, and *Erysipelothrix rhusiopathiae*. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused by *Neisseria meningitidis* and *Pasteurella*. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions.`,description:`Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms.\r
 \r
Natural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as *Streptococcus pneumoniae*, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (*S. agalactiae*), *S. viridans*, and *Enterococcus faecalis*. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as *Bacillus anthracis*, *Corynebacterium diphtheriae*, and *Erysipelothrix rhusiopathiae*. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused by *Neisseria meningitidis* and *Pasteurella*. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions.`},{name:"Carbenicillin",ATC_code:"J01CA03",EML:"No",value:1,"description.x":"Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.",description:"Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function."},{name:"Carindacillin",ATC_code:"J01CA05",EML:"No",value:1,"description.x":"Carindacillin or Carbenicillin isdanyl was an oral penicillin prodrug of carbenicillin marketed by Pfizer as Geocillin. It is no longer marketed in the United States.",description:"Carindacillin or Carbenicillin isdanyl was an oral penicillin prodrug of carbenicillin marketed by Pfizer as Geocillin. It is no longer marketed in the United States."},{name:"Clometocillin",ATC_code:"J01CE07",EML:"No",value:1,"description.x":"Beta-lactamase sensitive penicillins",description:"Beta-lactamase sensitive penicillins"},{name:"Cloxacillin",ATC_code:"J01CF02",EML:"Yes",value:1,"description.x":"A semi-synthetic penicillin antibiotic which is a chlorinated derivative of oxacillin.",description:"A semi-synthetic penicillin antibiotic which is a chlorinated derivative of oxacillin."},{name:"Dicloxacillin",ATC_code:"J01CF01",EML:"Yes (therapeutic alternative to cloxacillin)",value:1,"description.x":"One of the penicillins which is resistant to penicillinase.",description:"One of the penicillins which is resistant to penicillinase."},{name:"Epicillin",ATC_code:"J01CA07",EML:"No",value:1,"description.x":"Penicillins with extended spectrum",description:"Penicillins with extended spectrum"},{name:"Flucloxacillin",ATC_code:"J01CF05",EML:"Yes (therapeutic alternative to cloxacillin)",value:1,"description.x":"Antibiotic analog of cloxacillin.",description:"Antibiotic analog of cloxacillin."},{name:"Hetacillin",ATC_code:"J01CA18",EML:"No",value:1,"description.x":'Hetacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Hetacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Hetacillin results from the inhibition of cell wall synthesis and is mediated through Hetacillin binding to penicillin binding proteins (PBPs). Hetacillin has been withdrawn from the market since it has been discovered that it has no therapeutic advantage compared to non-ester derivatives like ampicillin.',description:'Hetacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Hetacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Hetacillin results from the inhibition of cell wall synthesis and is mediated through Hetacillin binding to penicillin binding proteins (PBPs). Hetacillin has been withdrawn from the market since it has been discovered that it has no therapeutic advantage compared to non-ester derivatives like ampicillin.'},{name:"Mecillinam",ATC_code:"J01CA11",EML:"No",value:1,"description.x":"Amidinopenicillanic acid derivative with broad spectrum antibacterial action. It is poorly absorbed if given orally and is used in urinary infections and typhus. Amdinocillin is not available in the United States.",description:"Amidinopenicillanic acid derivative with broad spectrum antibacterial action. It is poorly absorbed if given orally and is used in urinary infections and typhus. Amdinocillin is not available in the United States."},{name:"Metampicillin",ATC_code:"J01CA14",EML:"No",value:1,"description.x":"Metampicillin is a penicillin antibiotic prepared by the reaction of ampicillin with formaldehyde. It is hydrolysed in aqueous solution to form ampicillin. Hydrolysis is rapid under acid conditions like the stomach.",description:"Metampicillin is a penicillin antibiotic prepared by the reaction of ampicillin with formaldehyde. It is hydrolysed in aqueous solution to form ampicillin. Hydrolysis is rapid under acid conditions like the stomach."},{name:"Meticillin",ATC_code:"J01CF03",EML:"Yes (therapeutic alternative to cloxacillin)",value:1,"description.x":"One of the penicillins which is resistant to penicillinase but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.",description:"One of the penicillins which is resistant to penicillinase but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection."},{name:"Mezlocillin",ATC_code:"J01CA10",EML:"No",value:1,"description.x":"Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.",description:"Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections."},{name:"Nafcillin",ATC_code:"J01CF06",EML:"Yes (therapeutic alternative to cloxacillin)",value:1,"description.x":"A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections .",description:"A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections ."},{name:"Oxacillin",ATC_code:"J01CF04",EML:"Yes (therapeutic alternative to cloxacillin)",value:1,"description.x":"An antibiotic similar to flucloxacillin used in resistant staphylococci infections.",description:"An antibiotic similar to flucloxacillin used in resistant staphylococci infections."},{name:"Penamecillin",ATC_code:"J01CE06",EML:"No",value:1,"description.x":"Beta-lactamase sensitive penicillins",description:"Beta-lactamase sensitive penicillins"},{name:"Pheneticillin",ATC_code:"J01CE05",EML:"No",value:1,"description.x":"Pheneticillin (or phenethicillin) is a penicillin antibiotic which is approved for use internationally.",description:"Pheneticillin (or phenethicillin) is a penicillin antibiotic which is approved for use internationally."},{name:"Phenoxymethylpenicillin",ATC_code:"J01CE02",EML:"Yes",value:1,"description.x":"Phenoxymethylpenicillin is a narrow spectrum antibiotic also commonly referred to as Penicillin V or Penicillin VK. It is a phenoxymethyl analog of Penicillin G, or benzylpenicillin. An orally active naturally penicillin, phenoxymethylpenicillin is used to treat mild to moderate infections in the respiratory tract, skin, and soft tissues caused by penicillin G­-sensitive microorganisms. Phenoxymethylpenicillin has also be used in some cases as prophylaxis against susceptible organisms. While there have been no controlled clinical efficacy studies that were conducted, phenoxymethylpenicillin has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract, except for those who are at an elevated risk for endocarditis.label",description:"Phenoxymethylpenicillin is a narrow spectrum antibiotic also commonly referred to as Penicillin V or Penicillin VK. It is a phenoxymethyl analog of Penicillin G, or benzylpenicillin. An orally active naturally penicillin, phenoxymethylpenicillin is used to treat mild to moderate infections in the respiratory tract, skin, and soft tissues caused by penicillin G­-sensitive microorganisms. Phenoxymethylpenicillin has also be used in some cases as prophylaxis against susceptible organisms. While there have been no controlled clinical efficacy studies that were conducted, phenoxymethylpenicillin has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract, except for those who are at an elevated risk for endocarditis.label"},{name:"Piperacillin",ATC_code:"J01CA12",EML:"No",value:1,"description.x":"Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics.",description:"Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics."},{name:"Pivampicillin",ATC_code:"J01CA02",EML:"No",value:1,"description.x":"Pivalate ester analog of ampicillin.",description:"Pivalate ester analog of ampicillin."},{name:"Pivmecillinam",ATC_code:"J01CA08",EML:"No",value:1,"description.x":"Pivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa. It is active against gram-negative organisms and used as for amdinocillin. PubChem",description:"Pivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa. It is active against gram-negative organisms and used as for amdinocillin. PubChem"},{name:"Procaine-benzylpenicillin",ATC_code:"J01CE09",EML:"Yes",value:1,"description.x":"Procaine benzylpenicillin (INN), also known as procaine G penicillin, is an injectable antiobiotic. It is a poorly soluble salt form of penicillin which is a combination of naturally occuring benzylpenicillin (penicillin G) and the local anaesthetic agent procaine in equimolar amounts. Procaine benzylpenicillin is administered by deep intramuscular injection. It is slowly absorbed and hydrolyzed to benzylpenicillin. This drug is used where prolonged exposure to benzylpenicillin at a low concentration is required. This combination is aimed at reducing the pain and discomfort associated with a large intramuscular injection of penicillin. It is widely used in veterinary settings. Benzylpenicillin is active against a wide range of organisms and is the drug of first choice for many infections.",description:"Procaine benzylpenicillin (INN), also known as procaine G penicillin, is an injectable antiobiotic. It is a poorly soluble salt form of penicillin which is a combination of naturally occuring benzylpenicillin (penicillin G) and the local anaesthetic agent procaine in equimolar amounts. Procaine benzylpenicillin is administered by deep intramuscular injection. It is slowly absorbed and hydrolyzed to benzylpenicillin. This drug is used where prolonged exposure to benzylpenicillin at a low concentration is required. This combination is aimed at reducing the pain and discomfort associated with a large intramuscular injection of penicillin. It is widely used in veterinary settings. Benzylpenicillin is active against a wide range of organisms and is the drug of first choice for many infections."},{name:"Propicillin",ATC_code:"J01CE03",EML:"No",value:1,"description.x":"Beta-lactamase sensitive penicillins",description:"Beta-lactamase sensitive penicillins"},{name:"Sulbenicillin",ATC_code:"J01CA16",EML:"No",value:1,"description.x":"Penicillins with extended spectrum",description:"Penicillins with extended spectrum"},{name:"Talampicillin",ATC_code:"J01CA15",EML:"No",value:1,"description.x":"Penicillins with extended spectrum",description:"Penicillins with extended spectrum"},{name:"Temocillin",ATC_code:"J01CA17",EML:"No",value:1,"description.x":"Temocillin has been investigated in Infection, Liver Dysfunction, and Urinary Tract Infection.",description:"Temocillin has been investigated in Infection, Liver Dysfunction, and Urinary Tract Infection."},{name:"Ticarcillin",ATC_code:"J01CA13",EML:"No",value:1,"description.x":"An antibiotic derived from penicillin similar to carbenicillin in action.",description:"An antibiotic derived from penicillin similar to carbenicillin in action."}],children:[{name:"Access",children:[{name:"Amoxicillin",ATC_code:"J01CA04",EML:"Yes",value:1,"description.x":`Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.\r
\r
Amoxicillin was granted FDA approval on 18 January 1974.`,description:`Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.\r
\r
Amoxicillin was granted FDA approval on 18 January 1974.`},{name:"Ampicillin",ATC_code:"J01CA01 ",EML:"Yes",value:1,description:"Ampicillin is an antibiotic that belongs to the aminopenicillin class within the penicillin family. It's used to prevent and treat various bacterial infections such as respiratory and urinary tract infections, meningitis, salmonellosis, and endocarditis. Ampicillin can also be used to prevent group B streptococcal infection in newborns. It can be administered orally, by intramuscular injection, or intravenously. Source: Wikepedia"},{name:"Azidocillin",ATC_code:"J01CE04",EML:"No",value:1,"description.x":"Azidocillin is a penicillin antibiotic similir to ampicillin.",description:"Azidocillin is a penicillin antibiotic similir to ampicillin."},{name:"Bacampicillin",ATC_code:"J01CA06",EML:"No",value:1,"description.x":"Bacampicillin is a prodrug of ampicillin and is microbiologically inactive. It is absorbed following oral administration. During absorption from the gastrointestinal tract, bacampicillin is hydrolyzed by esterases present in the intestinal wall. It is microbiologically active as ampicillin, and exerts a bactericidal action through the inhibition of the biosynthesis of cell wall mucopeptides.  It is used to cure infection of upper and lower respiratory tract; skin and soft tissue; urinary tract and acute uncomplicated gonococcal urethritis etc.",description:"Bacampicillin is a prodrug of ampicillin and is microbiologically inactive. It is absorbed following oral administration. During absorption from the gastrointestinal tract, bacampicillin is hydrolyzed by esterases present in the intestinal wall. It is microbiologically active as ampicillin, and exerts a bactericidal action through the inhibition of the biosynthesis of cell wall mucopeptides.  It is used to cure infection of upper and lower respiratory tract; skin and soft tissue; urinary tract and acute uncomplicated gonococcal urethritis etc."},{name:"Benzathine-benzylpenicillin",ATC_code:"J01CE08",EML:"Yes",value:1,"description.x":`Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms.\r
 \r
Natural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as *Streptococcus pneumoniae*, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (*S. agalactiae*), *S. viridans*, and *Enterococcus faecalis*. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as *Bacillus anthracis*, *Corynebacterium diphtheriae*, and *Erysipelothrix rhusiopathiae*. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused by *Neisseria meningitidis* and *Pasteurella*. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions.`,description:`Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms.\r
 \r
Natural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as *Streptococcus pneumoniae*, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (*S. agalactiae*), *S. viridans*, and *Enterococcus faecalis*. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as *Bacillus anthracis*, *Corynebacterium diphtheriae*, and *Erysipelothrix rhusiopathiae*. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused by *Neisseria meningitidis* and *Pasteurella*. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions.`},{name:"Benzylpenicillin",ATC_code:"J01CE01",EML:"Yes",value:1,"description.x":`Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms.\r
 \r
Natural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as *Streptococcus pneumoniae*, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (*S. agalactiae*), *S. viridans*, and *Enterococcus faecalis*. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as *Bacillus anthracis*, *Corynebacterium diphtheriae*, and *Erysipelothrix rhusiopathiae*. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused by *Neisseria meningitidis* and *Pasteurella*. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions.`,description:`Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms.\r
 \r
Natural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as *Streptococcus pneumoniae*, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (*S. agalactiae*), *S. viridans*, and *Enterococcus faecalis*. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as *Bacillus anthracis*, *Corynebacterium diphtheriae*, and *Erysipelothrix rhusiopathiae*. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused by *Neisseria meningitidis* and *Pasteurella*. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions.`},{name:"Clometocillin",ATC_code:"J01CE07",EML:"No",value:1,"description.x":"Beta-lactamase sensitive penicillins",description:"Beta-lactamase sensitive penicillins"},{name:"Cloxacillin",ATC_code:"J01CF02",EML:"Yes",value:1,"description.x":"A semi-synthetic penicillin antibiotic which is a chlorinated derivative of oxacillin.",description:"A semi-synthetic penicillin antibiotic which is a chlorinated derivative of oxacillin."},{name:"Dicloxacillin",ATC_code:"J01CF01",EML:"Yes (therapeutic alternative to cloxacillin)",value:1,"description.x":"One of the penicillins which is resistant to penicillinase.",description:"One of the penicillins which is resistant to penicillinase."},{name:"Epicillin",ATC_code:"J01CA07",EML:"No",value:1,"description.x":"Penicillins with extended spectrum",description:"Penicillins with extended spectrum"},{name:"Flucloxacillin",ATC_code:"J01CF05",EML:"Yes (therapeutic alternative to cloxacillin)",value:1,"description.x":"Antibiotic analog of cloxacillin.",description:"Antibiotic analog of cloxacillin."},{name:"Hetacillin",ATC_code:"J01CA18",EML:"No",value:1,"description.x":'Hetacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Hetacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Hetacillin results from the inhibition of cell wall synthesis and is mediated through Hetacillin binding to penicillin binding proteins (PBPs). Hetacillin has been withdrawn from the market since it has been discovered that it has no therapeutic advantage compared to non-ester derivatives like ampicillin.',description:'Hetacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Hetacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Hetacillin results from the inhibition of cell wall synthesis and is mediated through Hetacillin binding to penicillin binding proteins (PBPs). Hetacillin has been withdrawn from the market since it has been discovered that it has no therapeutic advantage compared to non-ester derivatives like ampicillin.'},{name:"Mecillinam",ATC_code:"J01CA11",EML:"No",value:1,"description.x":"Amidinopenicillanic acid derivative with broad spectrum antibacterial action. It is poorly absorbed if given orally and is used in urinary infections and typhus. Amdinocillin is not available in the United States.",description:"Amidinopenicillanic acid derivative with broad spectrum antibacterial action. It is poorly absorbed if given orally and is used in urinary infections and typhus. Amdinocillin is not available in the United States."},{name:"Metampicillin",ATC_code:"J01CA14",EML:"No",value:1,"description.x":"Metampicillin is a penicillin antibiotic prepared by the reaction of ampicillin with formaldehyde. It is hydrolysed in aqueous solution to form ampicillin. Hydrolysis is rapid under acid conditions like the stomach.",description:"Metampicillin is a penicillin antibiotic prepared by the reaction of ampicillin with formaldehyde. It is hydrolysed in aqueous solution to form ampicillin. Hydrolysis is rapid under acid conditions like the stomach."},{name:"Meticillin",ATC_code:"J01CF03",EML:"Yes (therapeutic alternative to cloxacillin)",value:1,"description.x":"One of the penicillins which is resistant to penicillinase but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.",description:"One of the penicillins which is resistant to penicillinase but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection."},{name:"Nafcillin",ATC_code:"J01CF06",EML:"Yes (therapeutic alternative to cloxacillin)",value:1,"description.x":"A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections .",description:"A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections ."},{name:"Oxacillin",ATC_code:"J01CF04",EML:"Yes (therapeutic alternative to cloxacillin)",value:1,"description.x":"An antibiotic similar to flucloxacillin used in resistant staphylococci infections.",description:"An antibiotic similar to flucloxacillin used in resistant staphylococci infections."},{name:"Penamecillin",ATC_code:"J01CE06",EML:"No",value:1,"description.x":"Beta-lactamase sensitive penicillins",description:"Beta-lactamase sensitive penicillins"},{name:"Phenoxymethylpenicillin",ATC_code:"J01CE02",EML:"Yes",value:1,"description.x":"Phenoxymethylpenicillin is a narrow spectrum antibiotic also commonly referred to as Penicillin V or Penicillin VK. It is a phenoxymethyl analog of Penicillin G, or benzylpenicillin. An orally active naturally penicillin, phenoxymethylpenicillin is used to treat mild to moderate infections in the respiratory tract, skin, and soft tissues caused by penicillin G­-sensitive microorganisms. Phenoxymethylpenicillin has also be used in some cases as prophylaxis against susceptible organisms. While there have been no controlled clinical efficacy studies that were conducted, phenoxymethylpenicillin has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract, except for those who are at an elevated risk for endocarditis.label",description:"Phenoxymethylpenicillin is a narrow spectrum antibiotic also commonly referred to as Penicillin V or Penicillin VK. It is a phenoxymethyl analog of Penicillin G, or benzylpenicillin. An orally active naturally penicillin, phenoxymethylpenicillin is used to treat mild to moderate infections in the respiratory tract, skin, and soft tissues caused by penicillin G­-sensitive microorganisms. Phenoxymethylpenicillin has also be used in some cases as prophylaxis against susceptible organisms. While there have been no controlled clinical efficacy studies that were conducted, phenoxymethylpenicillin has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract, except for those who are at an elevated risk for endocarditis.label"},{name:"Pivampicillin",ATC_code:"J01CA02",EML:"No",value:1,"description.x":"Pivalate ester analog of ampicillin.",description:"Pivalate ester analog of ampicillin."},{name:"Pivmecillinam",ATC_code:"J01CA08",EML:"No",value:1,"description.x":"Pivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa. It is active against gram-negative organisms and used as for amdinocillin. PubChem",description:"Pivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa. It is active against gram-negative organisms and used as for amdinocillin. PubChem"},{name:"Procaine-benzylpenicillin",ATC_code:"J01CE09",EML:"Yes",value:1,"description.x":"Procaine benzylpenicillin (INN), also known as procaine G penicillin, is an injectable antiobiotic. It is a poorly soluble salt form of penicillin which is a combination of naturally occuring benzylpenicillin (penicillin G) and the local anaesthetic agent procaine in equimolar amounts. Procaine benzylpenicillin is administered by deep intramuscular injection. It is slowly absorbed and hydrolyzed to benzylpenicillin. This drug is used where prolonged exposure to benzylpenicillin at a low concentration is required. This combination is aimed at reducing the pain and discomfort associated with a large intramuscular injection of penicillin. It is widely used in veterinary settings. Benzylpenicillin is active against a wide range of organisms and is the drug of first choice for many infections.",description:"Procaine benzylpenicillin (INN), also known as procaine G penicillin, is an injectable antiobiotic. It is a poorly soluble salt form of penicillin which is a combination of naturally occuring benzylpenicillin (penicillin G) and the local anaesthetic agent procaine in equimolar amounts. Procaine benzylpenicillin is administered by deep intramuscular injection. It is slowly absorbed and hydrolyzed to benzylpenicillin. This drug is used where prolonged exposure to benzylpenicillin at a low concentration is required. This combination is aimed at reducing the pain and discomfort associated with a large intramuscular injection of penicillin. It is widely used in veterinary settings. Benzylpenicillin is active against a wide range of organisms and is the drug of first choice for many infections."},{name:"Propicillin",ATC_code:"J01CE03",EML:"No",value:1,"description.x":"Beta-lactamase sensitive penicillins",description:"Beta-lactamase sensitive penicillins"},{name:"Talampicillin",ATC_code:"J01CA15",EML:"No",value:1,"description.x":"Penicillins with extended spectrum",description:"Penicillins with extended spectrum"}]},{name:"Watch",children:[{name:"Aspoxicillin",ATC_code:"J01CA19",EML:"No",value:1,"description.x":"Penicillins with extended spectrum",description:"Penicillins with extended spectrum"},{name:"Azlocillin",ATC_code:"J01CA09",EML:"No",value:1,"description.x":"Azlocillin is a semisynthetic ampicillin-derived acylureido penicillin.",description:"Azlocillin is a semisynthetic ampicillin-derived acylureido penicillin."},{name:"Carbenicillin",ATC_code:"J01CA03",EML:"No",value:1,"description.x":"Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.",description:"Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function."},{name:"Carindacillin",ATC_code:"J01CA05",EML:"No",value:1,"description.x":"Carindacillin or Carbenicillin isdanyl was an oral penicillin prodrug of carbenicillin marketed by Pfizer as Geocillin. It is no longer marketed in the United States.",description:"Carindacillin or Carbenicillin isdanyl was an oral penicillin prodrug of carbenicillin marketed by Pfizer as Geocillin. It is no longer marketed in the United States."},{name:"Mezlocillin",ATC_code:"J01CA10",EML:"No",value:1,"description.x":"Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.",description:"Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections."},{name:"Pheneticillin",ATC_code:"J01CE05",EML:"No",value:1,"description.x":"Pheneticillin (or phenethicillin) is a penicillin antibiotic which is approved for use internationally.",description:"Pheneticillin (or phenethicillin) is a penicillin antibiotic which is approved for use internationally."},{name:"Piperacillin",ATC_code:"J01CA12",EML:"No",value:1,"description.x":"Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics.",description:"Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics."},{name:"Sulbenicillin",ATC_code:"J01CA16",EML:"No",value:1,"description.x":"Penicillins with extended spectrum",description:"Penicillins with extended spectrum"},{name:"Temocillin",ATC_code:"J01CA17",EML:"No",value:1,"description.x":"Temocillin has been investigated in Infection, Liver Dysfunction, and Urinary Tract Infection.",description:"Temocillin has been investigated in Infection, Liver Dysfunction, and Urinary Tract Infection."},{name:"Ticarcillin",ATC_code:"J01CA13",EML:"No",value:1,"description.x":"An antibiotic derived from penicillin similar to carbenicillin in action.",description:"An antibiotic derived from penicillin similar to carbenicillin in action."}]}]},{name:"Beta-lactam/beta-lactamase-inhibitor",data:[{name:"Amoxicillin/clavulanic-acid",ATC_code:"J01CR02",EML:"Yes",value:1,description:"Amoxicillin/clavulanic acid, commonly known as co-amoxiclav or amox-clav, is an antibiotic medication used for treating various bacterial infections. It's a combination of amoxicillin, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor. This combination is effective against a range of infections including otitis media, streptococcal pharyngitis, pneumonia, cellulitis, urinary tract infections, and animal bites. It is administered orally or by injection. Common side effects can include diarrhea, vomiting, and allergic reactions, and it's generally considered safe during pregnancy. This medication was approved for medical use in the United States in 1984 and is listed on the World Health Organization's List of Essential Medicines. Source: Wikepedia"},{name:"Ampicillin/sulbactam",ATC_code:"J01CR01",EML:"No",value:1,description:"Ampicillin/sulbactam is a combination medication consisting of the antibiotic ampicillin and sulbactam, a beta-lactamase inhibitor. This combination is used to treat various infections, particularly those caused by bacteria resistant to beta-lactam antibiotics. Sulbactam enhances the effect of ampicillin by inhibiting the enzyme that breaks down ampicillin, allowing it to effectively kill the bacteria. Ampicillin/sulbactam is effective against a range of gram-positive and gram-negative bacteria, as well as anaerobes. Source: Wikepedia"},{name:"Piperacillin/tazobactam",ATC_code:"J01CR05",EML:"Yes",value:1,description:"Piperacillin/tazobactam, marketed under names like Tazocin and Zosyn, is a combination medication that includes the antibiotic piperacillin and the β-lactamase inhibitor tazobactam. This combination is effective against many Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa. It's commonly used for treating infections like pelvic inflammatory disease, intra-abdominal infections, pneumonia, cellulitis, and sepsis, and is administered via intravenous injection. Some common side effects are headaches, sleep disturbances, rashes, nausea, constipation, and diarrhea. It's generally considered safe for use during pregnancy and breastfeeding. Piperacillin/tazobactam was approved for medical use in the United States in 1993 and is on the World Health Organization's List of Essential Medicines. Source: Wikepedia"},{name:"Sultamicillin",ATC_code:"J01CR04",EML:"No",value:1,description:"Sultamicillin has been used in trials studying the prevention and treatment of Ventilator Associated Pneumonia and Chronic Obstructive Pulmonary Disease (COPD).","description.x":"Sultamicillin has been used in trials studying the prevention and treatment of Ventilator Associated Pneumonia and Chronic Obstructive Pulmonary Disease (COPD)."}],children:[{name:"Access",children:[{name:"Amoxicillin/clavulanic-acid",ATC_code:"J01CR02",EML:"Yes",value:1,description:"Amoxicillin/clavulanic acid, commonly known as co-amoxiclav or amox-clav, is an antibiotic medication used for treating various bacterial infections. It's a combination of amoxicillin, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor. This combination is effective against a range of infections including otitis media, streptococcal pharyngitis, pneumonia, cellulitis, urinary tract infections, and animal bites. It is administered orally or by injection. Common side effects can include diarrhea, vomiting, and allergic reactions, and it's generally considered safe during pregnancy. This medication was approved for medical use in the United States in 1984 and is listed on the World Health Organization's List of Essential Medicines. Source: Wikepedia"},{name:"Ampicillin/sulbactam",ATC_code:"J01CR01",EML:"No",value:1,description:"Ampicillin/sulbactam is a combination medication consisting of the antibiotic ampicillin and sulbactam, a beta-lactamase inhibitor. This combination is used to treat various infections, particularly those caused by bacteria resistant to beta-lactam antibiotics. Sulbactam enhances the effect of ampicillin by inhibiting the enzyme that breaks down ampicillin, allowing it to effectively kill the bacteria. Ampicillin/sulbactam is effective against a range of gram-positive and gram-negative bacteria, as well as anaerobes. Source: Wikepedia"},{name:"Sultamicillin",ATC_code:"J01CR04",EML:"No",value:1,description:"Sultamicillin has been used in trials studying the prevention and treatment of Ventilator Associated Pneumonia and Chronic Obstructive Pulmonary Disease (COPD).","description.x":"Sultamicillin has been used in trials studying the prevention and treatment of Ventilator Associated Pneumonia and Chronic Obstructive Pulmonary Disease (COPD)."}]},{name:"Watch",children:[{name:"Piperacillin/tazobactam",ATC_code:"J01CR05",EML:"Yes",value:1,description:"Piperacillin/tazobactam, marketed under names like Tazocin and Zosyn, is a combination medication that includes the antibiotic piperacillin and the β-lactamase inhibitor tazobactam. This combination is effective against many Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa. It's commonly used for treating infections like pelvic inflammatory disease, intra-abdominal infections, pneumonia, cellulitis, and sepsis, and is administered via intravenous injection. Some common side effects are headaches, sleep disturbances, rashes, nausea, constipation, and diarrhea. It's generally considered safe for use during pregnancy and breastfeeding. Piperacillin/tazobactam was approved for medical use in the United States in 1993 and is on the World Health Organization's List of Essential Medicines. Source: Wikepedia"}]}]},{name:"Monobactams",data:[{name:"Aztreonam",ATC_code:"J01DF01",EML:"No",value:1,"description.x":"A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.",description:"A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms."},{name:"Carumonam",ATC_code:"J01DF02",EML:"No",value:1,"description.x":"Monobactams",description:"Monobactams"}],children:[{name:"Reserve",children:[{name:"Aztreonam",ATC_code:"J01DF01",EML:"No",value:1,"description.x":"A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.",description:"A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms."},{name:"Carumonam",ATC_code:"J01DF02",EML:"No",value:1,"description.x":"Monobactams",description:"Monobactams"}]}]},{name:"Carbapenems",data:[{name:"Biapenem",ATC_code:"J01DH05",EML:"No",value:1,"description.x":"Biapenem has been used in trials studying the treatment of Bacterial Infections.",description:"Biapenem has been used in trials studying the treatment of Bacterial Infections."},{name:"Doripenem",ATC_code:"J01DH04",EML:"No",value:1,"description.x":"Doripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem carried an increased risk of death and lower clinical cure rates, resulting in a premature termination of the trial. The FDA revised the doripenem label in 2014 to include a warning against use in ventilator-associated pneumonia and to reiterate its safety and efficacy for its approved indications.",description:"Doripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem carried an increased risk of death and lower clinical cure rates, resulting in a premature termination of the trial. The FDA revised the doripenem label in 2014 to include a warning against use in ventilator-associated pneumonia and to reiterate its safety and efficacy for its approved indications."},{name:"Ertapenem",ATC_code:"J01DH03",EML:"No",value:1,"description.x":"Ertapenem is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics. It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections.",description:"Ertapenem is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics. It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections."},{name:"Imipenem/cilastatin",ATC_code:"J01DH51",EML:"Yes (therapeutic alternative to meropenem)",value:1,description:"Imipenem/cilastatin, marketed under the name Primaxin, is an antibiotic used to treat a variety of bacterial infections, including pneumonia, sepsis, endocarditis, joint infections, intra-abdominal infections, and urinary tract infections. It is administered via injection into a vein or muscle. Common side effects include nausea, diarrhea, and pain at the injection site, along with potential allergic reactions such as anaphylaxis. It works by interfering with bacteria's cell wall formation and is included in the carbapenem family of medications. Cilastatin prevents the breakdown of imipenem, enhancing its effectiveness. This drug combination was first sold in 1987 and is listed on the World Health Organization's List of Essential Medicines. Source: Wikepedia"},{name:"Imipenem/cilastatin/relebactam",ATC_code:"J01DH56",EML:"No",value:1,description:"Imipenem/cilastatin/relebactam, sold under the brand name Recarbrio, is a combination antibiotic used for treating complicated urinary tract infections, complicated intra-abdominal infections, and hospital-acquired and ventilator-associated bacterial pneumonia in adults. It is administered via intravenous injection. Common adverse reactions include nausea, diarrhea, headache, fever, increased liver enzymes, anemia, hypokalemia (low potassium), and hyponatremia (low sodium). This combination enhances the activity of imipenem against certain bacteria by incorporating relebactam, a β-lactamase inhibitor. The FDA approved Recarbrio in 2019 for its current uses. Source: Wikepedia"},{name:"Meropenem",ATC_code:"J01DH02",EML:"Yes",value:1,"description.x":`Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.\r
\r
In August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of meropenem and  and is intravenously admininstered. The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria.`,description:`Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.\r
\r
In August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of meropenem and  and is intravenously admininstered. The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria.`},{name:"Meropenem/vaborbactam",ATC_code:"J01DH52",EML:"Yes",value:1,description:"Meropenem/vaborbactam, marketed under brand names like Vabomere, is a combination medication used for treating complicated urinary tract infections, complicated abdominal infections, and hospital-acquired pneumonia. It comprises meropenem, a β-lactam antibiotic, and vaborbactam, a β-lactamase inhibitor. Administered through intravenous injection, it is effective against certain types of bacteria, including those that produce β-lactamases. Common side effects may include headache, injection site inflammation, nausea, diarrhea, liver inflammation, and low blood potassium. Approved for use in the United States in 2017 and Europe in 2018, it is also listed on the World Health Organization's List of Essential Medicines. Source: Wikepedia"},{name:"Panipenem",ATC_code:"J01DH55",EML:"No",value:1,description:"Panipenem is a carbapenem antibiotic typically used in combination with betamipron. It is known for its effectiveness against a variety of bacterial infections but is notably not used in the United States. This antibiotic forms part of a class known for their broad-spectrum activity, particularly against Gram-negative and Gram-positive aerobic and anaerobic bacteria. Source: Wikepedia"},{name:"Tebipenem",ATC_code:"J01DH06",EML:"No",value:1,"description.x":"Carbapenems",description:"Carbapenems"}],children:[{name:"Watch",children:[{name:"Biapenem",ATC_code:"J01DH05",EML:"No",value:1,"description.x":"Biapenem has been used in trials studying the treatment of Bacterial Infections.",description:"Biapenem has been used in trials studying the treatment of Bacterial Infections."},{name:"Doripenem",ATC_code:"J01DH04",EML:"No",value:1,"description.x":"Doripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem carried an increased risk of death and lower clinical cure rates, resulting in a premature termination of the trial. The FDA revised the doripenem label in 2014 to include a warning against use in ventilator-associated pneumonia and to reiterate its safety and efficacy for its approved indications.",description:"Doripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem carried an increased risk of death and lower clinical cure rates, resulting in a premature termination of the trial. The FDA revised the doripenem label in 2014 to include a warning against use in ventilator-associated pneumonia and to reiterate its safety and efficacy for its approved indications."},{name:"Ertapenem",ATC_code:"J01DH03",EML:"No",value:1,"description.x":"Ertapenem is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics. It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections.",description:"Ertapenem is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics. It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections."},{name:"Imipenem/cilastatin",ATC_code:"J01DH51",EML:"Yes (therapeutic alternative to meropenem)",value:1,description:"Imipenem/cilastatin, marketed under the name Primaxin, is an antibiotic used to treat a variety of bacterial infections, including pneumonia, sepsis, endocarditis, joint infections, intra-abdominal infections, and urinary tract infections. It is administered via injection into a vein or muscle. Common side effects include nausea, diarrhea, and pain at the injection site, along with potential allergic reactions such as anaphylaxis. It works by interfering with bacteria's cell wall formation and is included in the carbapenem family of medications. Cilastatin prevents the breakdown of imipenem, enhancing its effectiveness. This drug combination was first sold in 1987 and is listed on the World Health Organization's List of Essential Medicines. Source: Wikepedia"},{name:"Meropenem",ATC_code:"J01DH02",EML:"Yes",value:1,"description.x":`Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.\r
\r
In August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of meropenem and  and is intravenously admininstered. The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria.`,description:`Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.\r
\r
In August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of meropenem and  and is intravenously admininstered. The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria.`},{name:"Panipenem",ATC_code:"J01DH55",EML:"No",value:1,description:"Panipenem is a carbapenem antibiotic typically used in combination with betamipron. It is known for its effectiveness against a variety of bacterial infections but is notably not used in the United States. This antibiotic forms part of a class known for their broad-spectrum activity, particularly against Gram-negative and Gram-positive aerobic and anaerobic bacteria. Source: Wikepedia"},{name:"Tebipenem",ATC_code:"J01DH06",EML:"No",value:1,"description.x":"Carbapenems",description:"Carbapenems"}]},{name:"Reserve",children:[{name:"Imipenem/cilastatin/relebactam",ATC_code:"J01DH56",EML:"No",value:1,description:"Imipenem/cilastatin/relebactam, sold under the brand name Recarbrio, is a combination antibiotic used for treating complicated urinary tract infections, complicated intra-abdominal infections, and hospital-acquired and ventilator-associated bacterial pneumonia in adults. It is administered via intravenous injection. Common adverse reactions include nausea, diarrhea, headache, fever, increased liver enzymes, anemia, hypokalemia (low potassium), and hyponatremia (low sodium). This combination enhances the activity of imipenem against certain bacteria by incorporating relebactam, a β-lactamase inhibitor. The FDA approved Recarbrio in 2019 for its current uses. Source: Wikepedia"},{name:"Meropenem/vaborbactam",ATC_code:"J01DH52",EML:"Yes",value:1,description:"Meropenem/vaborbactam, marketed under brand names like Vabomere, is a combination medication used for treating complicated urinary tract infections, complicated abdominal infections, and hospital-acquired pneumonia. It comprises meropenem, a β-lactam antibiotic, and vaborbactam, a β-lactamase inhibitor. Administered through intravenous injection, it is effective against certain types of bacteria, including those that produce β-lactamases. Common side effects may include headache, injection site inflammation, nausea, diarrhea, liver inflammation, and low blood potassium. Approved for use in the United States in 2017 and Europe in 2018, it is also listed on the World Health Organization's List of Essential Medicines. Source: Wikepedia"}]}]},{name:"1st-gen-cephalosporins",data:[{name:"Cefacetrile",ATC_code:"J01DB10",EML:"No",value:1,"description.x":"A derivative of 7-aminocephalosporanic acid.",description:"A derivative of 7-aminocephalosporanic acid."},{name:"Cefadroxil",ATC_code:"J01DB05",EML:"No",value:1,"description.x":"Long-acting, broad-spectrum, water-soluble, cephalexin derivative.",description:"Long-acting, broad-spectrum, water-soluble, cephalexin derivative."},{name:"Cefalexin",ATC_code:"J01DB01",EML:"Yes",value:1,"description.x":"Cephalexin is the first of the first generation cephalosporins. This antibiotic contains a  beta lactam and a dihydrothiazide. Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis.A179083,Label Cephalexin was approved by the FDA on 4 January 1971.",description:"Cephalexin is the first of the first generation cephalosporins. This antibiotic contains a  beta lactam and a dihydrothiazide. Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis.A179083,Label Cephalexin was approved by the FDA on 4 January 1971."},{name:"Cefaloridine",ATC_code:"J01DB02",EML:"No",value:1,"description.x":"Cephaloridine or cefaloridine is a first generation semisynthetic cephalosporin. It is derived from cephalosporin C and is a zwitterion at physiological pH.",description:"Cephaloridine or cefaloridine is a first generation semisynthetic cephalosporin. It is derived from cephalosporin C and is a zwitterion at physiological pH."},{name:"Cefalotin",ATC_code:"J01DB03",EML:"No",value:1,"description.x":"Cefalotin is a cephalosporin antibiotic.",description:"Cefalotin is a cephalosporin antibiotic."},{name:"Cefapirin",ATC_code:"J01DB08",EML:"No",value:1,"description.x":"Cefapirin (INN, also spelled cephapirin), commonly marketed under the trade name Cefadyl, is a first-generation cephalosporin antibiotic that is available in injectable formulations. Production for use in humans has been discontinued in the United States. Cefapirin is partly plasma-bound and is effective against gram-negative and gram-positive organisms.",description:"Cefapirin (INN, also spelled cephapirin), commonly marketed under the trade name Cefadyl, is a first-generation cephalosporin antibiotic that is available in injectable formulations. Production for use in humans has been discontinued in the United States. Cefapirin is partly plasma-bound and is effective against gram-negative and gram-positive organisms."},{name:"Cefatrizine",ATC_code:"J01DB07",EML:"No",value:1,"description.x":"First-generation cephalosporins",description:"First-generation cephalosporins"},{name:"Cefazedone",ATC_code:"J01DB06",EML:"No",value:1,"description.x":"First-generation cephalosporins",description:"First-generation cephalosporins"},{name:"Cefazolin",ATC_code:"J01DB04",EML:"Yes",value:1,"description.x":"A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.",description:"A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine."},{name:"Cefradine",ATC_code:"J01DB09",EML:"No",value:1,"description.x":"A semi-synthetic cephalosporin antibiotic.",description:"A semi-synthetic cephalosporin antibiotic."},{name:"Cefroxadine",ATC_code:"J01DB11",EML:"No",value:1,"description.x":"Cefroxadine is an orally available cephalosporin antibiotic. As part of its drug class, it shares structural properties to cefalexin as well as its activity spectrum. It was used in Italy but has since been withdrawn.",description:"Cefroxadine is an orally available cephalosporin antibiotic. As part of its drug class, it shares structural properties to cefalexin as well as its activity spectrum. It was used in Italy but has since been withdrawn."},{name:"Ceftezole",ATC_code:"J01DB12",EML:"No",value:1,"description.x":"First-generation cephalosporins",description:"First-generation cephalosporins"}],children:[{name:"Access",children:[{name:"Cefacetrile",ATC_code:"J01DB10",EML:"No",value:1,"description.x":"A derivative of 7-aminocephalosporanic acid.",description:"A derivative of 7-aminocephalosporanic acid."},{name:"Cefadroxil",ATC_code:"J01DB05",EML:"No",value:1,"description.x":"Long-acting, broad-spectrum, water-soluble, cephalexin derivative.",description:"Long-acting, broad-spectrum, water-soluble, cephalexin derivative."},{name:"Cefalexin",ATC_code:"J01DB01",EML:"Yes",value:1,"description.x":"Cephalexin is the first of the first generation cephalosporins. This antibiotic contains a  beta lactam and a dihydrothiazide. Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis.A179083,Label Cephalexin was approved by the FDA on 4 January 1971.",description:"Cephalexin is the first of the first generation cephalosporins. This antibiotic contains a  beta lactam and a dihydrothiazide. Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis.A179083,Label Cephalexin was approved by the FDA on 4 January 1971."},{name:"Cefaloridine",ATC_code:"J01DB02",EML:"No",value:1,"description.x":"Cephaloridine or cefaloridine is a first generation semisynthetic cephalosporin. It is derived from cephalosporin C and is a zwitterion at physiological pH.",description:"Cephaloridine or cefaloridine is a first generation semisynthetic cephalosporin. It is derived from cephalosporin C and is a zwitterion at physiological pH."},{name:"Cefalotin",ATC_code:"J01DB03",EML:"No",value:1,"description.x":"Cefalotin is a cephalosporin antibiotic.",description:"Cefalotin is a cephalosporin antibiotic."},{name:"Cefapirin",ATC_code:"J01DB08",EML:"No",value:1,"description.x":"Cefapirin (INN, also spelled cephapirin), commonly marketed under the trade name Cefadyl, is a first-generation cephalosporin antibiotic that is available in injectable formulations. Production for use in humans has been discontinued in the United States. Cefapirin is partly plasma-bound and is effective against gram-negative and gram-positive organisms.",description:"Cefapirin (INN, also spelled cephapirin), commonly marketed under the trade name Cefadyl, is a first-generation cephalosporin antibiotic that is available in injectable formulations. Production for use in humans has been discontinued in the United States. Cefapirin is partly plasma-bound and is effective against gram-negative and gram-positive organisms."},{name:"Cefatrizine",ATC_code:"J01DB07",EML:"No",value:1,"description.x":"First-generation cephalosporins",description:"First-generation cephalosporins"},{name:"Cefazedone",ATC_code:"J01DB06",EML:"No",value:1,"description.x":"First-generation cephalosporins",description:"First-generation cephalosporins"},{name:"Cefazolin",ATC_code:"J01DB04",EML:"Yes",value:1,"description.x":"A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.",description:"A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine."},{name:"Cefradine",ATC_code:"J01DB09",EML:"No",value:1,"description.x":"A semi-synthetic cephalosporin antibiotic.",description:"A semi-synthetic cephalosporin antibiotic."},{name:"Cefroxadine",ATC_code:"J01DB11",EML:"No",value:1,"description.x":"Cefroxadine is an orally available cephalosporin antibiotic. As part of its drug class, it shares structural properties to cefalexin as well as its activity spectrum. It was used in Italy but has since been withdrawn.",description:"Cefroxadine is an orally available cephalosporin antibiotic. As part of its drug class, it shares structural properties to cefalexin as well as its activity spectrum. It was used in Italy but has since been withdrawn."},{name:"Ceftezole",ATC_code:"J01DB12",EML:"No",value:1,"description.x":"First-generation cephalosporins",description:"First-generation cephalosporins"}]}]},{name:"2nd-gen-cephalosporins",data:[{name:"Cefaclor",ATC_code:"J01DC04",EML:"No",value:1,"description.x":"Semisynthetic, broad-spectrum antibiotic derivative of cephalexin.",description:"Semisynthetic, broad-spectrum antibiotic derivative of cephalexin."},{name:"Cefamandole",ATC_code:"J01DC03",EML:"No",value:1,"description.x":"Cefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, cefamandole nafate. It is no longer marketed in the United States.",description:"Cefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, cefamandole nafate. It is no longer marketed in the United States."},{name:"Cefbuperazone",ATC_code:"J01DC13",EML:"No",value:1,"description.x":"Second-generation cephalosporins",description:"Second-generation cephalosporins"},{name:"Cefmetazole",ATC_code:"J01DC09",EML:"No",value:1,"description.x":"A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.",description:"A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted."},{name:"Cefminox",ATC_code:"J01DC12",EML:"No",value:1,"description.x":"Cefminox (INN) is a second generation cephalosporin antibiotic. It is approved for use in Japan.",description:"Cefminox (INN) is a second generation cephalosporin antibiotic. It is approved for use in Japan."},{name:"Cefonicid",ATC_code:"J01DC06",EML:"No",value:1,"description.x":"A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections.",description:"A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections."},{name:"Ceforanide",ATC_code:"J01DC11",EML:"No",value:1,"description.x":"Ceforanide is administered parenterally. It has a longer elimination half-life than any currently available cephalosporin. Its activity is very similar to that of cefamandole, another second-generation cephalosporin antibiotic, except that ceforanide is less active against most gram-positive organisms. Many coliforms, including Escherichia coli, Klebsiella, Enterobacter, and Proteus, are susceptible to ceforanide, as are most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species.",description:"Ceforanide is administered parenterally. It has a longer elimination half-life than any currently available cephalosporin. Its activity is very similar to that of cefamandole, another second-generation cephalosporin antibiotic, except that ceforanide is less active against most gram-positive organisms. Many coliforms, including Escherichia coli, Klebsiella, Enterobacter, and Proteus, are susceptible to ceforanide, as are most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species."},{name:"Cefotetan",ATC_code:"J01DC05",EML:"No",value:1,"description.x":"A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.",description:"A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms."},{name:"Cefotiam",ATC_code:"J01DC07",EML:"No",value:1,"description.x":"One of the cephalosporins that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.",description:"One of the cephalosporins that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms."},{name:"Cefoxitin",ATC_code:"J01DC01",EML:"No",value:1,"description.x":"Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by Streptomyces lactamdurans.",description:"Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by Streptomyces lactamdurans."},{name:"Cefprozil",ATC_code:"J01DC10",EML:"No",value:1,"description.x":"Cefprozil is a cephalosporin antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and skin, bronchitis, and others.",description:"Cefprozil is a cephalosporin antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and skin, bronchitis, and others."},{name:"Cefuroxime",ATC_code:"J01DC02",EML:"Yes",value:1,"description.x":"Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.",description:"Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus."},{name:"Flomoxef",ATC_code:"J01DC14",EML:"No",value:1,"description.x":"Flomoxef has been used in trials studying the treatment of Urinary Tract Infection.",description:"Flomoxef has been used in trials studying the treatment of Urinary Tract Infection."},{name:"Loracarbef",ATC_code:"J01DC08",EML:"No",value:1,"description.x":"Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.",description:"Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid."}],children:[{name:"Watch",children:[{name:"Cefaclor",ATC_code:"J01DC04",EML:"No",value:1,"description.x":"Semisynthetic, broad-spectrum antibiotic derivative of cephalexin.",description:"Semisynthetic, broad-spectrum antibiotic derivative of cephalexin."},{name:"Cefamandole",ATC_code:"J01DC03",EML:"No",value:1,"description.x":"Cefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, cefamandole nafate. It is no longer marketed in the United States.",description:"Cefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, cefamandole nafate. It is no longer marketed in the United States."},{name:"Cefbuperazone",ATC_code:"J01DC13",EML:"No",value:1,"description.x":"Second-generation cephalosporins",description:"Second-generation cephalosporins"},{name:"Cefmetazole",ATC_code:"J01DC09",EML:"No",value:1,"description.x":"A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.",description:"A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted."},{name:"Cefminox",ATC_code:"J01DC12",EML:"No",value:1,"description.x":"Cefminox (INN) is a second generation cephalosporin antibiotic. It is approved for use in Japan.",description:"Cefminox (INN) is a second generation cephalosporin antibiotic. It is approved for use in Japan."},{name:"Cefonicid",ATC_code:"J01DC06",EML:"No",value:1,"description.x":"A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections.",description:"A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections."},{name:"Ceforanide",ATC_code:"J01DC11",EML:"No",value:1,"description.x":"Ceforanide is administered parenterally. It has a longer elimination half-life than any currently available cephalosporin. Its activity is very similar to that of cefamandole, another second-generation cephalosporin antibiotic, except that ceforanide is less active against most gram-positive organisms. Many coliforms, including Escherichia coli, Klebsiella, Enterobacter, and Proteus, are susceptible to ceforanide, as are most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species.",description:"Ceforanide is administered parenterally. It has a longer elimination half-life than any currently available cephalosporin. Its activity is very similar to that of cefamandole, another second-generation cephalosporin antibiotic, except that ceforanide is less active against most gram-positive organisms. Many coliforms, including Escherichia coli, Klebsiella, Enterobacter, and Proteus, are susceptible to ceforanide, as are most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species."},{name:"Cefotetan",ATC_code:"J01DC05",EML:"No",value:1,"description.x":"A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.",description:"A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms."},{name:"Cefotiam",ATC_code:"J01DC07",EML:"No",value:1,"description.x":"One of the cephalosporins that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.",description:"One of the cephalosporins that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms."},{name:"Cefoxitin",ATC_code:"J01DC01",EML:"No",value:1,"description.x":"Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by Streptomyces lactamdurans.",description:"Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by Streptomyces lactamdurans."},{name:"Cefprozil",ATC_code:"J01DC10",EML:"No",value:1,"description.x":"Cefprozil is a cephalosporin antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and skin, bronchitis, and others.",description:"Cefprozil is a cephalosporin antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and skin, bronchitis, and others."},{name:"Cefuroxime",ATC_code:"J01DC02",EML:"Yes",value:1,"description.x":"Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.",description:"Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus."},{name:"Flomoxef",ATC_code:"J01DC14",EML:"No",value:1,"description.x":"Flomoxef has been used in trials studying the treatment of Urinary Tract Infection.",description:"Flomoxef has been used in trials studying the treatment of Urinary Tract Infection."},{name:"Loracarbef",ATC_code:"J01DC08",EML:"No",value:1,"description.x":"Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.",description:"Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid."}]}]},{name:"3rd-gen-cephalosporins",data:[{name:"Cefcapene-pivoxil",ATC_code:"J01DD17",EML:"No",value:1,"description.x":"Third-generation cephalosporins",description:"Third-generation cephalosporins"},{name:"Cefdinir",ATC_code:"J01DD15",EML:"No",value:1,"description.x":"Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class. It has been proven to be effective for the treatment of common bacterial infections in the ear, sinus, throat, lungs, and skin. Cefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie. Because of its chemical structure, it is effective against organisms that are resistant to first-line cephalosporin therapy due to the production of beta-lactamase enzymes.",description:"Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class. It has been proven to be effective for the treatment of common bacterial infections in the ear, sinus, throat, lungs, and skin. Cefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie. Because of its chemical structure, it is effective against organisms that are resistant to first-line cephalosporin therapy due to the production of beta-lactamase enzymes."},{name:"Cefditoren-pivoxil",ATC_code:"J01DD16",EML:"No",value:1,"description.x":"Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.",description:"Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma."},{name:"Cefetamet-pivoxil",ATC_code:"J01DD10",EML:"No",value:1,"description.x":"Third-generation cephalosporins",description:"Third-generation cephalosporins"},{name:"Cefixime",ATC_code:"J01DD08",EML:"Yes",value:1,"description.x":"Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall.",description:"Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall."},{name:"Cefmenoxime",ATC_code:"J01DD05",EML:"No",value:1,"description.x":"Cefmenoxime is a novel broad-spectrum and third-generation cephalosporin antibiotic that is typically used in the treatment of female gynecologic and obstetric infections. It is reported to exhibit high activity against a wide variety of gram-positive and gram-negative bacteria.",description:"Cefmenoxime is a novel broad-spectrum and third-generation cephalosporin antibiotic that is typically used in the treatment of female gynecologic and obstetric infections. It is reported to exhibit high activity against a wide variety of gram-positive and gram-negative bacteria."},{name:"Cefodizime",ATC_code:"J01DD09",EML:"No",value:1,"description.x":"Third-generation cephalosporins",description:"Third-generation cephalosporins"},{name:"Cefoperazone",ATC_code:"J01DD12",EML:"No",value:1,"description.x":"Cefoperazone is a semisynthetic broad-spectrum cephalosporin proposed to be effective against Pseudomonas infections. It is a third-generation antiobiotic agent and it is used in the treatment of various bacterial infections caused by susceptible organisms in the body, including respiratory tract infections, peritonitis, skin infections, endometritis, and bacterial septicemia. While its clinical use has been discontinued in the U.S., cefoperazone is available in several European countries most commonly under the product name, Sulperazon.",description:"Cefoperazone is a semisynthetic broad-spectrum cephalosporin proposed to be effective against Pseudomonas infections. It is a third-generation antiobiotic agent and it is used in the treatment of various bacterial infections caused by susceptible organisms in the body, including respiratory tract infections, peritonitis, skin infections, endometritis, and bacterial septicemia. While its clinical use has been discontinued in the U.S., cefoperazone is available in several European countries most commonly under the product name, Sulperazon."},{name:"Cefotaxime",ATC_code:"J01DD01",EML:"Yes",value:1,"description.x":"Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).",description:"Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis)."},{name:"Cefpiramide",ATC_code:"J01DD11",EML:"No",value:1,"description.x":"Cefpiramide is a third-generation cephalosporin antibiotic.",description:"Cefpiramide is a third-generation cephalosporin antibiotic."},{name:"Cefpodoxime-proxetil",ATC_code:"J01DD13",EML:"No",value:1,"description.x":"Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.",description:"Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime."},{name:"Cefsulodin",ATC_code:"J01DD03",EML:"No",value:1,"description.x":"Third-generation cephalosporins",description:"Third-generation cephalosporins"},{name:"Ceftazidime",ATC_code:"J01DD02",EML:"Yes",value:1,"description.x":`Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding proteins" (PBPs). β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis, loss of cell integrity, and ultimately bacterial cell death. Ceftazidime is a third-generation cephalosporin with broad-spectrum antibacterial activity, including against some treatment-resistant bacteria such as Pseudomonas aeruginosa.\r
\r
Ceftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-β-lactam β-lactamase inhibitor avibactam to treat a variety of bacterial infections.`,description:`Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding proteins" (PBPs). β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis, loss of cell integrity, and ultimately bacterial cell death. Ceftazidime is a third-generation cephalosporin with broad-spectrum antibacterial activity, including against some treatment-resistant bacteria such as Pseudomonas aeruginosa.\r
\r
Ceftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-β-lactam β-lactamase inhibitor avibactam to treat a variety of bacterial infections.`},{name:"Ceftazidime/avibactam",ATC_code:"J01DD52",EML:"Yes",value:1,description:"Ceftazidime/avibactam, marketed as Avycaz among other names, is a combination medication consisting of ceftazidime, a cephalosporin antibiotic, and avibactam, a β-lactamase inhibitor. This medication is primarily used to treat complicated intra-abdominal infections, urinary tract infections, and pneumonia, especially when other options are not suitable. Administered through intravenous injection, it can cause side effects such as nausea, fever, liver problems, and pain at the injection site. Approved for medical use in the United States and the European Union in 2015, it is included in the World Health Organization's List of Essential Medicines. However, increasing cases of resistance to this medication have been reported. Source: Wikepedia"},{name:"Cefteram-pivoxil",ATC_code:"J01DD18",EML:"No",value:1,description:"Cefteram-pivoxil is an orally administered prodrug of cefteram, a third-generation cephalosporin antibiotic. It's designed to be absorbed from the gastrointestinal tract and then converted into its active form, cefteram, in the body. This antibiotic is effective against a wide range of Gram-positive and Gram-negative bacteria, making it useful for treating various bacterial infections. Cefteram-pivoxil is particularly noted for its effectiveness against certain types of bacteria that are resistant to other cephalosporins. It's commonly used in the treatment of respiratory tract infections and other bacterial infections where oral administration is preferred or necessary. Source: Wikepedia"},{name:"Ceftibuten",ATC_code:"J01DD14",EML:"No",value:1,"description.x":"Ceftibuten is a third-generation cephalosporin antibiotic that is orally-administered. It is typically used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.",description:"Ceftibuten is a third-generation cephalosporin antibiotic that is orally-administered. It is typically used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis."},{name:"Ceftizoxime",ATC_code:"J01DD07",EML:"No",value:1,"description.x":"A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders.",description:"A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders."},{name:"Ceftriaxone",ATC_code:"J01DD04",EML:"Yes",value:1,"description.x":"Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges, eyes, and inner ear. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing.",description:"Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges, eyes, and inner ear. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing."},{name:"Latamoxef",ATC_code:"J01DD06",EML:"No",value:1,"description.x":"Latamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.",description:"Latamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections."}],children:[{name:"Watch",children:[{name:"Cefcapene-pivoxil",ATC_code:"J01DD17",EML:"No",value:1,"description.x":"Third-generation cephalosporins",description:"Third-generation cephalosporins"},{name:"Cefdinir",ATC_code:"J01DD15",EML:"No",value:1,"description.x":"Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class. It has been proven to be effective for the treatment of common bacterial infections in the ear, sinus, throat, lungs, and skin. Cefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie. Because of its chemical structure, it is effective against organisms that are resistant to first-line cephalosporin therapy due to the production of beta-lactamase enzymes.",description:"Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class. It has been proven to be effective for the treatment of common bacterial infections in the ear, sinus, throat, lungs, and skin. Cefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie. Because of its chemical structure, it is effective against organisms that are resistant to first-line cephalosporin therapy due to the production of beta-lactamase enzymes."},{name:"Cefditoren-pivoxil",ATC_code:"J01DD16",EML:"No",value:1,"description.x":"Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.",description:"Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma."},{name:"Cefetamet-pivoxil",ATC_code:"J01DD10",EML:"No",value:1,"description.x":"Third-generation cephalosporins",description:"Third-generation cephalosporins"},{name:"Cefixime",ATC_code:"J01DD08",EML:"Yes",value:1,"description.x":"Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall.",description:"Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall."},{name:"Cefmenoxime",ATC_code:"J01DD05",EML:"No",value:1,"description.x":"Cefmenoxime is a novel broad-spectrum and third-generation cephalosporin antibiotic that is typically used in the treatment of female gynecologic and obstetric infections. It is reported to exhibit high activity against a wide variety of gram-positive and gram-negative bacteria.",description:"Cefmenoxime is a novel broad-spectrum and third-generation cephalosporin antibiotic that is typically used in the treatment of female gynecologic and obstetric infections. It is reported to exhibit high activity against a wide variety of gram-positive and gram-negative bacteria."},{name:"Cefodizime",ATC_code:"J01DD09",EML:"No",value:1,"description.x":"Third-generation cephalosporins",description:"Third-generation cephalosporins"},{name:"Cefoperazone",ATC_code:"J01DD12",EML:"No",value:1,"description.x":"Cefoperazone is a semisynthetic broad-spectrum cephalosporin proposed to be effective against Pseudomonas infections. It is a third-generation antiobiotic agent and it is used in the treatment of various bacterial infections caused by susceptible organisms in the body, including respiratory tract infections, peritonitis, skin infections, endometritis, and bacterial septicemia. While its clinical use has been discontinued in the U.S., cefoperazone is available in several European countries most commonly under the product name, Sulperazon.",description:"Cefoperazone is a semisynthetic broad-spectrum cephalosporin proposed to be effective against Pseudomonas infections. It is a third-generation antiobiotic agent and it is used in the treatment of various bacterial infections caused by susceptible organisms in the body, including respiratory tract infections, peritonitis, skin infections, endometritis, and bacterial septicemia. While its clinical use has been discontinued in the U.S., cefoperazone is available in several European countries most commonly under the product name, Sulperazon."},{name:"Cefotaxime",ATC_code:"J01DD01",EML:"Yes",value:1,"description.x":"Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).",description:"Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis)."},{name:"Cefpiramide",ATC_code:"J01DD11",EML:"No",value:1,"description.x":"Cefpiramide is a third-generation cephalosporin antibiotic.",description:"Cefpiramide is a third-generation cephalosporin antibiotic."},{name:"Cefpodoxime-proxetil",ATC_code:"J01DD13",EML:"No",value:1,"description.x":"Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.",description:"Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime."},{name:"Cefsulodin",ATC_code:"J01DD03",EML:"No",value:1,"description.x":"Third-generation cephalosporins",description:"Third-generation cephalosporins"},{name:"Ceftazidime",ATC_code:"J01DD02",EML:"Yes",value:1,"description.x":`Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding proteins" (PBPs). β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis, loss of cell integrity, and ultimately bacterial cell death. Ceftazidime is a third-generation cephalosporin with broad-spectrum antibacterial activity, including against some treatment-resistant bacteria such as Pseudomonas aeruginosa.\r
\r
Ceftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-β-lactam β-lactamase inhibitor avibactam to treat a variety of bacterial infections.`,description:`Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding proteins" (PBPs). β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis, loss of cell integrity, and ultimately bacterial cell death. Ceftazidime is a third-generation cephalosporin with broad-spectrum antibacterial activity, including against some treatment-resistant bacteria such as Pseudomonas aeruginosa.\r
\r
Ceftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-β-lactam β-lactamase inhibitor avibactam to treat a variety of bacterial infections.`},{name:"Cefteram-pivoxil",ATC_code:"J01DD18",EML:"No",value:1,description:"Cefteram-pivoxil is an orally administered prodrug of cefteram, a third-generation cephalosporin antibiotic. It's designed to be absorbed from the gastrointestinal tract and then converted into its active form, cefteram, in the body. This antibiotic is effective against a wide range of Gram-positive and Gram-negative bacteria, making it useful for treating various bacterial infections. Cefteram-pivoxil is particularly noted for its effectiveness against certain types of bacteria that are resistant to other cephalosporins. It's commonly used in the treatment of respiratory tract infections and other bacterial infections where oral administration is preferred or necessary. Source: Wikepedia"},{name:"Ceftibuten",ATC_code:"J01DD14",EML:"No",value:1,"description.x":"Ceftibuten is a third-generation cephalosporin antibiotic that is orally-administered. It is typically used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.",description:"Ceftibuten is a third-generation cephalosporin antibiotic that is orally-administered. It is typically used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis."},{name:"Ceftizoxime",ATC_code:"J01DD07",EML:"No",value:1,"description.x":"A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders.",description:"A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders."},{name:"Ceftriaxone",ATC_code:"J01DD04",EML:"Yes",value:1,"description.x":"Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges, eyes, and inner ear. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing.",description:"Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges, eyes, and inner ear. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing."},{name:"Latamoxef",ATC_code:"J01DD06",EML:"No",value:1,"description.x":"Latamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.",description:"Latamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections."}]},{name:"Reserve",children:[{name:"Ceftazidime/avibactam",ATC_code:"J01DD52",EML:"Yes",value:1,description:"Ceftazidime/avibactam, marketed as Avycaz among other names, is a combination medication consisting of ceftazidime, a cephalosporin antibiotic, and avibactam, a β-lactamase inhibitor. This medication is primarily used to treat complicated intra-abdominal infections, urinary tract infections, and pneumonia, especially when other options are not suitable. Administered through intravenous injection, it can cause side effects such as nausea, fever, liver problems, and pain at the injection site. Approved for medical use in the United States and the European Union in 2015, it is included in the World Health Organization's List of Essential Medicines. However, increasing cases of resistance to this medication have been reported. Source: Wikepedia"}]}]},{name:"4th-gen-cephalosporins",data:[{name:"Cefepime",ATC_code:"J01DE01",EML:"No",value:1,"description.x":"Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, and has greater activity against both compared to third-generation antibiotics. Cefepime is normally used to treat severe nosocomial pneumonia and infections caused by multi-resistant microorganisms such as Pseudomonas aeruginosa, and is also indicated for the empirical treatment of febrile neutropenia. The popularity of its third-generation predecessors, its clinical efficacy, and the high prevalence of multidrug-resistant bacteria might be some of the factors leading to an increase in the use of cefepime. The activity of cefepime against Enterobacteriaceae, Pseudomonas aeruginosa, and Staphylococcus aureus is due to its high stability toward beta-lactamases. In general, cefepime seems to be well tolerated; however, patients treated with this antibiotic, especially those with renal impairment, may develop neurotoxicity.",description:"Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, and has greater activity against both compared to third-generation antibiotics. Cefepime is normally used to treat severe nosocomial pneumonia and infections caused by multi-resistant microorganisms such as Pseudomonas aeruginosa, and is also indicated for the empirical treatment of febrile neutropenia. The popularity of its third-generation predecessors, its clinical efficacy, and the high prevalence of multidrug-resistant bacteria might be some of the factors leading to an increase in the use of cefepime. The activity of cefepime against Enterobacteriaceae, Pseudomonas aeruginosa, and Staphylococcus aureus is due to its high stability toward beta-lactamases. In general, cefepime seems to be well tolerated; however, patients treated with this antibiotic, especially those with renal impairment, may develop neurotoxicity."},{name:"Cefoselis",ATC_code:"to be assigned",EML:"No",value:1,description:"Cefoselis is a fourth-generation cephalosporin antibiotic. It's widely used in Japan and China for treating various gram-positive and gram-negative infections. Clinical studies have shown its effectiveness in treating respiratory and urinary tract infections. Source: Wikepedia"},{name:"Cefozopran",ATC_code:"J01DE03",EML:"No",value:1,"description.x":"Fourth-generation cephalosporins",description:"Fourth-generation cephalosporins"},{name:"Cefpirome",ATC_code:"J01DE02",EML:"No",value:1,"description.x":"Fourth-generation cephalosporins",description:"Fourth-generation cephalosporins"}],children:[{name:"Watch",children:[{name:"Cefepime",ATC_code:"J01DE01",EML:"No",value:1,"description.x":"Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, and has greater activity against both compared to third-generation antibiotics. Cefepime is normally used to treat severe nosocomial pneumonia and infections caused by multi-resistant microorganisms such as Pseudomonas aeruginosa, and is also indicated for the empirical treatment of febrile neutropenia. The popularity of its third-generation predecessors, its clinical efficacy, and the high prevalence of multidrug-resistant bacteria might be some of the factors leading to an increase in the use of cefepime. The activity of cefepime against Enterobacteriaceae, Pseudomonas aeruginosa, and Staphylococcus aureus is due to its high stability toward beta-lactamases. In general, cefepime seems to be well tolerated; however, patients treated with this antibiotic, especially those with renal impairment, may develop neurotoxicity.",description:"Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, and has greater activity against both compared to third-generation antibiotics. Cefepime is normally used to treat severe nosocomial pneumonia and infections caused by multi-resistant microorganisms such as Pseudomonas aeruginosa, and is also indicated for the empirical treatment of febrile neutropenia. The popularity of its third-generation predecessors, its clinical efficacy, and the high prevalence of multidrug-resistant bacteria might be some of the factors leading to an increase in the use of cefepime. The activity of cefepime against Enterobacteriaceae, Pseudomonas aeruginosa, and Staphylococcus aureus is due to its high stability toward beta-lactamases. In general, cefepime seems to be well tolerated; however, patients treated with this antibiotic, especially those with renal impairment, may develop neurotoxicity."},{name:"Cefoselis",ATC_code:"to be assigned",EML:"No",value:1,description:"Cefoselis is a fourth-generation cephalosporin antibiotic. It's widely used in Japan and China for treating various gram-positive and gram-negative infections. Clinical studies have shown its effectiveness in treating respiratory and urinary tract infections. Source: Wikepedia"},{name:"Cefozopran",ATC_code:"J01DE03",EML:"No",value:1,"description.x":"Fourth-generation cephalosporins",description:"Fourth-generation cephalosporins"},{name:"Cefpirome",ATC_code:"J01DE02",EML:"No",value:1,"description.x":"Fourth-generation cephalosporins",description:"Fourth-generation cephalosporins"}]}]},{name:"Other-cephalosporins",data:[{name:"Cefiderocol",ATC_code:"J01DI04",EML:"Yes",value:2,"description.x":`Cefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other β-lactam antibiotics.FDA Label Unlike other agents in this category, cefiderocol is a siderophore able to undergo active transport into the bacterial cell through iron channels. It represents a significant addition to antibacterial treatment option as it has proven to be effective *in vitro* against multidrug resistant strains including extended spectrum β-lactamase producers and carbapenemase producing bacteria.\r
\r
Cefiderocol was granted designation as a Qualified Infectious Disease Product and granted priority review status by the FDA on November 14, 2019. It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available.FDA Label This indication was supported by a positive clinical trial composed of 448 patients with complicated urinary tract infections which demonstrated a 72.6% rate of symptom resolution and bacterial eradication with cefiderocol compared to 54.6% with the comparator, imipenem/cilastatin. A concern noted in the trial was a 0.3% higher rate of all cause mortality, the cause of which has not been determined.`,description:`Cefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other β-lactam antibiotics.FDA Label Unlike other agents in this category, cefiderocol is a siderophore able to undergo active transport into the bacterial cell through iron channels. It represents a significant addition to antibacterial treatment option as it has proven to be effective *in vitro* against multidrug resistant strains including extended spectrum β-lactamase producers and carbapenemase producing bacteria.\r
\r
Cefiderocol was granted designation as a Qualified Infectious Disease Product and granted priority review status by the FDA on November 14, 2019. It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available.FDA Label This indication was supported by a positive clinical trial composed of 448 patients with complicated urinary tract infections which demonstrated a 72.6% rate of symptom resolution and bacterial eradication with cefiderocol compared to 54.6% with the comparator, imipenem/cilastatin. A concern noted in the trial was a 0.3% higher rate of all cause mortality, the cause of which has not been determined.`}],children:[{name:"Reserve",children:[{name:"Cefiderocol",ATC_code:"J01DI04",EML:"Yes",value:2,"description.x":`Cefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other β-lactam antibiotics.FDA Label Unlike other agents in this category, cefiderocol is a siderophore able to undergo active transport into the bacterial cell through iron channels. It represents a significant addition to antibacterial treatment option as it has proven to be effective *in vitro* against multidrug resistant strains including extended spectrum β-lactamase producers and carbapenemase producing bacteria.\r
\r
Cefiderocol was granted designation as a Qualified Infectious Disease Product and granted priority review status by the FDA on November 14, 2019. It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available.FDA Label This indication was supported by a positive clinical trial composed of 448 patients with complicated urinary tract infections which demonstrated a 72.6% rate of symptom resolution and bacterial eradication with cefiderocol compared to 54.6% with the comparator, imipenem/cilastatin. A concern noted in the trial was a 0.3% higher rate of all cause mortality, the cause of which has not been determined.`,description:`Cefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other β-lactam antibiotics.FDA Label Unlike other agents in this category, cefiderocol is a siderophore able to undergo active transport into the bacterial cell through iron channels. It represents a significant addition to antibacterial treatment option as it has proven to be effective *in vitro* against multidrug resistant strains including extended spectrum β-lactamase producers and carbapenemase producing bacteria.\r
\r
Cefiderocol was granted designation as a Qualified Infectious Disease Product and granted priority review status by the FDA on November 14, 2019. It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available.FDA Label This indication was supported by a positive clinical trial composed of 448 patients with complicated urinary tract infections which demonstrated a 72.6% rate of symptom resolution and bacterial eradication with cefiderocol compared to 54.6% with the comparator, imipenem/cilastatin. A concern noted in the trial was a 0.3% higher rate of all cause mortality, the cause of which has not been determined.`}]}]},{name:"5th-gen cephalosporins",data:[{name:"Ceftaroline-fosamil",ATC_code:"J01DI02 ",EML:"No",value:1,description:"Ceftaroline fosamil, known under the brand names Teflaro in the US and Zinforo in Europe, is a cephalosporin antibiotic with anti-MRSA activity. It is a prodrug of ceftaroline and is effective against methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive bacteria. While it retains broad-spectrum activity against Gram-negative bacteria, its effectiveness in this regard is relatively weaker. Ceftaroline fosamil is currently being investigated for treating community-acquired pneumonia and complicated skin and skin structure infection. It was developed by Forest Laboratories under a license from Takeda and received FDA approval in 2010 for the treatment of community-acquired bacterial pneumonia and acute bacterial skin infections. Source: Wikepedia"},{name:"Ceftobiprole-medocaril",ATC_code:"J01DI01",EML:"No",value:1,description:"Ceftobiprole medocaril is a ceftobiprole prodrug.","description.x":"Ceftobiprole medocaril is a ceftobiprole prodrug."},{name:"Ceftolozane/tazobactam",ATC_code:"J01DI54",EML:"Yes",value:1,description:"Ceftolozane/tazobactam, marketed under the brand name Zerbaxa, is a combination antibiotic used for treating complicated urinary tract and intra-abdominal infections in adults. It consists of ceftolozane, a cephalosporin antibiotic, and tazobactam, a β-lactamase inhibitor. This combination is effective against gram-negative bacteria that are resistant to conventional antibiotics. Common side effects include nausea, headache, constipation, diarrhea, and fever. It was approved for medical use in the United States in 2014 and the European Union in 2015 and is included in the World Health Organization's List of Essential Medicines. Source: Wikepedia"}],children:[{name:"Reserve",children:[{name:"Ceftaroline-fosamil",ATC_code:"J01DI02 ",EML:"No",value:1,description:"Ceftaroline fosamil, known under the brand names Teflaro in the US and Zinforo in Europe, is a cephalosporin antibiotic with anti-MRSA activity. It is a prodrug of ceftaroline and is effective against methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive bacteria. While it retains broad-spectrum activity against Gram-negative bacteria, its effectiveness in this regard is relatively weaker. Ceftaroline fosamil is currently being investigated for treating community-acquired pneumonia and complicated skin and skin structure infection. It was developed by Forest Laboratories under a license from Takeda and received FDA approval in 2010 for the treatment of community-acquired bacterial pneumonia and acute bacterial skin infections. Source: Wikepedia"},{name:"Ceftobiprole-medocaril",ATC_code:"J01DI01",EML:"No",value:1,description:"Ceftobiprole medocaril is a ceftobiprole prodrug.","description.x":"Ceftobiprole medocaril is a ceftobiprole prodrug."},{name:"Ceftolozane/tazobactam",ATC_code:"J01DI54",EML:"Yes",value:1,description:"Ceftolozane/tazobactam, marketed under the brand name Zerbaxa, is a combination antibiotic used for treating complicated urinary tract and intra-abdominal infections in adults. It consists of ceftolozane, a cephalosporin antibiotic, and tazobactam, a β-lactamase inhibitor. This combination is effective against gram-negative bacteria that are resistant to conventional antibiotics. Common side effects include nausea, headache, constipation, diarrhea, and fever. It was approved for medical use in the United States in 2014 and the European Union in 2015 and is included in the World Health Organization's List of Essential Medicines. Source: Wikepedia"}]}]},{name:"Penems",data:[{name:"Faropenem",ATC_code:"J01DI03",EML:"No",value:2,"description.x":"Faropenem has been used in trials studying the treatment of Tuberculosis, Pulmonary Tuberculosis, and Community Acquired Pneumonia.",description:"Faropenem has been used in trials studying the treatment of Tuberculosis, Pulmonary Tuberculosis, and Community Acquired Pneumonia."}],children:[{name:"Reserve",children:[{name:"Faropenem",ATC_code:"J01DI03",EML:"No",value:2,"description.x":"Faropenem has been used in trials studying the treatment of Tuberculosis, Pulmonary Tuberculosis, and Community Acquired Pneumonia.",description:"Faropenem has been used in trials studying the treatment of Tuberculosis, Pulmonary Tuberculosis, and Community Acquired Pneumonia."}]}]},{name:"Beta-lactamase-inhibitors",data:[{name:"Sulbactam",ATC_code:"J01CG01",EML:"No",value:1,"description.x":"Sulbactam is a β-lactamase inhibitor given in combination with β-lactam antibiotics to inhibit β-lactamase, an enzyme produced by bacteria that destroys antibiotic activity.",description:"Sulbactam is a β-lactamase inhibitor given in combination with β-lactam antibiotics to inhibit β-lactamase, an enzyme produced by bacteria that destroys antibiotic activity."},{name:"Tazobactam",ATC_code:"J01CG02",EML:"No",value:1,"description.x":`Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms. It is combined with Piperacillin and Ceftolozane for the treatment of a variety of bacterial infections.\r
\r
Piperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014FDA label, providing wider antibacterial coverage for gram-negative infections. In June 2019, ceftolozane-tazobactam was approved by the FDA for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, which are significant causes of morbidity and mortality in hospitalized patients.`,description:`Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms. It is combined with Piperacillin and Ceftolozane for the treatment of a variety of bacterial infections.\r
\r
Piperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014FDA label, providing wider antibacterial coverage for gram-negative infections. In June 2019, ceftolozane-tazobactam was approved by the FDA for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, which are significant causes of morbidity and mortality in hospitalized patients.`}],children:[{name:"Access",children:[{name:"Sulbactam",ATC_code:"J01CG01",EML:"No",value:1,"description.x":"Sulbactam is a β-lactamase inhibitor given in combination with β-lactam antibiotics to inhibit β-lactamase, an enzyme produced by bacteria that destroys antibiotic activity.",description:"Sulbactam is a β-lactamase inhibitor given in combination with β-lactam antibiotics to inhibit β-lactamase, an enzyme produced by bacteria that destroys antibiotic activity."}]},{name:"Watch",children:[{name:"Tazobactam",ATC_code:"J01CG02",EML:"No",value:1,"description.x":`Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms. It is combined with Piperacillin and Ceftolozane for the treatment of a variety of bacterial infections.\r
\r
Piperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014FDA label, providing wider antibacterial coverage for gram-negative infections. In June 2019, ceftolozane-tazobactam was approved by the FDA for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, which are significant causes of morbidity and mortality in hospitalized patients.`,description:`Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms. It is combined with Piperacillin and Ceftolozane for the treatment of a variety of bacterial infections.\r
\r
Piperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014FDA label, providing wider antibacterial coverage for gram-negative infections. In June 2019, ceftolozane-tazobactam was approved by the FDA for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, which are significant causes of morbidity and mortality in hospitalized patients.`}]}]}]}],At={name:vt,children:wt};let Te=0;function sa(i){i.id=Te,Te++,i.children&&i.children.forEach(sa)}function xt(i){const e=ce(i);return e.sum(a=>a.value).sort((a,t)=>t.value-a.value),sa(e),e}const Se=xt(At),Fi=Gi(et().size([2*Math.PI,Se.height+1])(Se));function Me(i,e,a){const t=i.slice();return t[15]=e[a],t}function Ie(i,e,a){const t=i.slice();return t[15]=e[a],t}function _e(i){let e,a;return e=new ft({props:{color:Je(i[15]),d:i[15],handleHover:i[10],arc_d3:i[8],fill_opacity:i[1]&&i[15].data.name!=i[1]?.1:i[1]&&i[15].data.name==i[1]?.7:Pe(i[15]),pointer_events:te(i[15].current)?"auto":"none",handleClick:i[9],handleSelection:i[2]}}),{c(){qi(e.$$.fragment)},m(t,n){Ci(e,t,n),a=!0},p(t,n){const o={};n&16&&(o.color=Je(t[15])),n&16&&(o.d=t[15]),n&256&&(o.arc_d3=t[8]),n&18&&(o.fill_opacity=t[1]&&t[15].data.name!=t[1]?.1:t[1]&&t[15].data.name==t[1]?.7:Pe(t[15])),n&16&&(o.pointer_events=te(t[15].current)?"auto":"none"),n&4&&(o.handleSelection=t[2]),e.$set(o)},i(t){a||(G(e.$$.fragment,t),a=!0)},o(t){Z(e.$$.fragment,t),a=!1},d(t){Ti(e,t)}}}function Ee(i){let e,a;return e=new gt({props:{dy:"0.35em",radius:i[3],fontSize:i[0]?"29px":"20px",fill_opacity:+ze(i[15].current),d:i[15],title:i[15].data.name}}),{c(){qi(e.$$.fragment)},m(t,n){Ci(e,t,n),a=!0},p(t,n){const o={};n&8&&(o.radius=t[3]),n&1&&(o.fontSize=t[0]?"29px":"20px"),n&16&&(o.fill_opacity=+ze(t[15].current)),n&16&&(o.d=t[15]),n&16&&(o.title=t[15].data.name),e.$set(o)},i(t){a||(G(e.$$.fragment,t),a=!0)},o(t){Z(e.$$.fragment,t),a=!1},d(t){Ti(e,t)}}}function Le(i){let e,a=i[5].data.name+"",t,n,o,s=i[5].depth>0&&ke(i);return{c(){e=X("text"),t=j(a),s&&s.c(),o=se(),b(e,"class","middle-text svelte-1xdunt6"),b(e,"text-anchor","middle"),b(e,"font-size",n=i[0]?"55px":"35px"),b(e,"dominant-baseline","middle"),b(e,"pointer-events","none")},m(c,m){z(c,e,m),T(e,t),s&&s.m(c,m),z(c,o,m)},p(c,m){m&32&&a!==(a=c[5].data.name+"")&&li(t,a),m&1&&n!==(n=c[0]?"55px":"35px")&&b(e,"font-size",n),c[5].depth>0?s?s.p(c,m):(s=ke(c),s.c(),s.m(o.parentNode,o)):s&&(s.d(1),s=null)},d(c){c&&(k(e),k(o)),s&&s.d(c)}}}function ke(i){let e,a,t=Be(i[5])+"",n,o;return{c(){e=X("text"),a=j("⏎  "),n=j(t),b(e,"class","small-text svelte-1xdunt6"),b(e,"text-anchor","lower"),b(e,"font-size",o=i[0]?"30px":"20px"),b(e,"dominant-baseline","middle"),b(e,"pointer-events","none"),b(e,"y","40")},m(s,c){z(s,e,c),T(e,a),T(e,n)},p(s,c){c&32&&t!==(t=Be(s[5])+"")&&li(n,t),c&1&&o!==(o=s[0]?"30px":"20px")&&b(e,"font-size",o)},d(s){s&&k(e)}}}function Ne(i){let e,a=i[7].data.name+"",t,n;return{c(){e=X("text"),t=j(a),b(e,"class","hover-text svelte-1xdunt6"),b(e,"text-anchor","middle"),b(e,"font-size",n=i[0]?"50px":"35px"),b(e,"dominant-baseline","middle"),b(e,"pointer-events","none")},m(o,s){z(o,e,s),T(e,t)},p(o,s){s&128&&a!==(a=o[7].data.name+"")&&li(t,a),s&1&&n!==(n=o[0]?"50px":"35px")&&b(e,"font-size",n)},d(o){o&&k(e)}}}function Ct(i){let e,a,t,n,o,s,c,m,d=Q(i[4].descendants().slice(1)),r=[];for(let h=0;h<d.length;h+=1)r[h]=_e(Ie(i,d,h));const f=h=>Z(r[h],1,1,()=>{r[h]=null});let p=Q(i[4].descendants().slice(1)),y=[];for(let h=0;h<p.length;h+=1)y[h]=Ee(Me(i,p,h));const x=h=>Z(y[h],1,1,()=>{y[h]=null});let w=!i[7]&&Le(i),v=i[7]&&Ne(i);return{c(){e=X("svg"),a=X("g");for(let h=0;h<r.length;h+=1)r[h].c();t=X("g");for(let h=0;h<y.length;h+=1)y[h].c();n=X("circle"),w&&w.c(),o=se(),v&&v.c(),b(t,"pointer-events","none"),b(t,"text-anchor","middle"),M(t,"user-select","none"),b(n,"r",i[3]),b(n,"fill","white"),b(n,"pointer-events","auto"),M(n,"cursor","pointer"),b(e,"viewBox",i[6]),b(e,"class","svelte-1xdunt6")},m(h,l){z(h,e,l),T(e,a);for(let u=0;u<r.length;u+=1)r[u]&&r[u].m(a,null);T(e,t);for(let u=0;u<y.length;u+=1)y[u]&&y[u].m(t,null);T(e,n),w&&w.m(e,null),T(e,o),v&&v.m(e,null),s=!0,c||(m=[U(n,"click",i[12]),U(n,"mouseover",i[13])],c=!0)},p(h,[l]){if(l&1814){d=Q(h[4].descendants().slice(1));let u;for(u=0;u<d.length;u+=1){const g=Ie(h,d,u);r[u]?(r[u].p(g,l),G(r[u],1)):(r[u]=_e(g),r[u].c(),G(r[u],1),r[u].m(a,null))}for(Qi(),u=d.length;u<r.length;u+=1)f(u);$i()}if(l&25){p=Q(h[4].descendants().slice(1));let u;for(u=0;u<p.length;u+=1){const g=Me(h,p,u);y[u]?(y[u].p(g,l),G(y[u],1)):(y[u]=Ee(g),y[u].c(),G(y[u],1),y[u].m(t,null))}for(Qi(),u=p.length;u<y.length;u+=1)x(u);$i()}(!s||l&8)&&b(n,"r",h[3]),h[7]?w&&(w.d(1),w=null):w?w.p(h,l):(w=Le(h),w.c(),w.m(e,o)),h[7]?v?v.p(h,l):(v=Ne(h),v.c(),v.m(e,null)):v&&(v.d(1),v=null),(!s||l&64)&&b(e,"viewBox",h[6])},i(h){if(!s){for(let l=0;l<d.length;l+=1)G(r[l]);for(let l=0;l<p.length;l+=1)G(y[l]);s=!0}},o(h){r=r.filter(Boolean);for(let l=0;l<r.length;l+=1)Z(r[l]);y=y.filter(Boolean);for(let l=0;l<y.length;l+=1)Z(y[l]);s=!1},d(h){h&&k(e),Ai(r,h),Ai(y,h),w&&w.d(),v&&v.d(),c=!1,ii(m)}}}let Ki=1e3,De=1e3;function te(i){return i.y1<=3&&i.y0>=1&&i.x1>i.x0}function ze(i){return i.y1<=3&&i.y0>=1&&(i.y1-i.y0)*(i.x1-i.x0)>.01}function Je(i){let e=i;if(e.data.name=="Access"||e.parent.data.name=="Access")return"#32965D";if(e.data.name=="Watch"||e.parent.data.name=="Watch")return"#E0BE36";if(e.data.name=="Reserve"||e.parent.data.name=="Reserve")return"#D52941";for(;e.depth>1;)e=e.parent;if(e.data.name=="Beta-Lactams")return"#EBEBEB";if(e.data.name=="Other")return"#DAD2D8"}function Pe(i){return te(i.current)?i.depth==1?.8:i.depth==2||i.children?.6:.4:0}function Be(i){let e=[];for(;i.depth>0;)i=i.parent,e.unshift(i.data.name);return e.join("/")}function Tt(i,e,a){let t,n,o,s,c,m;W(i,Fi,l=>a(4,m=l));let{smallScreen:d=!1}=e,{selectedAntibiotic:r=null}=e,{handleSelection:f=null}=e,p=0,y=m.descendants().find(l=>l.id==p);m.each(l=>l.current=l);function x(l){l.parent!=y.parent&&(p=l.id,a(5,y=m.descendants().find(u=>u.id==p)),Fi.update(u=>(u.each(g=>g.current={x0:Math.max(0,Math.min(1,(g.x0-l.x0)/(l.x1-l.x0)))*2*Math.PI,x1:Math.max(0,Math.min(1,(g.x1-l.x0)/(l.x1-l.x0)))*2*Math.PI,y0:Math.max(0,g.y0-l.depth),y1:Math.max(0,g.y1-l.depth)}),u)))}function w(l){l?l.children?a(7,t=null):a(7,t=l):a(7,t=null)}const v=()=>{y.parent&&x(y.parent),y.parent?f(y.parent.data.name):f(y.data.name)},h=()=>{a(7,t=null)};return i.$$set=l=>{"smallScreen"in l&&a(0,d=l.smallScreen),"selectedAntibiotic"in l&&a(1,r=l.selectedAntibiotic),"handleSelection"in l&&a(2,f=l.handleSelection)},i.$$.update=()=>{if(i.$$.dirty&2066&&r!=null&&r!=o){let l=m.descendants().find(u=>u.data.name==r);l&&l.parent&&x(l.parent),a(11,o=r)}i.$$.dirty&8&&a(8,s=ut().startAngle(l=>l.x0).endAngle(l=>l.x1).padAngle(l=>Math.min((l.x1-l.x0)/2,.005)).padRadius(n*1.5).innerRadius(l=>l.y0*n).outerRadius(l=>Math.max(l.y0*n,l.y1*n-1)))},a(7,t=null),a(3,n=Ki/6),a(11,o=""),a(6,c=`${Ki/-2} ${De/-2} ${Ki} ${De}`),[d,r,f,n,m,y,c,t,s,x,w,o,v,h]}class St extends Mi{constructor(e){super(),Si(this,e,Tt,Ct,bi,{smallScreen:0,selectedAntibiotic:1,handleSelection:2})}}function Mt(i,{delay:e=0,duration:a=400,easing:t=ne}={}){const n=+getComputedStyle(i).opacity;return{delay:e,duration:a,easing:t,css:o=>`opacity: ${o*n}`}}function Fe(i,e,a){const t=i.slice();return t[17]=e[a],t}function qe(i,e,a){const t=i.slice();return t[20]=e[a],t}function Ge(i,e,a){const t=i.slice();return t[23]=e[a],t}function Re(i){let e,a;return{c(){e=I("option"),e.__value=a=i[23],pe(e,e.__value)},m(t,n){z(t,e,n)},p(t,n){n&32&&a!==(a=t[23])&&(e.__value=a,pe(e,e.__value))},d(t){t&&k(e)}}}function Oe(i){let e,a=Q(i[10].descendants().slice(1)),t=[];for(let n=0;n<a.length;n+=1)t[n]=We(qe(i,a,n));return{c(){e=I("div");for(let n=0;n<t.length;n+=1)t[n].c();b(e,"class","antibiotic-description svelte-1vnjnb3")},m(n,o){z(n,e,o);for(let s=0;s<t.length;s+=1)t[s]&&t[s].m(e,null)},p(n,o){if(o&1025){a=Q(n[10].descendants().slice(1));let s;for(s=0;s<a.length;s+=1){const c=qe(n,a,s);t[s]?t[s].p(c,o):(t[s]=We(c),t[s].c(),t[s].m(e,null))}for(;s<t.length;s+=1)t[s].d(1);t.length=a.length}},d(n){n&&k(e),Ai(t,n)}}}function He(i){let e,a=i[20].data.description+"",t;return{c(){e=I("p"),t=j(a)},m(n,o){z(n,e,o),T(e,t)},p(n,o){o&1024&&a!==(a=n[20].data.description+"")&&li(t,a)},d(n){n&&k(e)}}}function We(i){let e,a=i[20].data.name==i[0]&&He(i);return{c(){a&&a.c(),e=se()},m(t,n){a&&a.m(t,n),z(t,e,n)},p(t,n){t[20].data.name==t[0]?a?a.p(t,n):(a=He(t),a.c(),a.m(e.parentNode,e)):a&&(a.d(1),a=null)},d(t){t&&k(e),a&&a.d(t)}}}function je(i){let e,a,t,n,o,s,c,m,d,r,f,p,y,x,w,v,h=Q(i[9]),l=[];for(let u=0;u<h.length;u+=1)l[u]=Ue(Fe(i,h,u));return{c(){e=I("h2"),e.textContent="AWaRe Category Definitions (Source: WHO):",a=F(),t=I("div"),n=I("div"),o=I("h2"),s=j("Access"),c=F(),m=I("h2"),d=j("Watch"),r=F(),f=I("h2"),p=j("Reserve"),y=F(),x=I("ul");for(let u=0;u<l.length;u+=1)l[u].c();b(e,"class","svelte-1vnjnb3"),M(o,"opacity",i[6]=="Access"?1:.2),M(o,"background","#77B48E"),b(o,"class","svelte-1vnjnb3"),M(m,"opacity",i[6]=="Watch"?1:.2),M(m,"background","#E9D17A"),b(m,"class","svelte-1vnjnb3"),M(f,"opacity",i[6]=="Reserve"?1:.2),M(f,"background","#E56F7B"),b(f,"class","svelte-1vnjnb3"),M(n,"display","flex"),M(n,"justify-content","flex-start"),b(t,"class","WHO-descriptions svelte-1vnjnb3")},m(u,g){z(u,e,g),z(u,a,g),z(u,t,g),T(t,n),T(n,o),T(o,s),T(n,c),T(n,m),T(m,d),T(n,r),T(n,f),T(f,p),T(t,y),T(t,x);for(let A=0;A<l.length;A+=1)l[A]&&l[A].m(x,null);w||(v=[U(o,"click",i[13]),U(m,"click",i[14]),U(f,"click",i[15])],w=!0)},p(u,g){if(g&64&&M(o,"opacity",u[6]=="Access"?1:.2),g&64&&M(m,"opacity",u[6]=="Watch"?1:.2),g&64&&M(f,"opacity",u[6]=="Reserve"?1:.2),g&512){h=Q(u[9]);let A;for(A=0;A<h.length;A+=1){const L=Fe(u,h,A);l[A]?l[A].p(L,g):(l[A]=Ue(L),l[A].c(),l[A].m(x,null))}for(;A<l.length;A+=1)l[A].d(1);l.length=h.length}},d(u){u&&(k(e),k(a),k(t)),Ai(l,u),w=!1,ii(v)}}}function Ue(i){let e,a=i[17]+"",t;return{c(){e=I("li"),t=j(a),b(e,"class","svelte-1vnjnb3")},m(n,o){z(n,e,o),T(e,t)},p(n,o){o&512&&a!==(a=n[17]+"")&&li(t,a)},d(n){n&&k(e)}}}function Ve(i){let e,a,t,n,o=i[4]&&Ye();return{c(){e=I("div"),a=I("div"),t=j(i[3]),n=F(),o&&o.c(),b(a,"class","badge svelte-1vnjnb3"),M(a,"background",i[3]=="Access"?"#77B48E":i[3]=="Watch"?"#E9D17A":i[3]=="Reserve"?"#E56F7B":"white"),b(e,"class","badges-container svelte-1vnjnb3")},m(s,c){z(s,e,c),T(e,a),T(a,t),T(e,n),o&&o.m(e,null)},p(s,c){c&8&&li(t,s[3]),c&8&&M(a,"background",s[3]=="Access"?"#77B48E":s[3]=="Watch"?"#E9D17A":s[3]=="Reserve"?"#E56F7B":"white"),s[4]?o||(o=Ye(),o.c(),o.m(e,null)):o&&(o.d(1),o=null)},d(s){s&&k(e),o&&o.d()}}}function Ye(i){let e;return{c(){e=I("div"),e.textContent="WHO Essential Drug",b(e,"class","badge svelte-1vnjnb3"),M(e,"background","#4899A8")},m(a,t){z(a,e,t)},d(a){a&&k(e)}}}function It(i){let e,a,t,n,o,s,c,m,d,r,f,p,y,x,w,v,h,l,u,g,A,L,O,V,Y,H,J=Q(i[5]),_=[];for(let D=0;D<J.length;D+=1)_[D]=Re(Ge(i,J,D));let C=i[0]&&Oe(i),S=!i[0]&&je(i),N=i[0]&&Ve(i);return{c(){e=I("div"),a=I("img"),o=F(),s=I("div"),c=I("h1"),c.textContent="ANTIBIOTICS AWaRe TOOL",m=F(),d=I("div"),r=I("input"),f=F(),p=I("datalist");for(let D=0;D<_.length;D+=1)_[D].c();y=F(),C&&C.c(),x=F(),S&&S.c(),w=F(),N&&N.c(),v=F(),h=I("div"),h.innerHTML="",l=F(),u=I("div"),g=I("div"),g.innerHTML='<h2 style="margin-right: 1rem;">Credits</h2> <a href="https://github.com/rorywhite200/antibiotic-aware-viz" target="_blank" class="svelte-1vnjnb3"><svg width="25" height="25" viewBox="0 0 98 96" xmlns="http://www.w3.org/2000/svg" class="svelte-1vnjnb3"><path fill-rule="evenodd" clip-rule="evenodd" d="M48.854 0C21.839 0 0 22 0 49.217c0 21.756 13.993 40.172 33.405 46.69 2.427.49 3.316-1.059 3.316-2.362 0-1.141-.08-5.052-.08-9.127-13.59 2.934-16.42-5.867-16.42-5.867-2.184-5.704-5.42-7.17-5.42-7.17-4.448-3.015.324-3.015.324-3.015 4.934.326 7.523 5.052 7.523 5.052 4.367 7.496 11.404 5.378 14.235 4.074.404-3.178 1.699-5.378 3.074-6.6-10.839-1.141-22.243-5.378-22.243-24.283 0-5.378 1.94-9.778 5.014-13.2-.485-1.222-2.184-6.275.486-13.038 0 0 4.125-1.304 13.426 5.052a46.97 46.97 0 0 1 12.214-1.63c4.125 0 8.33.571 12.213 1.63 9.302-6.356 13.427-5.052 13.427-5.052 2.67 6.763.97 11.816.485 13.038 3.155 3.422 5.015 7.822 5.015 13.2 0 18.905-11.404 23.06-22.324 24.283 1.78 1.548 3.316 4.481 3.316 9.126 0 6.6-.08 11.897-.08 13.526 0 1.304.89 2.853 3.316 2.364 19.412-6.52 33.405-24.935 33.405-46.691C97.707 22 75.788 0 48.854 0z" fill="#24292f"></path></svg></a> <a href="https://www.linkedin.com/in/rory-white-5a954819a/" target="_blank" class="svelte-1vnjnb3"><svg height="25" viewBox="0 0 72 72" width="25" xmlns="http://www.w3.org/2000/svg" class="svelte-1vnjnb3"><g fill="none" fill-rule="evenodd"><path d="M8,72 L64,72 C68.418278,72 72,68.418278 72,64 L72,8 C72,3.581722 68.418278,-8.11624501e-16 64,0 L8,0 C3.581722,8.11624501e-16 -5.41083001e-16,3.581722 0,8 L0,64 C5.41083001e-16,68.418278 3.581722,72 8,72 Z" fill="#007EBB"></path><path d="M62,62 L51.315625,62 L51.315625,43.8021149 C51.315625,38.8127542 49.4197917,36.0245323 45.4707031,36.0245323 C41.1746094,36.0245323 38.9300781,38.9261103 38.9300781,43.8021149 L38.9300781,62 L28.6333333,62 L28.6333333,27.3333333 L38.9300781,27.3333333 L38.9300781,32.0029283 C38.9300781,32.0029283 42.0260417,26.2742151 49.3825521,26.2742151 C56.7356771,26.2742151 62,30.7644705 62,40.051212 L62,62 Z M16.349349,22.7940133 C12.8420573,22.7940133 10,19.9296567 10,16.3970067 C10,12.8643566 12.8420573,10 16.349349,10 C19.8566406,10 22.6970052,12.8643566 22.6970052,16.3970067 C22.6970052,19.9296567 19.8566406,22.7940133 16.349349,22.7940133 Z M11.0325521,62 L21.769401,62 L21.769401,27.3333333 L11.0325521,27.3333333 L11.0325521,62 Z" fill="#FFF"></path></g></svg></a>',A=F(),L=I("p"),L.innerHTML=`This website was created by Rory White using Svelte and d3/js. Data was sourced from the <a href="https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.04">WHO AWaRe Classification 2023.</a>
   Antibiotic descriptions are from the <a href="https://go.drugbank.com">Drugbank</a> database (Attribution-NonCommercial 4.0 International) and Wikipedia. Text descriptions of the WHO AWaRe categories are from the <a href="https://aware.essentialmeds.org/groups">AWaRe website.</a> The visualization mechanics were adapted from Mike Bostock&#39;s Zoomable Sunburst.`,b(a,"width",t=i[7]/2),b(a,"class","diagram svelte-1vnjnb3"),la(a.src,n="diagram.png")||b(a,"src",n),b(a,"alt","Description"),b(c,"class","svelte-1vnjnb3"),b(r,"class","search-bar svelte-1vnjnb3"),b(r,"list","antibiotics"),b(r,"type","text"),b(r,"placeholder","Search for an antibiotic..."),r.value=i[0],b(p,"id","antibiotics"),b(d,"class","combined-container svelte-1vnjnb3"),b(s,"class","top-flex svelte-1vnjnb3"),M(s,"flex-shrink","1"),b(g,"class","logo-flex svelte-1vnjnb3"),M(g,"display","flex"),M(g,"align-items","center"),M(g,"height","fit-content"),M(g,"line-height","1"),M(L,"margin-top","0"),M(L,"line-height","1.5"),M(L,"padding-right","0.5rem"),b(u,"class","credits svelte-1vnjnb3"),M(u,"width","100vw"),M(u,"font-size","0.9rem"),M(u,"background","#D6D6D6"),M(u,"position",i[1]?"relative":"absolute"),M(u,"bottom","0"),M(u,"left","0"),M(u,"padding","0.1rem 3rem 2rem 3rem"),M(u,"color","#393030"),b(e,"class","left-panel svelte-1vnjnb3"),b(e,"style",i[8]),ci(()=>i[16].call(e))},m(D,P){z(D,e,P),T(e,a),T(e,o),T(e,s),T(s,c),T(s,m),T(s,d),T(d,r),T(d,f),T(d,p);for(let E=0;E<_.length;E+=1)_[E]&&_[E].m(p,null);T(d,y),C&&C.m(d,null),T(s,x),S&&S.m(s,null),T(s,w),N&&N.m(s,null),T(s,v),T(s,h),T(e,l),T(e,u),T(u,g),T(u,A),T(u,L),O=ta(e,i[16].bind(e)),Y||(H=[U(r,"focus",i[12]),U(r,"input",function(){yi(i[2])&&i[2].apply(this,arguments)})],Y=!0)},p(D,[P]){if(i=D,P&128&&t!==(t=i[7]/2)&&b(a,"width",t),P&1&&r.value!==i[0]&&(r.value=i[0]),P&32){J=Q(i[5]);let E;for(E=0;E<J.length;E+=1){const ni=Ge(i,J,E);_[E]?_[E].p(ni,P):(_[E]=Re(ni),_[E].c(),_[E].m(p,null))}for(;E<_.length;E+=1)_[E].d(1);_.length=J.length}i[0]?C?C.p(i,P):(C=Oe(i),C.c(),C.m(d,null)):C&&(C.d(1),C=null),i[0]?S&&(S.d(1),S=null):S?S.p(i,P):(S=je(i),S.c(),S.m(s,w)),i[0]?N?N.p(i,P):(N=Ve(i),N.c(),N.m(s,v)):N&&(N.d(1),N=null),P&2&&M(u,"position",i[1]?"relative":"absolute"),P&256&&b(e,"style",i[8])},i(D){D&&(V||ci(()=>{V=Ia(e,Mt,{duration:300}),V.start()}))},o:R,d(D){D&&k(e),Ai(_,D),C&&C.d(),S&&S.d(),N&&N.d(),O(),Y=!1,ii(H)}}}function _t(i,e,a){let t,n,o,s;W(i,Fi,g=>a(10,s=g));let{smallScreen:c=!1}=e,{mediumScreen:m=!1}=e,{selectedAntibiotic:d=null}=e,{handleSelection:r=null}=e,{selectedAntibioticWHOStatus:f=null}=e,{selectedAntibioticEssential:p=null}=e,{antibioticsList:y=[]}=e,x=0;const w=()=>a(0,d=null),v=()=>a(6,n="Access"),h=()=>a(6,n="Watch"),l=()=>a(6,n="Reserve");function u(){x=this.clientHeight,a(7,x)}return i.$$set=g=>{"smallScreen"in g&&a(11,c=g.smallScreen),"mediumScreen"in g&&a(1,m=g.mediumScreen),"selectedAntibiotic"in g&&a(0,d=g.selectedAntibiotic),"handleSelection"in g&&a(2,r=g.handleSelection),"selectedAntibioticWHOStatus"in g&&a(3,f=g.selectedAntibioticWHOStatus),"selectedAntibioticEssential"in g&&a(4,p=g.selectedAntibioticEssential),"antibioticsList"in g&&a(5,y=g.antibioticsList)},i.$$.update=()=>{i.$$.dirty&64&&a(9,t=n=="Access"?["first or second choice antibiotics","offer the best therapeutic value, while minimizing the potential for resistance"]:n=="Watch"?["first or second choice antibiotics","only indicated for specific, limited number of infective syndromes","more prone to be a target of antibiotic resistance and thus prioritized as targets of stewardship programs and monitoring"]:["“last resort”","highly selected patients (life-threatening infections due to multi-drug resistant bacteria)","closely monitored and prioritized as targets of stewardship programs to ensure their continued effectiveness"]),i.$$.dirty&2&&a(8,o=m?"height: 100vh; position: absolute !important; left: -2rem; width: 100%; box-sizing: border-box;":"position: relative; height: 100vh; max-width: 50%; width: 33%;")},a(6,n="Access"),[d,m,r,f,p,y,n,x,o,t,s,c,w,v,h,l,u]}class Et extends Mi{constructor(e){super(),Si(this,e,_t,It,bi,{smallScreen:11,mediumScreen:1,selectedAntibiotic:0,handleSelection:2,selectedAntibioticWHOStatus:3,selectedAntibioticEssential:4,antibioticsList:5})}}function Xe(i){let e,a,t,n,o;return{c(){e=X("svg"),a=X("path"),b(a,"d","M16 132h416c8.837 0 16-7.163 16-16V76c0-8.837-7.163-16-16-16H16C7.163 60 0 67.163 0 76v40c0 8.837 7.163 16 16 16zm0 160h416c8.837 0 16-7.163 16-16v-40c0-8.837-7.163-16-16-16H16c-8.837 0-16 7.163-16 16v40c0 8.837 7.163 16 16 16zm0 160h416c8.837 0 16-7.163 16-16v-40c0-8.837-7.163-16-16-16H16c-8.837 0-16 7.163-16 16v40c0 8.837 7.163 16 16 16z"),b(e,"class",t=he(i[1]?"menu-bars-svg rotated rotate":"menu-bars-svg rotate")+" svelte-q38l9n"),b(e,"xmlns","http://www.w3.org/2000/svg"),b(e,"viewBox","0 0 448 512")},m(s,c){z(s,e,c),T(e,a),n||(o=U(e,"click",i[10]),n=!0)},p(s,c){c&2&&t!==(t=he(s[1]?"menu-bars-svg rotated rotate":"menu-bars-svg rotate")+" svelte-q38l9n")&&b(e,"class",t)},d(s){s&&k(e),n=!1,o()}}}function Ke(i){let e,a;return e=new Et({props:{selectedAntibioticEssential:i[3],antibioticsList:i[8],handleSelection:i[9],selectedAntibiotic:i[4],selectedAntibioticWHOStatus:i[2],mediumScreen:i[5],smallScreen:i[6]}}),{c(){qi(e.$$.fragment)},m(t,n){Ci(e,t,n),a=!0},p(t,n){const o={};n&8&&(o.selectedAntibioticEssential=t[3]),n&16&&(o.selectedAntibiotic=t[4]),n&4&&(o.selectedAntibioticWHOStatus=t[2]),n&32&&(o.mediumScreen=t[5]),n&64&&(o.smallScreen=t[6]),e.$set(o)},i(t){a||(G(e.$$.fragment,t),a=!0)},o(t){Z(e.$$.fragment,t),a=!1},d(t){Ti(e,t)}}}function Lt(i){let e,a,t,n,o,s,c;t=new St({props:{handleSelection:i[9],selectedAntibiotic:i[4],smallScreen:i[6]}});let m=i[5]&&Xe(i),d=(i[1]||!i[5])&&Ke(i);return{c(){e=I("main"),a=I("div"),qi(t.$$.fragment),n=F(),m&&m.c(),o=F(),d&&d.c(),M(a,"height","95%"),M(a,"max-width",i[5]?"93vw":"50vw"),M(a,"aspect-ratio","1"),M(a,"padding-top","0.5rem"),b(e,"class","svelte-q38l9n"),ci(()=>i[11].call(e))},m(r,f){z(r,e,f),T(e,a),Ci(t,a,null),T(e,n),m&&m.m(e,null),T(e,o),d&&d.m(e,null),s=ta(e,i[11].bind(e)),c=!0},p(r,[f]){const p={};f&16&&(p.selectedAntibiotic=r[4]),f&64&&(p.smallScreen=r[6]),t.$set(p),(!c||f&32)&&M(a,"max-width",r[5]?"93vw":"50vw"),r[5]?m?m.p(r,f):(m=Xe(r),m.c(),m.m(e,o)):m&&(m.d(1),m=null),r[1]||!r[5]?d?(d.p(r,f),f&34&&G(d,1)):(d=Ke(r),d.c(),G(d,1),d.m(e,null)):d&&(Qi(),Z(d,1,1,()=>{d=null}),$i())},i(r){c||(G(t.$$.fragment,r),G(d),c=!0)},o(r){Z(t.$$.fragment,r),Z(d),c=!1},d(r){r&&k(e),Ti(t),m&&m.d(),d&&d.d(),s()}}}function kt(i,e,a){let t,n,o,s,c,m,d,r,f;W(i,Fi,v=>a(12,d=v)),W(i,ve,v=>a(0,r=v)),W(i,we,v=>a(7,f=v));let p=[];d.each(v=>{v.children||p.push(v.data.name)}),p.sort();function y(v){let h;v.target&&p.includes(v.target.value)?h=v.target.value:p.includes(v)?h=v:h=null,a(4,o=h),o?(a(2,s=d.descendants().find(l=>l.data.name==o).parent.data.name),d.descendants().find(l=>l.data.name==o).data.EML=="Yes"?a(3,c=!0):a(3,c=!1)):a(2,s=null)}function x(){a(1,m=!m)}function w(){r=this.clientWidth,ve.set(r),f=this.clientHeight,we.set(f)}return i.$$.update=()=>{i.$$.dirty&1&&a(6,t=r<600),i.$$.dirty&1&&a(5,n=r<1e3)},a(4,o=null),a(2,s=null),a(3,c=null),a(1,m=!1),[r,m,s,c,o,n,t,f,p,y,x,w]}class Nt extends Mi{constructor(e){super(),Si(this,e,kt,Lt,bi,{})}}new Nt({target:document.getElementById("app")});
